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Abstract 
 
Retrovirus vector-mediated insertional mutagenesis (IM) can lead to serious 
cancerous risks in gene therapy. Although multiple cases of IM-induced 
malignancies have been reported in clinical trials with gammaretroviral vectors, 
no evidence for malignancies has been reported with HIV-derived lentiviral 
vectors (LVs). However, the 2010 clinical trial for ß-thalassaemia had reported 
the clonal dominance of erythroblasts in one patient. This was caused by the LV 
integration into the HMGA2 gene locus and the up-regulation of HMGA2 protein 
by the formation of host-vector chimeric transcripts (Cavazzana-Calvo et al., 
2010). The observed pattern of splicing in the HMGA2 locus, splice-in, is splicing 
from a host splice donor to a vector splice acceptor. Considering that this 
literature is the first and only evidence that implies mutagenicity of LVs, We 
thought that formation of splice-in fusion transcripts could be a key factor to 
contribute potential LV-mediated IM. Therefore, we set our aim of investigating 
the mechanism of splice-in caused by vector integration by designing a novel LV 
model that can induce splice-in fusion transcripts, and by applying to an in vitro 
IM assay previously established by our group (Bokhoven et al., 2009). The IM 
assay utilise IL-3 dependent Bcl15 cell transformation into IL-3 independent, 
which can be analysed for the transformation mechanism via LV integration. 
Phenotypic analysis of the isolated mutant clone (the IL-3I clone) suggested 
secretion of autocrine factors and the cause of which was interrogated by 
molecular analysis. Additionally, the IL-3I clone and two bulk populations from 
different steps of an IM assay were subjected to RNA sequencing (RNA-Seq) to 
compare the isolated host genes and investigate chimeric mRNAs. Importantly, 
RNA-Seq identified the Angpt1 fusion transcript but in the splice-out form using a 
cryptic vector SD as a possible cause for cell transformation of the IL-3I clone. 
This gene locus has Retroviral Tagged Cancer Gene Database (RTCGD) hits 
and was also detected by LM-PCR. A variety of splice sites were used in the 
detected possible fusion mRNAs. To confirm, Angpt1 loci is the major cause of 
IL-3 independence and the pattern of splice sites use depend integration site; 
further analysis is required and discussed in the final chapter. 
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PBS   Primer Binding Site  
PCLs   Packaging Cell Lines  
PCR   Polymerase Chain Reaction  
PD   Parkinson’s Disease  
PFA   Paraformaldehyde  
PGK   Phosphoglycerate Kinase  
PIC   Pre-Integration Complex  
PID   Primary Immunodeficiencies  
pim-1 Proto-Oncogene Serine/Threonine-Protein Kinase 
Pim-1 
PMOs   Phosphorodiamidate Morpholino Oligomers  
PNS   Peripheral Nervous Systems  
PPT   Polypurine Tract  
PR   Protease  
Psi, ψ    Packaging Signal  
PtdIns(4,5)P2  Phosphatidylinositol 4,5-Bisphosphate  
puroR   Puromycin Resistant  
qPCR   Quantitative PCR  
RACE   Rapid Amplification Of cDNA Ends  
RBD   RNA-Binding Domain  
RCVs   Replication Competent Viruses  
RER   Rough Endoplasmic Reticulum  
REV-A   Reticuloendotheliosis Virus Strain A  
RRE   Rev-Response Element  
RSV   Rous Sarcoma Virus  
RT   Reverse Transcriptase  
RTC   Reverse Transcription Complex  
RTCGD   Retroviral Tagged Cancer Gene Database 
RVs   Retroviral Vectors  
s   Second  
SA   Splice Acceptor  
SAMHD1  Sam Domain, And HD Domain-Containing Protein 1  
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SD    Splice Donor  
SEM   Standard Error Of Mean  
SERINC3  Serine Incorporator 3  
SERINC5  Serine Incorporator 5  
SFFV   Spleen Focus-Forming Virus  
SIN   Self-Inactivating  
SIV   Simian Immunodeficiency Virus  
SMA   Spinal Muscular Atrophy  
SMN1   Survival Motor Neuron 1  
snRNPs   Small Nuclear Ribonucleoproteins  
SR   Serine/Arginine  
SU   Surface Glycoprotein  
TAE Buffer  Tris-Base, Acetic Acid And EDTA Buffer  
TAR   Transactivation Response  
Tat   Transactivator Protein  
TCR   T Cell Receptor  
TH   Tyrosine Hydroxylase  
tk   Thymidine Kinase gene  
Tm   Melting Temperature  
TM   Transmembrane Glycoprotein  
TNBC   Triple Negative Breast Cancer  
TNPO3   Transportin 3  
TRIM5a   Tripartile Motif Protein 5 alpha  
tRNA   Transfer RNA  
TSG101   Tumour Susceptibility Gene 101  
u   Unit  
U2AF   U2 Auxiliary Factor  
UBIQ   Ubiquitin Promoter  
UTR   Untranslated Region  
VLCFAs   Very Long Chain Fatty Acids  
VPS4   Atpase Vacuolar Protein Sorting 4  
VSV-G   Vesicular Stomatitis Virus  
WAS   Wiskott-Aldrich Syndrome  
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WPRE Woodchuck Hepatitis Virus Posttrascriptional 
Regulatory Elements  
WT   Wild-Type  
X-CGD   X-Linked Chronic Granulomatous Disease  
X-SCID   X-Linked Severe Combined Immunodeficiency  
ZFNs   Zinc Finger Nucleases  
µ    Micro  
%   Percentage  
6HB   Six-Helical Bundle 
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1 Introduction 
 
1.1 Retrovirus biology 
 
1.1.1 Virus discovery 
 
The first retrovirus to be discovered was the Rous sarcoma virus, which was 
isolated from tumours in chickens that were being processed by the poultry meat 
industry (Rous, 1910). Retroviruses were then isolated from a range of wild and 
domesticated animals (Shope and Hurst, 1933) (Bittner, 1942) (Sweet and 
Hilleman, 1960) (Weiss and Vogt, 2011).  
 
The first human retrovirus was not isolated until 1980 when human T-cell 
leukaemia virus type 1 (HTLV-1) was found in T cells cultured from leukaemia 
patients (Poiesz et al., 1980). This development of methods for cultivating T cells, 
following the discovery of T cell growth factor interleukin-2 (IL-2), also allowed 
the discovery of human immunodeficiency virus (HIV) in 1984 (Gallo, 2005) 
(Barre-Sinoussi et al., 1983). HIV is widely known as the cause of acquired 
immune deficiency syndrome (AIDS), which is characterised by the occurrence 
of opportunistic infection due to immune suppression. In order to seek strategies 
to treat AIDS, HIV has been extensively studied and characterised. However, in 
2015 36.7 million people were still suffering from AIDS worldwide 
(http://www.who.int/hiv/data/en/). HIV has two subtypes, 1 and 2. In this thesis, 
“HIV” denotes HIV-1 because this is the major subtype causing the pandemic 
and because the lentiviral vectors I studied are based on HIV-1. 
 
After its isolation in 1984, infectious molecular clones of HIV were isolated and 
the genomic sequence was published in 1985 (Wain-Hobson et al., 1985). Then 
the molecular clones were engineered to produce replication-defective HIV 
vectors which could be used for gene delivery to eukaryotic cells (Zufferey et al., 
1997). Nowadays, lentiviral vectors based on HIV are widely used in laboratories. 
Their application is extended in clinical gene therapy; lentiviral vectors can be 
used in various therapeutic strategies, such as a functional gene or cDNA 
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delivery, shRNA delivery, and gene-editing. Clinical trials using lentiviral vectors 
are reported in inheritable disorders such as hematological, storage and 
neurodegenerative diseases as well as cancer (Naldini, 2015). The details are 
described in the 1.4 Gene therapy section. 
 
This thesis focuses on the characterisation of a model HIV vector and identifies 
vector-host fusion transcripts to analyse their potential effect on vector genome 
expression and transduced cell gene expression. Because HIV vectors integrate 
into the target cell genome they have the potential to cause insertional 
mutagenesis (IM), leading to the transformation of the transduced cells. My 
study requires an understanding of basic retrovirus biology such as genome 
structure and life cycle. Therefore, the introduction starts with retrovirus biology, 
followed by vectorology and vector application in clinical trials. In addition, as the 
splicing pattern in host-vector fusion transcripts is of interest, the final section of 
this introduction describes the mechanism of splicing and explains 
splicing-mediated genetic disorders.  
 
1.1.2 Retrovirus taxonomy 
 
Virus taxonomy is defined by a consensus group of properties, agreed by the 
International Committee on Taxonomy of Viruses (ICTV) and the virus 
classification is publicly accessible online (http://www.ictvonline.org/).  
 
Retroviridae is one of 82 families of viruses listed and is subdivided into two 
sub-families, Orthoretrovirinae and Spumaretrovirinae. Orthoretrovirinae has six 
genera and Spumaretrovirinae has one genus. HIV belongs to Lentiviruses in 
Orthoretrovirinae (Table 1-1). 
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Subfamily Genus Species 
Orthoretrovirinae Alpharetrovirus e.g. Rous sarcoma virus 
 
Betaretrovirus e.g. Mouse mammary tumor virus  
 
Deltaretrovirus e.g. Bovine leukaemia virus 
 
Epsilonretrovirus e.g. Walleye dermal sarcoma virus 
 
Gammaretrovirus e.g. Murine leukaemia virus  
 
Lentivirus Bovine immunodeficiency virus 
 
 
Caprine arthritis encephalitis virus 
 
 
Equine infectious anemia virus 
 
 
Feline immunodeficiency virus 
 
 
Human immunodeficiency virus 1 
 
 
Human immunodeficiency virus 2 
 
 
Puma lentivirus 
 
 
Simian immunodeficiency virus 
 
 
Visna/maedi virus 
Spumaretrovirinae Spumavirus e.g. Simian foamy virus 
Table 1-1 Retrovirus taxonomy  
The virus taxonomy of retroviruses was extracted from http://www. ictvonline.org/. 
Human immunodeficiency virus 1 is highlighted in bold with an underline. 
 
 
1.1.3 Retrovirus genome structure 
 
The RNA genome of all retroviruses encodes three open reading frames (ORF) 
corresponding to the major virus proteins, Gag, Pol and Env; these are flanked 
by parts of the long terminal repeat (LTR) at both 5’ and 3’ ends. The complexity 
of the genome structure differs between retroviruses. For instance, Murine 
leukaemia virus (MLV) has the simplest genome organisation with only the three 
major structural genes, gag, pol, and env, which encode polyproteins cleaved 
during viral assembly (Cullen, 1992) (Fig.1-1, MLV). The gag gene encodes viral 
core proteins: matrix (MA), p12, capsid (CA), and nucleocapsid (NC). The pol 
gene encodes enzymes necessary for viral replication: protease (PR), reverse 
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transcriptase (RT), and integrase (IN). The env gene encodes the viral 
transmembrane (TM) and surface (SU) glycoproteins. HIV has a more 
complicated genomic structure than MLV, with additional six genes encoding 
regulatory proteins (Tat and Rev) and accessory proteins (Vif, Vpr, Vpu and Nef). 
In addition, the HIV gag precursor polyprotein has a different structure to MLV as 
it contains a p6 region that is involved in the budding of virion particles, whereas 
in MLV this function lies in the p12 protein. 
 
The 5’ end of the HIV RNA genome possesses R and U5 sequences followed by 
a packaging signal (ψ) required for incorporation of the genomic RNA into viral 
particles (Hayashi et al., 1992). At the 3’ end of the HIV genome R is repeated 
followed by U3. The repeated R sequence on the both ends plays an important 
role in reverse transcription (Fig.1-1, HIV). 
 
 
Fig.1-1 Proviral genome structure of MLV and HIV 
Structural and regulatory genes (within a green box) composing of each viral genome 
and their positions are illustrated. LTR: long terminal repeat; PBS: primer binding site; 
ψ: packaging signal; cPPT: central polypurine tract; PPT: poluporine tract; RRE: rev 
response element; ss: splice site. Figure reprinted from (Giacca and Zacchigna, 2012). 
 
  
MLV                               HIV 
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1.2 HIV life cycle 
 
1.2.1 Virus entry into a host cell 
Virus entry into host cells is the initial step of the life cycle of the retrovirus. Two 
steps are required for virus entry; engagement of virus env with a surface 
receptor and co-receptor of a host cell, and the subsequent fusion of virus and 
host membranes.  
 
1.2.2 Binding of virus envelope to host cell plasma membrane 
 
The initial step of the retrovirus lifecycle is virus entry into a target cell, initiated 
by binding of the virus envelope to host cell plasma membranes (reviewed in 
(Overbaugh et al., 2001) (Wilen et al., 2012)). Initial attachment of the retrovirus 
virion to a host cell surface can occur relatively non-specifically (Sherer et al., 
2010). Following this, the envelope must engage with the host receptor proteins 
involved in virus entry. For HIV this is the CD4 membrane glycoprotein and a 
G-protein-coupled chemokine receptor. CD4 is a member of the immunoglobulin 
superfamily and functions to enhance T cell receptor (TCR)-mediated signals by 
engaging with major histocompatibility complex class II (MHC II) that loads 
antigen on and leads to subsequent activation and differentiation (Tubo and 
Jenkins, 2014). CD4 is expressed mainly on helper T cells, but also on 
monocytes, macrophages, and dendritic cells. The chemokine receptors, also 
called co-receptors, include cysteine-cysteine chemokine receptor 5 (CCR5) 
(Choe et al., 1996) or/and chemokine (C-X-C motif) receptor 4 (CXCR4) (Feng 
et al., 1996).  
 
The viral env is a homotrimer of non-covalently linked heterodimers of 
glycosylated protein 120 (gp120) and gp41. The gp120 binds to the CD4 primary 
receptor on the host cell plasma membrane (Kwong et al., 1998). This triggers a 
conformational change in Env, which is necessary for subsequent co-receptor 
binding via one of five variable loops within gp120. This co-receptor binding 
induces exposures of hydrophobic gp41 fusion peptides, resulting in the fusion 
peptide being inserted into the host cell membrane (Chan et al., 1997). 
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Membrane fusion occurs when each gp41 in the trimer folds at a hinge region, 
bringing an amino-terminal helical region (HR-N) and a carboxy-teminal helical 
region (HR-C) to form a six-helical bundle (6HB) (Weissenhorn et al., 1997). This 
hydrophobic fusion peptide insertion results in transmembrane anchors in two 
bilayers in direct apposition, which plays a crucial role in overcoming the 
hydration force (Weissenhorn et al., 1997). The HIV virion and the host plasma 
membrane have been reported to fuse in a pH-independent manner (McClure et 
al., 1990). However, another study showed virus fusion also occurred in an 
endosomal compartment after virus binding and uptake by endocytosis 
(Miyauchi et al., 2009). 
 
Following fusion, the HIV virion core is released into the cytoplasm and 
rearranged to form a complex for conducting reverse transcription, called the 
reverse transcription complex (RTC). The RTC of Molony MLV (MoMLV) 
contains the viral RNA genome, RT, IN and CA. The HIV RTC is more complex, 
containing MA and Vpr together with RT and IN (Hu and Hughes, 2012). 
 
1.2.3 Reverse transcription 
 
Retroviruses package two copies of positive strand RNA. Reverse transcription 
is one of the defining features of retroviridae discovered in 1970 by two research 
groups independently (Baltimore, 1970) (Temin and Mizutani, 1970). This 
changed the accepted concept of the unidirectional flow of genetic information, 
the so-called “central dogma” which stated that DNA is required to synthesise 
RNA that is required to synthesise protein. Reverse transcription uses the two 
copies of the positive strand RNA genome to make viral double-stranded DNA 
using the viral RT enzyme. HIV RT is a heterodimer comprised of a p66 and a 
p51 subunit, which is derived from the processed Gag-Pol precursor protein by 
viral protease into a biologically active form of the enzyme (Goel et al., 1993). 
Reverse transcription also generates two copies of the long terminal repeat 
(LTR) on each end of the double stranded DNA genome, the sequence of which 
is necessary for DNA integration (Yoshinaga and Fujiwara, 1995).  
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1.2.4 Overview of the mechanism of reverse transcription 
 
The process of reverse transcription is described in Fig.1-2. HIV reverse 
transcription (reviewed in (Hu and Hughes, 2012)) is initiated by a transfer RNA 
(tRNA) (Lys3) bound to the primer binding site (PBS) that is located immediately 
downstream of U5 in the 5’ LTR of the HIV RNA genome (Marquet et al., 1995) 
(Ratner et al., 1985). This primes the synthesis of minus strand cDNA from the 5’ 
end of the RNA genome including U5 and R, termed strong stop. This RNA 
within this hybrid is degraded by the RNase H function of RT (Molling et al., 
1971). The newly synthesised strong stop cDNA then hybrises with the 3’ end of 
the RNA genome because the R sequence is present there. This first strand 
transfer leads to the extension of minus strand DNA synthesis to 5’ end of the 
template RNA genome. During this step, the template RNA is degraded by 
RNase H, except the regions highly resistant to RNase H digestion, namely a 3’ 
polypurine tract (PPT) and the central polypurine tract (cPPT). These purine-rich 
sequences serve as the primers to synthesise the positive strand DNA. 
Extension of the positive strand DNA is terminated when RT encounters a 
methylated nucleotide in the tRNA primer. In most retroviruses, RNase H 
cleavages the entire tRNA primer; however, in HIV RNase H cleaves at one 
nucleotide from the 3’ end of tRNA leaving one additional A at the 5’ end of the 
minus strand DNA. Then, using the complementary PBS sequence appearing 
on both DNA strands, the second strand transfer occurs. This annealing of PBS 
sequences leads to a circular DNA intermediate with DNA synthesis proceeding 
on both strands along each template. In order to copy LTR on both ends of viral 
DNA, strand displacement synthesis occurs to make the DNA blunt-ended 
(Fuentes et al., 1996). The completion of reverse transcription results in a longer 
product than the RNA genome as the provirus DNA genome has the same copy 
of U3-R-U5 LTR at both ends. 
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Fig.1-2 The process of reverse transcription 
(A) Reverse transcription is initiated by tRNA (Lys3) binding to PBS. (B) Strand 
extension from the tRNA (Lys3) generates a minus strand strong stop composed of U5 
and R. The RNase H function of RT degrades the template RNA within the hybrid. (C) 
The strong stop transfers to the 3’ end of the RNA genome utilising another R sequence. 
Minus strand extension and subsequent degradation of template RNA, except cPPT and 
PPT, occurred. (D) Positive strand extension is initiated from cPPT and PPT. (E) PBS 
sequence on both strands leads to a circular form of the genome, which allows the 
completion of a DNA extension of a positive strand. (F) LTR is copied on each end of the 
synthesised DNA. Figure reprinted from (Onafuwa-Nuga and Telesnitsky, 2009). 
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Interestingly, the presence of multiple transcription initiation sites on the RNA 
genome affects the speed of the positive strand DNA synthesis. This was 
demonstrated by HIV infection on 293T and activated CD4+ T cells, showing that 
the positive strand DNA synthesis was faster than that of the minus strand 
(Thomas et al., 2007). In addition to the contribution of the cPPT to increase the 
efficiency of reverse transcription, cPPT was proposed to be necessary for 
nuclear import of viral RTC (Zennou et al., 2000). Completion of reverse 
transcription and the formation of the three-stranded DNA flap on the cPPT lead 
to maturation of RTC into PIC (Arhel et al., 2007).  
 
When vaccines or drugs to prevent or treat the AIDS epidemic are considered, 
the extensive HIV diversity caused by an accumulation of mutations presents a 
huge problem such as the emergence of resistant species (Clavel and Hance, 
2004) (Praparattanapan et al., 2012). Examination of viral sequences in single 
infected individuals showed that viral sequences diverge rapidly after infection 
(Keele et al., 2008). This diversity is facilitated by a high error rate of reverse 
transcription and the diploid particles with two RNA genomes that allow a 
combination of mutations. In addition, complicated steps in reverse transcription 
also contribute to increasing the genomic diversity of HIV. Firstly, the template 
exchanges twice (tRNA transfers to 3’ end (on plus-strand RNA) and PBS 
transfers to 5’ end (on minus strand DNA)) causing recombination events at a 
high rate in vivo. Secondly, the RT enzyme has no proof-reading activity, 
causing high mutation rates at reverse transcription (Takeuchi et al., 1988) 
(Preston et al., 1988). 
 
1.2.5 Viral uncoating 
 
HIV uncoating is the next crucial step for producing an infectious virus and is 
structurally characterised by a loss of viral capsid prior to the entry of the viral 
genome into the nucleus (Arhel, 2010) (Campbell and Hope, 2015). Uncoating is 
known to take place at the early stage of HIV infection and accompanies with the 
transition between reverse transcription complex (RTC) and pre-integration 
complex (PIC) (Arhel et al., 2007). HIV conical capsid cone contains the viral 
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RNA genome, viral proteins (CA, NC, RT, IN, Vpr), and some cellular proteins 
such as cyclophilin A (CypA). Within the protected environment generated by 
capsid pores, successful reverse transcription takes place (Jacques et al., 2016). 
The shape and stability of the capsid cone affect viral infectivity by reducing the 
efficiency of reverse transcription, which was demonstrated by introducing point 
mutations in the capsid, which led to either hyperstable or unstable capsids or to 
capsids with aberrant morphologies and caused a reduction in infectivity 
(Forshey et al., 2002). 
 
Although the functional importance of viral uncoating to successful virus 
replication is getting clearer, the location and timing of uncoating are still poorly 
elucidated because of difficulties in measuring the process (Campbell and Hope, 
2015). When HIV proviral genome accesses host cellular chromatin through the 
nuclear pore, uncoating is definitely required because the diameter of viral 
capsid exceeds that of the nuclear pore (more details in 1.2.7 nuclear import of 
the reverse transcribed virus genome). A substantial difference in mass between 
HIV-1 complex in cytoplasmic and nuclear suggests the occurrence of uncoating 
before nuclear entry (Iordanskiy et al., 2006). Therefore, the failure of uncoating 
leads to an accumulation of HIV-1 complexes at the cytoplasmic surface of the 
nuclear membrane (Arhel et al., 2007). In addition, recent studies revealed that 
the timing of some degree of uncoating is associated with reverse transcription. 
Inhibition of reverse transcription delays uncoating suggesting that uncoating 
occurs later than the initiation of reverse transcription (Hulme et al., 2011). 
Another study showed that a remnant of the hexagonal CA lattice stays intact as 
the PIC traffics to the nucleus (Ambrose and Aiken, 2014). This uncoating model 
shows that CA is not completely removed in the cytoplasm and some capsid is 
associated with PIC in the nucleus. In contrast, a different study supports that 
CA removal may start when RTC arrives at the nuclear pore complex (NPC) to 
protect the replicating HIV genome from the host DNA sensor and induction of 
host immune reaction (Lahaye et al., 2013) (Rasaiyaah et al., 2013). The 
observation of intact cores at the NPC also supports this uncoating model (Arhel 
et al., 2007).  
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1.2.7 Nuclear import of the reverse transcribed virus genome 
 
The HIV PIC, composed of virus genome MA, IN and Vpr, facilitates nuclear 
import (Matreyek and Engelman, 2013) allowing access to host cell chromatin 
and integration in non-dividing cells (Naldini et al., 1996). In contrast, 
gammaretroviruses, such as MLV, require a breakdown of the nuclear 
membrane during mitosis (Roe et al., 1993) explaining why they only infect 
dividing cells. Although the molecular mechanism of nuclear entry of PIC is still 
poorly understood, one possible hypothesis is nuclear localisation signals 
(NLSs) present in all of PIC components (Zennou et al., 2000) (Bukrinsky et al., 
1993) (Gallay et al., 1997) (Heinzinger et al., 1994). However, HIV lacking Vpr 
(Agostini et al., 2000), or cPPT (Dvorin et al., 2002), could infect non-dividing 
cells productively suggesting that these NLSs are not essential for nuclear 
import. In addition, the role of the NLS in MA has been disputed (Freed et al., 
1995). The IN NLS is therefore likely the most critical. When reverse 
transcription is completed, IN hydrolyses the extremities of the linear viral DNA 
to be ready for integration (see more details in 1.2.8). 
 
The HIV PIC must pass through NPCs to traverse from the cytoplasm into the 
nucleus (Matreyek and Engelman, 2013). NPCs cross the nuclear membrane 
and are responsible for highly selective and bidirectional transport of various 
proteins and ribonucleoprotein (Wente and Rout, 2010). Theoretically, 
molecules up to 9 nm in diameter (~60 kDa for a globular protein) can be 
transported through NPCs by diffusion. However, the HIV PIC is estimated to be 
considerably larger so needs to take a different strategy for migration into the 
nucleus (Mattaj and Englmeier, 1998). One mechanism of nuclear transport 
involves the interaction between the NLS within IN in the PIC and members of 
an importin-a protein family. The NLS is initially recognised by importin-a, then a 
heterodimer of importin-a, and importin-ß interacts with the cargo-receptor 
complex. This complex is transported through the NPC in an energy-dependent 
manner (Fassati et al., 2003). After the translocation of the complex, the cargo 
molecules are released into the nucleoplasm when the GTP-bound form of the 
GTPase Ran associates with importin-ß in the complex (Mattaj and Englmeier, 
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1998). 
 
Another mechanism that has been described involves the PIC docking to NPCs 
by some remaining CA molecules interacting with the nuclear transport factor 
NUP358 (Schaller et al., 2011). The PIC then engages other nuclear transport 
factors, NUP153 and cleavage and polyadenylation specific factor 6 (CPSF6). 
NUP358, NUP153, and CPSF6 at the nuclear pore likely act on PIC-associated 
CA to aid HIV infection. Transportin 3 (TNPO3) then allows nuclear import of 
PIC-associated CPSF6 possibly by binding to the C-terminal nuclear targeting 
the arginine/serine-rich domain of CPSF6 (Kataoka et al., 1999). Mutation of CA 
residues required for NUP358 interaction results in PIC nuclear import by the 
default importin a/b mechanism. Changes in the integration site preference were 
also observed (Schaller et al., 2011). 
 
1.2.8 Integration of viral DNA into host chromatin 
 
For HIV to maintain stable proviral DNA in the host cell and its progeny, 
integration is catalysed by the retroviral protein integrase (IN) (reviewed in 
(Krishnan and Engelman, 2012) (Craigie and Bushman, 2012)). The structure of 
retroviral IN was determined by crystal structure analysis of prototype foamy 
virus IN in complex with its cognate DNA (Hare et al., 2010). This revealed that 
integration complex is composed of a dimer of IN dimers and that each 
monomer plays a distinct role. In addition, an extended conformation of the inner 
monomer allows the contact with the viral LTR ends. HIV IN by inference also 
consists of three or four distinct structural and functional sub-domains, namely 
the N-terminal domain (NTD), the core catalytic domain (CCD), the C-terminal 
domain (CTD), and the N-terminal extension domain. 
 
The reaction steps of the DNA cutting and joining during integration were 
discovered by structural analysis of integration intermediates (Engelman et al., 
1991) (Fujiwara and Mizuuchi, 1988). The three steps to incorporate double 
stranded proviral DNA into host chromatin are described in Fig.1-3. Firstly, 
before the PIC enters the nucleus, IN removes two nucleotides from 3’ ends of 
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the double-stranded provirus DNA, resulting in CA-3’ sequence; this step is 
called 3’ processing. After nuclear entry of the PIC, the recessed 3’ ends attack 
phosphodiester bonds in the target host cell DNA strands to join one DNA strand. 
Four to six bases (four for MLV, five for HIV) of the targeted site remain single 
stranded; this step is called strand transfer. Host cell DNA repair fills in those 
gaps, generating a four to six base-pair duplication flanking the provirus. This 
final step is known as gap repair. 
 
During lentivirus integration, an interaction between the host protein lens 
epithelium-derived growth factor (LEDGF/p75) and IN is required to guide the 
PIC into the target sites on the host chromatin (Debyser et al., 2015). The 
N-terminal region of LEDGF/p75 possesses a nuclear localisation signal and a 
PWWP (Pro-Trp-Trp-Pro), chromatin binding elements, and A/T hook like 
elements, while the C-terminal of the LEDGF/p75 harbors the integrase-binding 
domain (IBD) that binds tightly to IN. The absence of LEDGF/p75 reduces virus 
infectivity (Llano et al., 2004) (Llano et al., 2006) and alters the degree of the HIV 
integration site in the transcription unit (Marshall et al., 2007).  
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Fig.1-3 The principle of HIV integration 
DNA bases are shown by coloured-balls. (A) The linear blunt-ended viral DNA (green 
and yellow) and target DNA (blue and red) prior to integration reaction. (B) 3' end 
processing of viral DNA. In most cases, two nucleotides are removed from each 3' end of 
the viral DNA. (C) The 3' ends created by 3' processing attack a pair of phosphodiester 
bonds in the target DNA. The 3' ends of the viral DNA are then joined to the 5' ends of 
the target DNA at the site of integration. The 5' ends of the viral DNA stay unjoined to the 
target DNA. (D) Provirus formation is completed when the two unpaired bases at the 5' 
ends of the viral DNA are removed, filling in the single-strand gaps between viral and 
target DNA, and the 5' ends of the viral DNA to target DNA is ligated. The 3' processing 
(B) and DNA-strand transfer steps to form the integration intermediate (C) are catalysed 
by IN. Subsequent steps are thought to be catalysed by cellular enzymes. (E) The 
integrated provirus in target DNA. Figure reprinted from (Craigie and Bushman, 2012) 
with permission. 
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1.2.9 Virus integration preference  
 
Integration site analysis became available upon the arrival of the complete 
human genome in 2001 (Lander et al., 2001) (Venter et al., 2001). In addition, 
the development of next-generation sequencing accelerated analysis of virus 
integration in a quantitative manner by collecting a much larger number of 
integration sites (Craigie and Bushman, 2012). 
 
Integration studies revealed that different retroviruses have different targeting 
bias in integration sites (Cavazza et al., 2013). For instance, MLV favors 
integration near transcription start sites and CpG islands, while HIV favors active 
transcription units (Wu et al., 2003). The favored integration sites of the 
retrovirus are either called “hotspots” or “common integration sites (CIS)”. CIS 
are associated with gammaretrovirus- or transposon-induced hematopoietic 
malignancies; therefore, those sites are selected by cell proliferation and 
oncogenesis (Suzuki et al., 2002). However, “hotspots” denotes the genomic 
region where integrations accumulate more than expected by chance in the 
absence of any selection process (Cattoglio et al., 2007).  
 
Molecular mechanisms of integration site targeting are yet to be clarified. The 
difference in the selection of the integration site between MLV and HIV is 
possibly due to the difference in cell state when each virus can infect, as HIV can 
infect non-dividing cells and will encounter different states of chromatin 
compared to those by MLV. Another possible factor to distinguish integration site 
selection between HIV and MLV is IN. Chimeric viruses based on HIV generated 
by swapping HIV IN with MLV IN showed similar integration site targeting to MLV 
(Lewinski et al., 2006), which revealed that integration site preference could be 
governed by IN. Host proteins to guide PIC interacting with IN into the targeted 
genomic site are different between MLV and HIV (reviewed in (Craigie and 
Bushman, 2014)). As in 1.2.8, HIV utilises the interaction with LEDGF/p75 for 
integration, while MLV also has different tethering factors, bromodomain and 
extra terminal (BET) protein 2, 3 and 4 (De Rijck et al., 2013). In addition, 
transporter proteins in 1.2.7 are also involved in integration site selection. Upon 
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factor knockdown, host proteins crucial for nuclear entry, TNPO3, NUP153, and 
NUP358 were found to be important for targeting HIV PICs to gene-dense 
regions in the chromatin (Ocwieja et al., 2011) (Koh et al., 2013). 
 
The integration site has been proposed as one factor that may influence vector 
safety. HIV-based vectors may be safer than MLV as they integrate into active 
genes but without preference for regions near the transcription start site. Other 
retrovirus family members, such as avian sarcoma-leukosis virus (ALSV), show 
even less specificity for gene-dense regions (Mitchell et al., 2004) and mouse 
mammary tumor virus (MMTV) is the most random integrator to date 
(Faschinger et al., 2008). However, integration site selection is only a preference 
and with a high number of integrants most genomic loci will be targeted. Also, 
the ability of a vector to affect neighbouring host gene expression is likely to be a 
greater problem than integration site selection.  
 
1.2.10 Virus gene expression 
 
HIV has a complex genome and requires the expression of accessory proteins 
as well as viral structure proteins; therefore, gene expression is controlled by 
more mechanisms than that of viruses with simple genomes such as MLV. HIV 
has two phases of gene expression; the initial expression of multiply spliced 
regulatory genes and the subsequent expression of singly/unspliced env, 
gag-pol and RNA genome (Karn and Stoltzfus, 2012). 
1.2.11 Transcription initiation for producing infectious HIV 
 
In order to produce infectious virus particles the integrated provirus needs to be 
transcribed then translated for viral protein expression. Transcription of HIV RNA 
is carried out by host RNA polymerase II. The HIV LTR possesses multiple DNA 
regulatory elements that participate in the cooperative binding of transcription 
initiation factor TFIID (Rittner et al., 1995). Transcription is initiated at the 
junction of U3 and R. In addition, NF-kB binding and other motifs within the LTR 
allow binding of inducible transcription factors, such as the NF-kB family and 
NFAT, so that transcription is coordinated with the cell activation status (Liu et al., 
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1992) (Kinoshita et al., 1998). 
 
One of the first proteins to be produced is the transactivator protein (Tat), 
translated from a multiply spliced RNA. Tat then provides a feedback loop to 
stimulate transcription initiation of HIV RNA by binding to a 59-nucleotide 
stem-loop structure on the HIV genome called the transactivation response 
(TAR) element (Gatignol, 2007). After the transcription through TAR, positive 
transcription elongation factor b (P-TEF-b) composed of cyclin T1 kinase 
(CycT1), cyclin-dependent kinase 9 (CDK9), and other accessory elongation 
factors are recruited to the TAR and increase the affinity of Tat with TAR (Zhang 
et al., 2000a). This results in hyper-phosphorylation of the C-terminal domain of 
RNA polymerase II and elongation factors, thereby stimulating efficient 
transcriptional elongation (Kim et al., 2002). 
 
Transcripts of HIV serve distinct functions; firstly, unspliced viral genomic RNA is 
packaged into the daughter virions (9 kb) or acts as a template for translation of 
structural protein (Gag and Gag-Pol). This transcript is also spliced for the 
production of diverse subgenomic mRNAs (Vif, Vpr, Vpu/Env, Tat, Rev, and 
Nef,) (Pollard and Malim, 1998).  
 
1.2.12 Viral RNA export from the nucleus to cytosol to express viral 
proteins 
 
At the early stage of infection, only fully spliced viral transcripts such as those 
encoding Tat, Rev, and Nef are exported to the cytoplasm using the nuclear 
export factor NXF1 that couples splicing to nuclear export (Stutz and Izaurralde, 
2003). Usually unspliced transcripts are retained within the nucleus and 
degraded by the host cellular surveillance system, nonsense mediated decay 
(NMD) (Chang et al., 2007). HIV needs a mechanism for the export of these 
unspliced transcripts into the cytoplasm; this is controlled by the expression level 
of the regulatory protein Rev. In later stages of infection the full-length unspliced 
HIV RNA genome, as well as 4-kb transcripts coding Env/Vpu, Vif, and Vpr, is 
exported by Rev binding to a cis-acting RNA element called Rev-response 
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element (RRE) within env (Pollard and Malim, 1998).  
 
Rev protein is imported into the nucleus by interacting with importin ß through its 
NLS that contains an arginin-rich sequence (Daugherty et al., 2010b). Rev then 
binds to RREs in HIV transcripts via its RNA-binding domain (RBD), which 
induces a conformational change and oligomerisation of the Rev protein onto the 
RRE (Daugherty et al., 2010a) (Daugherty et al., 2010b). Then, this complex 
interacts with the nucleocytoplasmic transport factor chromosome region 
maintenance 1 (Crm1), in conjunction with the GTP-bound form of the Ran 
GTPase (Cullen, 2003). Crm1 was found to form a dimer when it interacts with 
Rev-mRNA which promotes nuclear export (Booth et al., 2014). Dissociation of 
this complex in the cytoplasm is achieved by hydrolysis of Ran-bound GTP to 
GDP.  
 
1.2.13 Assembly of HIV viral components 
 
Virus assembly is then required to bring viral proteins and genomic RNA into a 
viral particle which can bud from the plasma membrane (Freed, 2015). The main 
structural protein, Gag, is synthesised as a 55 kDa precursor polyprotein in the 
cytoplasm from full-length viral RNA. The Gag precursor contains matrix (MA), 
capsid (CA), nucleocapsid (NC), and p6 domains, as well as two spacer 
peptides, SP1 and SP2. During the translation of Gag RNA, the 160 kDa GagPol 
precursor protein that encodes viral enzymes is synthesised by programmed 
ribosomal frameshift and expressed at approximately 5 % of the level of Gag 
(Shehu-Xhilaga et al., 2001).  
 
Viral RNA encapsidation is initiated by the NC domain of Gag recruiting viral 
genomic RNA following dimerisation of the RNA via its packaging signal ψ 
(Kutluay et al., 2014). Once the multimerised Gag arrives at the plasma 
membrane, it is anchored to the plasma membrane by insertion of its 
amino-terminal myristate within MA. This mechanism of targeting to the plasma 
membrane by the MA domain in Gag was demonstrated by mutations in MA, 
which resulted in mistargeting to the late endosome or multivesicular body 
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(MVB) (Ono and Freed, 2004). The same mistargeting result was found by 
depletion of plasma membrane phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4,5)P2), highly enriched in the inner leaflet of the plasma membrane, 
suggesting the importance of targeting to lipid rafts (Ono et al., 2004).  
 
The viral Env glycoproteins traffic via the secretory pathway from the rough 
endoplasmic reticulum (RER) through Golgi to vesicles that arrive at the plasma 
membrane. There are several possible non-mutually exclusive pathways for Env 
incorporation in retroviral particles (reviewed in (Checkley et al., 2011)); a 
passive process, co-targeting of Gag and Env to a common site on the plasma 
membrane, direct recruitment of Env by Gag, and the indirect recruitment of Env 
by Gag via host cell binding proteins. HIV interaction between Env and MA is 
suggested for Env incorporation in the assembling particle because MA mutants 
block Env incorporation (Murakami and Freed, 2000). 
  
1.2.14 HIV budding and release 
 
The assembled viral proteins undergo membrane fission for the release of 
daughter virions from the infected cells, which is mediated by the cellular 
endosomal sorting complexes required for the transport (ESCRT) pathway 
(reviewed in (Votteler and Sundquist, 2013)). The cellular function of this 
pathway is to sort ubiquitylated membrane proteins into the lumen of maturing 
endosomes or MVB and subsequent degradation or fusion with the plasma 
membrane to release extracellular exosomes. Recruitment of three broad 
classes of factors occurs in the ESCRT pathway: adaptor proteins, early-acting 
factors, and late-acting factors. Structural protein Gag is an example of the 
adaptor protein and recruits the early-acting factors that are related to 
subsequent recruitment of late-acting factors. Gag assembly recruits 
early-acting factors in the ESCRT pathway, tumour susceptibility gene 101 
(TSG101, a part of ESCRT-I) a subunit of ERCRT-I, ALG2-interacting protein X 
(ALIX), ESCRT-I, and ESCRT-II to form a complex (Göttlinger et al., 1991). HIV 
Gag has two late domain motifs; PT/SAP (Pro-Thr/Ser-Ala-Pro) and YPXL 
(Tyr-Pro-X-Leu, where X can be any amino acid). TSG101 interacts with the 
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PT/SAP motif and ALIX interacts with YPXL. ALIX is a protein that also interacts 
directly with both ESCRT-I and ESCRT-III in mammals. Membrane scission is 
driven by ESCRT-III polymerisation at the virus budding site in concert with the 
activation of the ATPase vacuolar protein sorting 4 (VPS4) (Baumgartel et al., 
2011). In addition, ESCRT-III protein CHMP4 subunits, possibly in a complex 
with CHMP2 and other ESCRT-III protein, form spiraling filaments within the 
neck of the budding virus, which promote membrane fission (Hanson et al., 
2008). 
 
1.2.15 HIV virion maturation  
 
Newly formed virion particles undergo maturation concomitant with budding (or 
immediately after) to make the virus infectious. During the maturation process 
triggered by PR cleavage of Gag and GagPol (Kaplan et al., 1993), the locations 
of processed viral proteins are dramatically rearranged (Schur et al., 2015) 
(Freed, 2015). In immature particles, Gag molecules are packaged in a radial 
manner then, following the cleavage of Gag, CA proteins reassemble to form a 
conical structure to wrap the viral RNA genome (Schur et al., 2015). 
 
1.2.16 Host restriction factors and accessory gene function 
 
Although HIV exploits host proteins in the replication cycle, host cells have 
developed defence systems against pathogens including HIV, called innate 
immune sensing (Kajaste-Rudnitski and Naldini, 2015). In particular, the intrinsic 
antiviral immunity via host restriction factors is characterised by an immediate 
and direct antiviral effect (Yan and Chen, 2012). Below is a description of some 
of the host restriction factors that prevent HIV infection. These factors can also 
be an inhibitor of LV-based vector transduction, which may determine the 
outcome of ex vivo gene therapy. 
 
The cytidine deaminase function of apolipoprotein B mRNA editing enzyme 
catalytic subunit 3G (APOBEC3G) protein catalyses the deamination of cytidine 
to uridine in single stranded DNA. This inhibits HIV infectivity by introducing 
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mutations in the viral sequence (Sheehy et al., 2002) (Zhang et al., 2003). In 
addition, APOBEC3G inhibits tRNA (Lys3) priming of reverse transcription and 
its removal process at the DNA minus strand synthesis (Guo et al., 2006) (Mbisa 
et al., 2007). However, HIV accessory protein Vif counteracts APOBEC3G and 
triggers its ubiquitilation that leads the degradation of APOBEC3G (Yu et al., 
2003).  
 
Tripartile motif protein 5 alpha (TRIM5a) blocks HIV infection in cells of Old 
World monkeys through recognition and degradation of the capsid lattice 
through its E3 ubiquitine ligase function. Interestingly, human TRIM5a has little 
or no antiviral effects against HIV (Stremlau et al., 2004). However, when 
choosing a primate model to test LV-based vector, this host restriction factor can 
affect transduction efficiency and impact the biological function of host cells. 
GTPase Mx2 does however interact with the HIV capsid and blocks HIV nuclear 
entry (Goujon et al., 2013) (Kane et al., 2013) (Liu et al., 2013).  
 
Sam domain, and HD domain-containing protein 1 (SAMHD1), inhibits the 
reverse transcription process by reducing the level of nucleotide pool. Many 
simian immunodeficiency viruses (SIVs) encode Vpx to interfere with the effect 
of SAMHD1. However, HIV lacks this protein thereby a block of HIV infection is 
observed in resting dendritic cells and T cells (Laguette et al., 2011) (Baldauf et 
al., 2012). 
 
A dimeric type II membrane glycoprotein tetherin inhibits the release of mature 
retrovirus particles and antagonised by a HIV accessory protein, Vpu (Neil et al., 
2008). Tetherin expressed at the cell surface is downregulated by counteracting 
by Vpu, whose pathway is mediated by ESCRT lysosomal degradation (Janvier et 
al., 2011). In contrast, the majority of SIVs use Nef to counteract the tetherin 
proteins of their non-human primate hosts (Zhang et al., 2009). The domain on 
human tetherin that is important to tetherin/Nef interaction is absent (Sauter, 2014) 
and Nef was thought nothing to do with the antagonism of human tetherin. 
However, an HIV strain (called group O) common in West-Central Africa 
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demonstrated the similar inhibitory effect of Nef against human tetherin 
(Serra-Moreno, 2014). 
 
The host integral membrane proteins, serine incorporator 3 (SERINC3) and 5 
(SERINC5), were recently described as host restriction factors which can be 
counteracted by Nef (Usami et al., 2015) (Rosa et al., 2015). Viral infectivity was 
reduced by the incorporation of SERINC3 or 5 into a Nef-defective HIV (Usami 
et al., 2015). In addition, an inhibition model via SEINC3 and 5 was proposed, 
which is mediated by prevention of the pore expansion between viral and cell 
membranes (Rosa et al., 2015).  
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1.3 Viral vectors 
 
1.3.1 Retroviral vectors as a delivery tool to introduce therapeutic genes 
into target cells 
 
The idea of virus genome as a tool for gene transfer came from the discovery of 
bacteriophage genome in E.coli as well as from tumour formation in mammal 
cells by infection of oncogenic retroviruses. Oncogenic retrovirus, such as avian 
reticuloendotheliosis virus strain A (REV-A) and MLV, were initially engineered 
as such promising candidates because of their broad tropism as well as 
integration capacity into the host genome. Permanent vector integrations allow 
long-term and stable gene expression in transduced host cells. All highly 
oncogenic viruses were engineered into being replication-defective by deleting 
the coding regions of viral proteins or by replacing them with an exogenous gene 
in order to reduce the production of replication competent viruses (RCVs).  
 
The first engineered vector tested on animal cells was based on oncoretrovirus 
vector MoMLV, carrying herpes simplex virus thymidine kinase gene (tk), driven 
by its own transcriptional promoter (Tabin et al., 1982). In the same study, the 
cell line producing MLV carrying the constructed vector plasmid as a genome 
was established by compensating with viral genes, whose cell line was later 
called packaging cell lines (PCLs). To reduce the risk of RCVs, the design of 
vector constructs was improved by separating gag-pol and env and splitting 
them on separate plasmids (Danos and Mulligan, 1988) (Miller et al., 1991). 
Later, env from another virus strain was borrowed to widen the tropism of 
produced vector viruses as described in 1.3.3. The ability to deliver genes via 
MLV vector to bone marrow stem cells from mouse and human were soon 
demonstrated (Williams et al., 1984) (Hock and Miller, 1986).  
 
The history of the lentiviral vector (LV) started as a tool to screen anti-HIV-1 
drugs (Sakuma et al., 2012). A replication-competent HIV vector encoding the 
chloramphenicol actyltransferase (CAT) gene, in the place of nef, was initially 
constructed for that purpose (Terwilliger et al., 1989). The infectivity of a 
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produced virus can be measured by its correlation with the enzyme activity of 
CAT. This vector was a promising model for screening anti-HIV drugs in a rapid 
and quantitative manner. Unlike MLV, LV was shown to be able to infect 
non-dividing cells, which widened the vector application to different cell types 
such as hematopoietic stem cells (HSCs) or neurons (Roe et al., 1993) (Naldini 
et al., 1996). This is a milestone of LV application to challenge a broader range 
of genetic diseases such as hematopoietic and neurodegenerative diseases 
(Naldini, 2015). In addition, in order to increase vector biosafety, the design of 
splitting virus structure-coding protein into multiple vectors was also applied to 
LV as described in the following section 1.3.2. Transient vector virus production 
is often exploited because the constant expression of gag-pol and env proteins 
can be cytotoxic in virus producer cells; however, some lentiviral vector-based 
PCLs have been developed, including WinPac that was established in our 
laboratory (Kafri et al., 1999) (Sanber et al., 2015). 
 
1.3.2 Vector ‘generations’- iterative improvements of vector safety and 
efficacy 
 
Vector ‘generations’ have been developed to achieve better biosafety features of 
lentiviral vectors (Sakuma et al., 2012) (Fig.1-4). The “generation” is loose 
terminology that does not include the replication-competent prototype of the LV.  
 
The first-generation replication-deficient recombinant HIV vectors are comprised 
of three vector components that provide viral genes necessary to produce 
virions: a packaging construct (gag-pol), viral envelope glycoprotein gene (env), 
and a gene of interest (Fig.1-4A). The vector carries the gene of interest together 
with HIV cis-acting elements such as LTRs, packaging signal (ψ), and RRE. By 
providing those viral components on separate plasmids, production of RCLs can 
be reduced because more recombination events are required for the production 
(Richardson et al., 1995). 
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Fig.1-4 Vector generations 
(A) First generation vector. All HIV proteins except Env are expressed in the packaging 
plasmid. Env is provided in a different vector. The vector plasmid has intact LTR. (B) 
Second generation vector removed most of the HIV proteins except Rev and Tat. (C) 
Third generation vector. Packaging plasmid encodes Gag and Pol. Rev is provided in a 
separate vector. The vector plasmid has self-inactivating LTRs. Figure reprinted from 
(Sakuma et al., 2012). 
 
 
The second generation vectors are focused on the exclusion of HIV accessary 
genes that are included in the design of the first-generation vector (Fig.1-4B). As 
mentioned in 1.1 Retrovirus biology, the accessary proteins Vif, Vpu, Vpr, and 
Nef are necessary for efficient propagation and virulence of HIV in primary cells 
or in vivo. However, exclusion of those elements did not change vector virus 
infectivity; therefore, this vector design without those viral elements became 
commonly used (Zufferey et al., 1997). 
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These vector generations contained HIV regulatory proteins Tat and Rev in the 
packaging plasmid because transcription of the early vector generation was 
tat-dependent. To achieve further vector safety, the 5’ U3 promoter region was 
replaced with a strong viral promoter from Cytomegalovirus (CMV) or Rous 
sarcoma virus (RSV), thereby tat is no longer necessary in a vector to generate 
vector genomic RNA (Fig.1-4C). This also led to the success in vector design 
without an enhancer/promoter region in the LTR, a self-inactivating (SIN) vector 
achieving high titre vector production. Rev is also provided in a separate vector. 
This four-plasmid system for vector production is nowadays called third 
generation vectors. 
 
1.3.3 Pseudotyping viral vectors to circumvent limited viral tropism 
 
The host range of retrovirus is determined and therefore limited by the nature of 
the retroviral envelope proteins (Hunter and Swanstrom, 1990). HIV can infect 
human cells expressing a CD4 receptor because HIV Env recognises it for the 
virus entry. To widen the tropism of the virus so that it is able to infect other cell 
types, Env glycoprotein can be replaced with that of a different virus strain such 
as the G protein from vesicular stomatitis virus (VSV-G). This process is called 
pseudotyping. Retrovirus is an attractive candidate as a vector vehicle because 
its envelope can be easily pseudotyped. The commonly used VSV-G has better 
stability than the retroviral or lentiviral envelope, therefore the VSV-G 
pseudotyped virus can be easily concentrated by ultracentrifugation without loss 
of infectivity (Burns et al., 1993). A recent study showed that the major receptor 
of VSV and VSV-G pseudotyped lentiviral vector was a low-density lipoprotein 
(LDL) receptor whose binding depends on the concentration of calcium ions 
(Finkelshtein et al., 2013). The drawback of VSV-G is cytotoxicity in high 
concentration (Hoffmann et al., 2010). This accelerated the study of discovering 
env proteins from other viral strains that can alternate with VSV-G. For instance, 
amphotropic MLV Env or RD114 Env-pseudotyped lentiviral vectors showed 
high vector titre in human CD34+ hematopoietic stem cells (Relander et al., 
2005). Again, the strength of VSV-G is its stability, hence those vectors 
pseudotyped with env protein of another retrovirus showed compromised 
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robustness and sensitiveness to the freeze-thaw cycle (Strang et al., 2004). 
 
1.3.4 Lentiviral vector accessory elements 
 
Exogenous elements are also playing an important role for transgene 
expression. The introduction of woodchuck hepatitis virus posttranscriptional 
regulatory elements (WPRE) in the vector can achieve improvement in titre and 
transgene expression (Zufferey et al., 1999). As examples for exogenous 
elements to prevent influences from the surrounding chromatin environment in 
which the vector integrates, insulator DNA sequences, such as chicken 
hypersensitive site 4 (cHS4) or human HNRPA2B1-CBX3 UCOE (A2UCOE), 
have been used. The promising element A2UCOE can block DNA 
methylation-mediated silencing; therefore, the target gene expression is 
position-independent. Our laboratory conducted the splicing site analysis of 
A2UCOE to find potential splice sites and develop the optimised form of the 
element by deleting them but without losing the gene silencing-resistance 
function (Knight et al., 2012).  
 
Codon optimisation is another strategy to increase vector titre and transgene 
expression that affects the level of immune reconstitution in the treatment of 
X-linked severe combined immunodeficiency (Moreno-Carranza et al., 2009). In 
this study, the titre of a cDNA-optimised vector was increased 10-fold by 
changing the GC content and removing the RNA instability motif in gp91phox 
cDNA for X-linked chronic granulomatous disease (X-CGD) treatment. Codon 
optimisation can also remove consensus and cryptic splice sites, which can 
contribute to reducing splicing-mediated side effects. 
 
Previously, MLV-derived gammaretroviral vectors (GRVs), with 
enhancer/promoter region in the LTR, upregulated oncogenes near integration 
sites and caused adverse events at a high rate in several clinical trials 
(Hacein-Bey-Abina et al., 2008) (Howe et al., 2008) (Braun et al., 2014). 
Therefore the design of LVs has been developed to attain safe profiles by 
lowering vector-derived side-effects (Schambach et al., 2013) (Sakuma et al., 
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2012). Oncogenic events were also observed by aberrant splicing between the 
integrated viral sequence and host sequence in fusion transcripts (Wang et al., 
2010). Most of the vector splice sites are to be removed from the vector 
backbone sequence because they can potentially contribute to aberrant splicing. 
However, all splice sites cannot be deleted because some splice sites are 
required for efficient virus production, such as the HIV major splice donor (D1) 
and a splice acceptor in the RRE/Env fragment (A7). In addition, cryptic splice 
sites are hidden in the vector backbone and this can also be the cause of 
generating chimeric transcripts (Cesana et al., 2012). Such aberrant transcripts 
are possibly kept at a low level owing to the elimination by NMD or nuclear 
retention because mostly immature polyadenylation is introduced into the 
transcripts (Moiani et al., 2012). However, the unexpected chimeric transcript 
can lead to clonal dominance or cancerous events when the chimeric products 
stabilise or destabilise the gene product and dysregulate the original function of 
the gene (Cavazzana-Calvo et al., 2010).  
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1.4 Gene therapy 
 
1.4.1 Gene therapy: gene addition and gene editing 
 
Gene therapy is the use of somatic cell genetic modification for medicinal 
purposes. There are two main types of gene therapy; gene addition and gene 
editing (Kaufmann et al., 2013) (Naldini, 2015). Gene addition involves 
delivering therapeutic nucleic acids (DNA or RNA) into a patient’s cells, usually 
by a viral vector, as these are at present more efficient than non-viral methods. 
Retroviral vectors (RVs), adenoviral vectors (AVs), and adeno-associated 
vectors	 (AAVs) are the most commonly used in clinical trials worldwide 
(http://www.abedia.com/wiley/) (Fig.1-5A). In contrast, site-directed gene-editing, 
using engineered site specific nucleases or CRISPR/Cas9, can be used to 
mutate unwanted genes or repair defective ones. So far, more than 60 % of 
gene therapy clinical trials have been performed to treat cancer while nearly 
10 % have been for monogenic disorder worldwide (Fig.1-5B). Because my PhD 
study focuses on cell transformation by LV, the application of LVs in various 
clinical trials is introduced in contrast to the difficulties of treatment by 
conventional GRVs. 
 
 
 
 
 
 
 
 
 
 
Fig.1-5 The technique of transferring therapeutic agents in gene therapy clinical 
trials (A) and the diseases treated by gene therapy clinical trials (B)  
The data were extracted from http://www.abedia.com/wiley/. 
 
A B 
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1.4.2 Ex vivo gene therapy and in vivo gene therapy  
 
In gene therapy, there are two ways to deliver therapeutic agents via viral 
vectors; ex vivo and in vivo. Ex vivo gene therapy delivers a therapeutic agent 
into patient-derived cells outside the body and re-infuses the engineered cells. 
My introduction will focus on the use of hematopoietic stem cells (HSCs). Some 
benefits of ex vivo gene therapy are that a lower dose of the vector is necessary 
and there are lower off-target effects such as ectopic expression and germ-line 
transmission. In contrast, in vivo gene therapy delivers a therapeutic agent 
directly into a patient’s body by injection. Non-viral vectors such as lipid- or 
polymer-based vectors are also an option in in vivo gene delivery. However, few 
of these have been used clinically because of the low efficiency of gene delivery 
compared to that of viral vectors (Putnam, 2006; Yin et al., 2014).  
 
1.4.3 Hematopoietic stem cell gene therapy (HSCGT) 
 
Patients with inheritable disorders, such as primary immunodeficiencies (PID), 
first became a target for treatment by allo-transplantation from human leukocyte 
antigen (HLA)-matched donors. However, this is not universally applicable 
because every patient does not have an HLA-matched donor leading to 
problems with graft-versus host diseases (GVHD) (Gennery et al., 2010) (Kang 
and Gennery) (Mukherjee and Thrasher, 2013). So gene therapy using 
patient-derived HSCs became the alternative life-saving strategy, overcoming 
those limitations. To date, LV-mediated HSCGT clinical trials are ongoing in a 
number of fields such as inherited immune deficiencies (WAS, X-SCID, CGD, 
ADA-SCID), neurodegenerative disorders (X-ALD, MLD), hematological 
disorders (ß-thalassaemia), Parkinson’s disease, and AIDS. LV-mediated gene 
therapy has progressed because of limitations in GRV-mediated gene therapy, 
in particular the detection of adverse events leading to cancer where the GRV 
LTR has caused upregulation of a gene neighbouring the integration site 
(Mitchell et al., 2004) (Yu et al., 1986). LV is potentially safer than GRV in this 
respect and is also more efficient in transducing HSC. To understand this 
historical shift of vector use in clinical trials I will introduce examples of LV use. 
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1.4.4 Gene therapy for primary immunodeficiencies (PIDs) 
 
Many monogenetic disorders which impair the hematological and immunological 
system require phenotypic correction in HSC or early progenitors because the 
gene mutation affects the generation and differentiation of a specific cell lineage 
(reviewed in (Kaufmann et al., 2013)). As such examples, here I introduce 
adenosine deaminase (ADA) deficiency, X-linked severe combined 
immunodeficiency (X-SCID), and Wiskott-Aldrich syndrome (WAS). On the other 
hand, other types of monogenic disorders such as chronic granulomatous 
disease (CGD), introduced in this section, result in functional impairments that 
only affect mature cells. 
 
1.4.4.1 Adenosine deaminase (ADA) deficiency and X-linked severe 
combined immunodeficiency (X-SCID) 
 
The autosomal recessive inherited disorder ADA deficiency shows disturbance 
of leukocyte development because of dysfunction of the ADA enzyme. ADA is 
ubiquitously expressed and the impairment of the enzyme causes accumulation 
of toxic purine metabolites in the thymus. Before the HSC gene therapy was 
available, the only possible treatment was an injection of a recombinant enzyme 
which could lead to treatment failure when antibodies against the enzyme were 
produced (Chan et al., 2005). In 1990 the first gene therapy clinical trial was 
initiated by an autologous transplantation of ex vivo gene modified 
T-lymphocytes by GRV (Blaese et al., 1995). The two treated children had an 
improved number of T-lymphocytes and ADA enzyme activity; however, they 
could not cease enzyme replacement therapy. Later, HSC was efficiently 
transduced with GRV and long-term sustained engraftment was achieved (Aiuti 
et al., 2002). To date, more than 40 patients with ADA deficiency have been 
treated and more than 70 % of the patients are off enzyme replacement therapy. 
In this disease GRVs have not given rise to adverse events. 
 
X-linked severe combined immunodeficiency (X-SCID), the most common form 
of SCID, has been another target since the early history of gene therapy. 
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X-SCID patients have dysfunction in the expression of the common 
gammachain of the IL-2 cytokine receptor that affects the development of T and 
natural killer (NK) cells and the function of B cells. In the late nineties, two 
GRV-mediated autologous HSC clinical trials were initiated (Gaspar et al., 2011) 
(Hacein-Bey-Abina et al., 2010). Over the follow-up period of nine years, the 20 
treated patients with X-SCID reconstituted normal numbers of T cells and 50 % 
of the treated patients no longer needed immunoglobin replacement therapy. 
However, vector integration-related adverse events were detected in five of the 
children; therefore, this identified a risk in the use of GRV for gene transfer in this 
clinical setting. This risk of side-effects stimulated the study of other alternative 
vectors, LVs, which is described in 1.5.3.1. 
 
1.4.4.2 Wiskott-Aldrich syndrome (WAS) clinical trial 
 
In contrast to ADA deficiencies and X-SCID, Wiskott-Aldrich syndrome 
manifests further downstream in the haematopoietic cell lineage in several types 
of mature cells. WAS is a rare inherited immunodeficiency characterised by 
infections, microthrombocytopenia, eczema, autoimmunity, and lymphoid 
malignancies (Galy and Thrasher, 2011). The cause of this disease is loss-of 
function mutations in WAS gene encoding WASP that regulates the actin 
cytoskeleton in hematopoietic lineages and precursor cells (Thrasher and Burns, 
2010) (Catucci et al., 2012). The mutations diminish WASP expression severely, 
which leads to abnormal thymopoiesis resulting in a low number of functional T 
cells. The first clinical trial for WAS was performed with a GRV (Klein et al., 
2000) (Klein et al., 2003). The treated patients showed significant therapeutic 
benefit with reconstitution of B/T/NK cells and monocytes. However, patients 
developed acute leukaemia at a high rate (seven out of 10 patients) caused by 
upregulation of oncogenes via vector integrations (Braun et al., 2014). Because 
of the need for a novel vector to replace the GRV, the first LV-mediated clinical 
trial for WAS was conducted at two different clinical centres in London and Paris 
(Hacein-Bey Abina et al., 2015). CD34+ HSCs transduction by a SIN LV carrying 
WAS cDNA whose expression is controlled by a 1.6 kb proximal WAS gene 
promoter (LV-w1.6W) was carried out (Charrier et al., 2007) (Scaramuzza et al., 
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2013). Out of the seven treated patients, six patients had improved disease 
symptoms (one patient died of an opportunistic viral infection). Using the same 
LV, three WAS patients with slightly lower severity of the disease were treated 
by re-infusing autologous bone marrow-derived CD34+ cells transduced with the 
LV-w1.6W (Aiuti et al., 2013). During the follow-up period of 20 to 32 months, all 
patients showed robustly multi lineage engraftment of gene-corrected cells in 
bone marrow and peripheral blood. All patients showed improved immune 
function, which resulted in amelioration of clinical manifestation of the disease. 
For the first time, the high-throughput integration site analysis was carried out in 
comparison with that of GRV in the same disease background (Boztug et al., 
2010). The discovery of common insertional sites (CIS) of LV-w1.6W (KDM2A, 
PACS1 and TNRC6C) may pose a concern in the biosafety although the typical 
GRV CIS was not observed in the MDS1 and EVI1 complex locus proteins EVI1 
(MECOM) and LMO2 that were reported in other clinical trials of PIDs.  
 
There was another attempt to develop an LV vector for WAS with better 
performance than LV-w1.6W by optimising the promoter. As a candidate, 
viral-derived MND promoter (myeloproliferative sarcoma virus enhancer, 
negative control region deleted, dl587rev primer-binding site substituted) was 
selected. MND is a highly constitutively active promoter and resistant to 
transcriptional silencing (Challita et al., 1995) (Halene et al., 1999). In contrast to 
LV-w1.6W, higher expression of WASP was achieved by the MND promoter, 
which caused better rescue of the development of the MZ (marginal zone) B cell 
than LV-w1.6W (Astrakhan et al., 2012). However, one mouse developed clonal 
dominance by vector integration suggesting a potential risk of MND in an LV. 
However, the clinical trial for adrenoleukodystrophy (ALD) used the MND 
promoter in LV without any adverse events (Cartier et al., 2009); therefore, MND 
may not be the sole determinant for clonal dominance.  
 
1.4.4.3 Chronic granulomatous disease (CGD) clinical trial  
 
CGD is a rare inherited immunodeficiency characterised by the dysfunction of 
mature phagocytes (e.g. neutrophils, monocytes, macrophages, and 
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eosinophils) responsible for eradicating ingested microorganisms. Mutations in 
genes encoding subunits of the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex (membrane-spanning subunits: gp91phox, p22phox, 
and cytosolic components: p47phox, p67phox, p40phox) cause CGD (Segal et al., 
2000) (Matute et al., 2009). 70 % of CGD patients are X-linked caused by 
mutations in the CYBB gene encoding catalytic subunit gp91Phox, 30 % have 
defects in p47phox (NCF-1), and only 5 % of the total patients have mutations in 
CYBA or NCF-1 encoding p22phox or p67phox, respectively. 
 
CGD is one of the most difficult diseases to treat by gene therapy, because 
therapeutic effects are not expected simply by correcting the expression of the 
defective gene (reviewed in (Grez et al., 2011)). Firstly, the transgene 
expression does not give a selective advantage to transduced cells; therefore, 
an intensive myeloablative conditioning is required. Secondly, correction in a 
large number of HSC is required owing to the short life-span of neutrophils that 
only last a few days. In the mid-1990s CGD clinical trials were initially attempted 
using GRVs at the National Institute of Health (NIH) (Malech et al., 1997). Five 
patients received an infusion of peripheral blood CD34+ cells transduced by 
p47phox-expressed GRV without conditioning. However, the granulocytes with 
p47phox expression were detected in the patients’ peripheral blood at only a low 
level. Later, another clinical trial at NIH was carried out using a higher, but still 
not ablative, a dose of busulfan (10 mg/kg) prior to administrating CD34+ cells 
transduced by GRV, MFGS-gp91phox (Kang et al., 2010). This improvement in 
conditioning led to improved initial gene-marking of the transduced cells. In one 
of the treated patients, the longer persistence of gene-marking was observed in 
neutrophils and monocytes for up to three years; however, the expression level 
was low in those transduced cells. The low survival rate of gene-corrected cells 
in these CGD trials could also be explained by the ectopic expression of the 
therapeutic genes. This leads to the production of a reactive oxygen species that 
may damage DNA after cell growth or induce apoptosis (Bedard and Krause, 
2007) (Yahata et al., 2011). 
 
Reflecting those treatment difficulties and the development of myelodysplasia by 
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GRV integration (more details in 1.5.3.2), nowadays LV is chosen for CGD 
treatment because of the highly efficient transduction of CD34+ cells and the 
safety advantage over GRV. In order to overcome the off-target ectopic 
expression of the therapeutic gene and the subsequent reduction of 
gene-marked cells, a dual-regulated LV was developed (Brown et al., 2006). 
This LV encodes gp91phox whose expression is controlled by a myeloid-specific 
promoter and micro RNA 126 (miR126) for posttranscriptional regulation of 
gp91phox (Chiriaco et al., 2014). NOD/SCID and X-CGD mice xenograft model 
that received the transduced HSCs demonstrated restoration of NADPH activity 
by the development of stage-specific regulation of gp91phox. 
 
1.4.5 Lysosomal storage disorders 
 
In this section, I introduce two inheritable neurodegenerative diseases: X-linked 
adrenoleukodystrophy (X-ALD) and metachromatic leukodystrophy (MLD). A 
patient with leukodystrophy shows abnormalities in white matter in the central 
nerve system (CNS) with or without the involvement of the peripheral nervous 
system (Vanderver et al., 2015).  
 
1.4.5.1 X-linked Adrenoleukodystrophy (X-ALD) clinical trial 
 
X-linked adrenoleukodystrophy (X-ALD) is a fatal demyelinating disease 
occurring at the frequency of 1:17,000 males (Biffi et al., 2011). X-ALD is caused 
by a deficiency in the ABCD1 gene, encoding ALD protein that is an adenosine 
triphosphate-binding cassette transporter. This dysfunction causes 
accumulation of very long-chain fatty acids (VLCFAs) and the subsequent 
defective ß oxidation in peroxisomes disrupts myelin maintenance (Mosser et al., 
1993) (Moser et al., 2007). ALD is a transmembrane peroxisomal protein; 
therefore, a cross-correction strategy using donor-derived cells to secrete the 
enzyme, as used for other storage disorders such as MLD, cannot be used. If 
the disease progression is at the early stage, disease progression can be 
stabilised by allotransplantation of HSCs if these are available. 
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The first beneficial autologous HSC gene therapy was carried out via LV 
expressing wild-type ABCD1 cDNA (CG1711 hALD) under the control of MND 
(myelo-proliferative sarcoma virus enhancer, negative control region deleted, 
dl587rev primer binding site substituted) in 2009 (Cartier et al., 2009). In the 
preclinical experiments, murine Sca-1+ cells used as a functionally equivalent of 
human CD34+ cells were transduced with CG1711 hALD and transplanted into 
ALD-/- mice. Although transplanted ALD Sca-1+ could replace 20 to 25 % of 
microglial cells, the neuropathological and clinical effects of the LV gene transfer 
were not evaluated because this mouse model does not develop cerebral 
demylination (Pujol et al., 2002). Therefore, the clinical trial was initiated without 
an accurate preclinical model for the outcome. However, after 24 to 30 months 
the two treated patients showed reconstitution of granulocytes, monocytes, and 
T and B cells expressing ALD protein. Integration sites were monitored over time 
and no obvious clonal skewing or dominance was observed. The patients also 
showed less progressive demyelination than historical controls. 
 
1.4.5.2 Metachromatic leukodystrophy (MLD) clinical trial 
 
Metachromatic leukodystrophy (MLD) is a neurodegenerative lysosomal storage 
disorder caused by a deficiency of arylsulfatase A (ARSA) because of mutations 
in ARSA (reviewed in (Fluharty, 2014)). ARSA deficiency is characterised by an 
accumulation of the enzyme substrate sulfatide in oligodendrocytes, microglia, 
and certain neurons of the central nervous system (CNS) and in Schwann cells 
and macrophages of the peripheral nervous systems (PNS). These 
accumulations lead to widespread demyelination and neurodegeneration 
leading to severe progressive motor and cognitive impairment. As a result, the 
affected children die within a few years. Diagnosis for MLD is based on 
measurement of the biological activities of the enzyme and/or characterisation of 
the gene mutations (Lorioli et al., 2014). The most common and severe form of 
MLD is the late infantile (LI) form (50 to 60 % of cases), with the onset of the 
disease within two years of life. As demonstrated in other gene therapy trials, 
allogenic hematopoietic stem cells transplantation (HSCT) is one therapeutic 
option for MLD, although the outcome seems only successful when treated at 
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the early stage of the disease course (Aubourg  et al., 1990) (Shapiro et al., 
2000). In the search for an alternative method for the treatment, the Arsa-/- 
mouse model demonstrated reconstitution of enzymatic activity of ARSA by a 
genetically modified HSC transplant (Biffi et al., 2004) (Biffi et al., 2006). The 
phenotype of Arsa-/- mice are mild, and not characterised by extensive 
demyelination, making it difficult to evaluate a clinical benefit; however, ARSA 
positive cells were successfully distributed in PNS as a possible source to 
provide the enzyme to the CNS.  
 
The first successful ex vivo hematopoietic stem cell gene therapy for MLD was 
carried out using LV to treat three pre-symptomatic children, with one or more 
siblings, with LI-MLD (Biffi et al., 2013). Bone marrow derived CD34+ cells were 
transduced by LV carrying ARSA cDNA under the control of the human 
phosphoglycerate kinase (PGK) promoter. In order to validate a long-term 
therapeutic effect for this treatment, the treated patients were followed up for 18 
to 24 months. During this time there was no abnormal cell expansion or clonal 
outgrowth caused by vector integration, which was profiled over time in different 
cell compartments such as progenitors, mature myeloid cells, and B/T lymphoid 
lineages. Although longer follow-up is required to measure safety and efficacy, 
this treatment had a successful outcome halting the disease progression of the 
demyelination in the patients’ brain by providing a therapeutic level of ARSA 
enzyme.  
 
1.4.6 ß-thalassaemia clinical trial 
 
ß-thalassaemia (ß-TM) is a microcytic hemolytic anemia that is fatal in severe 
cases (ß-TM major) unless transfusions of life-long red blood cells and iron 
chelation are available (reviewed in (Finotti et al., 2015)). Based on the WHO 
estimation, about 1-5 % of the world’s population might carry ß-TM and every 
year about 60,000 severely affected infants are born (Modell and Darlison, 2008). 
The imbalance of ß-globin and a-globin caused by mutations in the coding or 
control regions of the ß-globin gene results in ineffective erythropoiesis because 
the decreased amount of ß-globin produces free toxic a-globin in erythrocyte 
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cells that damages cell membranes. Among the severe ß-thalassaemia, ßE/ß0 is 
highly frequent. In this case, the one ß-globin allele is completely silent (ß0), 
while the other (ßE) has a missense mutation resulting in the amino-acid 
substitution of glutamic acid to lysine at position 26 of the ß-globin chain 
(GLU26LYS). Approximately 50 % of the ß-TM patients who have this 
combination of alleles require transfusions.  
 
GRV was initially developed as a model vector for ß-TM. The introduction of the 
locus control region (LCR) upstream from the β-globin gene cluster could 
achieve successful gene expression in a site-independent manner in erythroid 
cells (Grosveld et al., 1987). In human β-globin gene locus, there are four DNase 
I hypersensitive sites (HS) distributed over 20 kb upstream from it and the length 
of the HSs is tailored, leaving the core element (Chung et al., 1997). However, 
these elements led to instability of the GRV vector with low titre (Emery et al., 
1998). In contrast to the monogenic disorders described above, overall the 
GRV-mediated ß-globin gene transfer had limited success (Ellis and Pannell, 
2001). Therefore, LVs were then engineered because of a superior vector 
property to GRVs, such as vector transduction in non-dividing cells (Naldini et al., 
1996) and well-characterised nucleus-to-cytoplasmic export of unspliced mRNA 
that facilitated the inclusion of globin genes with intact introns, LCR fragments, 
and insulator elements (May et al., 2000).  
 
The first clinical trial was carried out treating two patients with severe ßE/ß0-TM 
(Cavazzana-Calvo et al., 2010). Bone marrow CD34+ cells transduced by the 
ß-globinA-T87Q vector (LentiGlobin® HPV569) were engrafted in the patients. This 
ß-globinT87Q works as a distinguishable protein marker against 
transfusion-derived ß-globin (Pawliuk et al., 2001). Although the first patient 
failed in the engraftments after full myeloablation, the second patient achieved 
transfusion-independence at 12-months after the treatment. In the latter patient, 
clonal expansion of erythrocytes by LV integration was observed (more details in 
the 1.5 insertional mutagenesis section); however, the transfusion	 
-independence is still maintained after more than seven years with a decreased 
percentage of the dominant clone. A different ß-TM clinical trial was performed 
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using LV with a CMV promoter in place of the U3 promoter/enhancer in the 5’ 
LTR (LentiGlobin® BB305). In contrast to HPV569, this vector does not have a 
cHS4 insulator in the 3’ LTR. Two patients with ßE/ß0-TM were treated and both 
became successfully transfusion independent at 3.5 and 6.5 months after the 
treatment, respectively. It is assumed that the higher vector copy number in 
CD34+ HSCs may contribute to this better outcome. Based on the successful 
outcome, three additional ßE/ß0-TM patients were enrolled in the U.S. study and 
the treatment is ongoing (Negre et al., 2016). 
 
1.4.7 Gene therapy for infectious diseases 
 
Acquired immune deficiency syndrome (AIDS) is caused by infection with human 
immunodeficiency virus (HIV). The first recognition of the AIDS epidemic was in 
1981 and still 37 million people are suffering from AIDS worldwide 
(http://www.who.int/hiv/en/) (Herrera-Carrillo and Berkhout, 2015). The majority 
of AIDS cases are caused by HIV-1 infection; however, some AIDS cases in 
West Africa are caused by HIV-2 infection (Nyamweya et al., 2013). The clinical 
trials for AIDS in this thesis deal with the treatment of HIV-1 infection. Immune 
function in a patient becomes impaired when the disease progresses because 
the number of CD4+ T cells is reduced. As a treatment, patients are assigned to 
life-long combinational antiviral therapy (cART) that significantly prolongs the 
patients’ life-span; however, there are some limitations to be overcome, such as 
the incomplete elimination of the virus reservoir and the cytotoxicity by long-term 
cART. 
 
The concept of the anti-HIV gene therapy is to interfere with crucial steps of the 
viral replication cycle by targeting viral protein or host cellular factors that are 
required for viral replication. The therapeutic strategy can be divided into two 
groups, RNA or protein-based therapies (Herrera-Carrillo and Berkhout, 2015). 
Autologous T cells, or CD34+ cells, have been engineered to express a surface 
fusion peptide, a mutant Rev molecule, or a ribozyme targeting viral vpr/tat. 
Safety and tolerance of these approaches have been demonstrated, however, 
the expression of therapeutic transcripts was not sustained.  
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The first LV-mediated clinical trial for AIDS was performed in five patients (who 
had failed at least two antiretroviral regimens previously) (Levine et al., 2006). 
Those patients were treated by a single infusion of CD4+ T cells transduced with 
HIV derived vector (VRX496) carrying intact LTRs and a 937-base antisense 
sequence against HIV env. This antisense gene is expressed by the 
transcription initiation from the vector 5’ LTR; therefore, tat expression is 
required which is only supplied by wild type HIV-1 in HIV-infected individuals. 
After the infusion of the transduced CD4+ T cells, one subject had declined viral 
loads and four subjects had increased CD4+ T cell counts. Three-year 
monitoring of the patients reported no adverse events. The same research group 
performed multiple infusions (three to six) of VRX496-Tcells in 17 HIV patients to 
test if the therapeutic efficacy is increased by multiple infusions (Tebas et al., 
2013). Although efficacy was not enhanced by multiple infusions, in the plasma 
sample of eight patients A to G substitutions in HIV env sequence were 
observed as a cause of replication impairment of HIV. Integration site analysis 
also showed no evidence of enrichment of integration sites near 
cancer-associated genes (e.g. LMO2, CCND2, SPAG6/BMI1, and EVI1), 
suggesting this LV-mediated treatment protocol has good biosafety.  
 
The CCR5 HIV co-receptor is a molecular target candidate to anti-HIV therapy 
by preventing the virus from entering cells. One intriguing case is known as 
“Berlin patient” (Hutter et al., 2009) (Hutter and Thiel, 2011). The patient who 
received a bone marrow transplant from a CCR5-Δ32 homozygous donor 
became free of detectable HIV load. CCR5-Δ32 is a natural mutation and the 
transplanted cells did not allow HIV cell entry because CCR5 is not expressed 
(Novembre et al., 2005). Therefore, HIV gene therapy targeting CCR5 became a 
promising strategy. Gene editing to target CCR5 by zinc finger nucleases (ZFNs) 
was also reported with its successful outcome including its biosafety (Tebas et 
al., 2014). 12 patients with chronic aviremic HIV infection were enrolled and 
treated by autologous CD4+ T cell transplantation. Over the follow-up period, 
without the disruption of antiretroviral therapy (36-week), CCR-modified cells 
persisted; thereby the HIV load in the blood was controlled in most of the 
patients according to the DNA levels of HIV. Based on those results by 
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transplantation of a single dose of the modified CD4 cells, a trial with the 
increased dose will be the next step. 
 
Another molecule candidate for anti-HIV therapy is a specific short hairpin RNA 
to CCR5 co-receptor and cell-membrane-anchored CD46 to inhibit virus fusion 
to the host cell membrane. The dual combination LV (LVsh5/CD46) that carries 
those elements was tested in the humanised bone marrow, liver, thymus (BLT), 
and mouse model (Burke et al., 2015). As previously shown (Wolstein et al., 
2014), this vector could prevent both R5 and X4-tropic HIV-1 infection in 
comparison to an untransduced control. Stable transgene expression was also 
observed up to six months. Phase I/II clinical trial to test the feasibility of this 
method using CD34+ HSPC and CD4+ T cells transduced by LVsh5/C46 is 
underway. 
 
1.4.8 T cell immune therapy 
 
Beyond the rare genetic disorders, gene therapy became one option to treat 
cancer by immune-based strategies via the expression of engineered receptors 
on the surface of patients’ T cells (reviewed in (Maus et al., 2014) (Naldini, 
2015)). This exploits the cancer-specific antigen or antiviral molecule to boost 
the adaptive immune response and eradicate tumours. In early studies, 
exogenous TCR expression reported a partial effect on tumours and off-target 
expression that damaged tissues (Robbins et al., 2015). In recent studies, 
synthetic chimeric antigen receptors (CARs) have been used. These synthetic 
molecules are composed of a single chain antibody (scFv) composed of heavy 
and light chain variable regions with a synthetic linker expressed on a 
transmembrane region and intracellular domains from T cell signalling molecules. 
Expression of CARs on patients’ T cells can circumvent tolerance of the T-cell 
repertoire and the requirement for MHC presentation (Maus et al., 2014). GRVs 
have been mainly used to introduce CAR into T cells because they can 
permanently and stably transduce T cells and safety is established from the 
integration standpoint in primary T cells (Scholler et al., 2012). LVs have also 
been used more recently. Hematologic malignancies are the first target of CAR T 
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cells because antigen receptors to be targeted on the tumours are well 
characterised. In addition, a relatively easy sampling of tumors and T-cells 
homing to hematologic organs such as blood, bone marrow, and lymph nodes 
are also the determinant of the choice of cancer. To date, CAR T cells were 
applied in B-cell malignancies by targeting CD19, CD20 or IgGκ, or acute 
myeloid leukaemia (AML) by targeting CD33 and Lewis-Y antigen. In addition, 
CD30 has also been investigated for Hodgkin disease treatment (Shakoor et al., 
2002). 
 
1.4.9 Parkinson’s disease clinical trials 
 
Parkinson’s disease (PD) is a neurodegenerative disease caused by insufficient 
production of dopamine in substantia nigra pars compacta (within midbrain) 
(reviewed in (Coune et al.)). Dopamine is a neurotransmitter that helps regulate 
body movements and other motor/cognitive functions. Five million people are 
estimated to be in the effect of PD worldwide with the prevalence of around 1 % 
in people aged 60 years (de Lau and Breteler, 2006). Oral administration of 
dopamine precursor (levodopa) is effective, but only to the patients at initial 
stages of the disease. 
 
AAVs have been mainly exploited to treat PD patients with advanced stage 
(LeWitt et al., 2011). Although the clinical trials demonstrated successful 
neuroprotection in such patients, AAV can accommodate up to 4.7 kb of an 
exogenous gene and this cloning capacity restricts the number of genes 
transferred into patients. So treatment with a non-primate LV based on the 
equine infectious anemia virus (EIAV) genome has also been studied 
(Mitrophanous et al., 1999) (Azzouz et al., 2002). The EIAV-derived vector 
ProSavin was tested in phase I/II clinical trial to treat PD patients in the 
advanced stage (Palfi et al., 2014). ProSavin carries three genes essential to 
synthesise dopamine (aminoacid decarboxylase (AADL), tyrosine hydroxylase 
(TH) and cyclohydrolase 1 (CH1)) in the SIN EIAV vector. During the 12-month 
follow-up, ProSavin was well tolerated in patients and all 15 treated patients 
showed an improvement in motor behavior. Importantly, no serious adverse 
 69 
events were observed, suggesting the EIAV-based vector is promising for the 
treatment of PD. 
  
 70 
1.5. Insertional mutagenesis  
 
1.5.1 Insertional mutagenesis: brief introduction 
 
Insertional mutagenesis (IM) is dysregulation of host cellular gene expression 
caused by retrovirus insertions into the host genome and can lead to clonal 
expansion or malignancies (reviewed in (Uren et al., 2005), (Knight et al., 2013)). 
IM was exploited in the forward genetic screening of novel oncogenes by slow 
transforming retroviruses that do not encode viral oncogenes so that tumour 
formation can be assessed by integrations. The identified oncogenes were then 
examined by overexpression in cell culture and lab animals to characterise the 
function and understand the molecular mechanisms of oncogenesis. In contrast 
to the beneficial aspect of IM, it can cause unwanted side effects such as 
leukaemia in treated patients at retrovirus vector-mediated gene therapy. 
Despite a positive effect by vector transduction at the early point of gene therapy, 
the follow-up study reported IM as a side effect of retroviral vector-derived gene 
therapy and led to life-threatening leukaemia in some patients. In such cases, 
the molecular mechanism of related genes affected by vector integration was 
studied by vector integration site identification and fusion mRNA expression. 
Furthermore, to prevent the IM from occurring in clinical trials, the methods for 
safety screening of tested vectors were developed. 
 
In this section, firstly the accepted molecular mechanisms of IM are described 
for a better understanding of how the proviral sequence dysregulates 
neighbouring genes. Secondly, clonal expansion or malignancies reported in 
gene therapy clinical trials to date are described. Together with the previous 
section (1.4 Gene therapy), those adverse events are important as knowledge 
because a newly designed vector with superior biosafety to GRVs can be 
invented based on them. In addition, the mechanism of gene dysregulation by 
vector integration is crucial to discover the new function of genes. Therefore the 
methods to study IM are described including integration site and chimeric 
transcript identification. Finally, LV IM-based forward genetics is introduced as a 
useful tool to identify novel genes resistant to cancer treatment or viral latency. 
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1.5.2.Molecular mechanisms of retroviral IM 
 
1.5.2.1 Activation of cellular gene transcription via viral elements in LTR  
 
Retroviral LTRs function for effective transcription of the viral genome, however 
especially the enhancer and promoter elements contribute to dysregulate host 
cellular gene transcription. Enhancer sequences in the U3 of retroviral LTR 
augment the activity of cellular promoters, sometimes over large distances, 
resulting in the up-regulation of targeted oncogenes (Cavalli and Misteli, 2013). 
Such enhancer mutation is found predominantly upstream of the affected gene 
in the antisense orientation or downstream in the sense orientation (Uren et al., 
2005). The reported malignancies at clinical trials by integrations of MLV-based 
GRV were also enhancer-driven because early tested GRV had intact viral LTRs 
(Hacein-Bey-Abina et al., 2008) (Howe et al., 2008) (Braun et al., 2014) (Stein et 
al., 2010).  
 
The promoter element in the 5’ LTR is another contributor to dysregulate host 
transcription by controlling transcription initiation within the 5’ LTR and leads to 
the formation of chimeric transcripts with host sequences by read-through 
(Bokhoven et al., 2009) (Cavazzana-Calvo et al., 2010). This type of IM pattern 
can be achieved by the sense integration to host sequence. The chimeric 
transcripts have truncation at the 5’ upstream part of the gene and splice sites 
within a vector. 
 
Polyadenylation signal within LTRs can disturb cellular transcription and lead to 
cancer formation. Such mRNAs generate truncated protein that can cause 
deleterious gain-of-function or dominant negative activity (Chang et al., 2007). 
For instance, proviral insertion in the 3’ untranslated region (UTR) of host mRNA 
removes regulatory elements, or destabilises motifs in it, by the sense 
polyadenylation signal in 3’ LTR and the antisense cryptic polyadenylation signal 
in the enhancer of 5’ LTR. As such, the IM example, the sense integration of 
MoMLV downstream of proto-oncogene serine/threonine-protein kinase Pim-1 
(pim-1), caused T cell lymphomas in mice (van Lohuizen et al., 1989). 
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Prematurely terminated pim-1 mRNA resulted in the truncation of the element of 
3’ terminal exon of the gene that reduces the stability of the mRNA, therefore the 
expression of pim-1 was upregulated. Besides, the pim-1 locus is also known as 
the most frequently targeted integration site by MoMLV (Bachmann and Moroy, 
2005). Similarly, activation of N-Myc was observed in tumours by truncation of 3’ 
of the mRNA by MLV integration in the 3’ UTR and premature polyadenylation at 
the 5’ LTR.  
 
1.5.2.2 Aberrant splicing 
 
The presence of a viral sequence in the genome by integration can generate 
chimeric mRNAs via known vectors or cryptic splice sites and the affected host 
sequence may be disrupted aberrantly. The disruption of the original host 
sequencing is called aberrant splicing. This can remove regulatory regions of the 
intact mRNA and contribute to the cancerous transformation of transduced cells 
by the up-regulation of protein expression. This type of IM was observed in cell 
culture, targeting the Ghr locus in vitro (Bokhoven et al., 2009) and in HMGA2 
locus in vivo (Cavazzana-Calvo et al., 2010). In both cases, the fusion 
transcripts contributed to the up-regulation of the gene product and led to clonal 
expansions. The initiation of fusion mRNAs, whether vector or host sequence is 
first, makes a difference in the splicing pattern which changes the use of the 
splice site between the vector and host sequence. For instance, the Ghr locus 
had integration of GRV with intact LTR in the same orientation with the host 
transcript. Transcription was initiated within the 5’ LTR and spliced to the SA of 
Ghr exon 2. This pattern of aberrant splicing is splice-out. While SIN LV 
integration in HMGA2 also had integration in the same direction, transcription 
started from the host sequence because the vector has a deletion in the U3 of 
LTRs. Therefore HMGA2 exon 3 was spliced into a vector sequence within the 5’ 
U3. This splicing pattern is called “splice-in”. 
 
1.5.2.3 Inactivation of tumour suppressor genes 
 
Oncogene activation is also caused by inactivation of tumour suppressor genes. 
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As to tumorigenesis by inactivation of tumour suppressor genes, Knudoson’s 
“two-hit” hypothesis is well known (Knudson, 1971). This theory is that a gene on 
both alleles in the diploid genome needs to be mutated for cancer formation. 
However, it was proved that the “two-hit” is not necessarily a pre-requisite. 
Instead, in some cases, gene mutation in one allele is sufficient to reduce the 
level of gene expression to inactive the gene. This is called haplo-insufficiency of 
tumour suppressor genes. For instance, the comparison study between p53 
deficient heterozygous (p53+/-) mice and wild type mice also demonstrated that 
the reduced amount of p53 could cause cancerous transformation of cells 
(Venkatachalam et al., 1998). Vector integration can be the cause of 
haplo-insufficiency and the subsequent cell transformation. In a mouse BM 
transplant model, SIN-LV integration in Ebf1 caused acute B-lymphoblastic 
leukaemia (B-ALL) (Heckl et al., 2012). This integration into intron 8 of Ebf1 
resulted in initiating the transcript within the vector and truncation of exon 1 to 8 
of this gene product, which led to the downregulation of overall Ebf1. The 
reduction of Ebf1 expression contributed to strong STAT5 upregulation and 
caused the B-ALL. Another example was transduction of LV.SF.LTR 
(HIV-derived LV with spleen focus-forming virus (SFFV) promoter insertion in the 
U3 region) in in vivo genotoxicity assay using tumour prone Cdkn2a–/– murine 
hematopoietic stem/progenitor cells (Montini et al., 2009). In a myeloid and a 
lymphoid tumour generated by the same LV, Nsd1 was downregulation by about 
40 % by integration in the intron 5 and 6 in the opposite direction to the 
transcriptional direction, but the detailed mechanism by which the vector 
integration reduces the gene product is not described. Importantly, 
haplo-insufficiency of NSD1 is the major cause of developmental disorder Sotos 
syndrome and is associated with malignancies (Martinez-Glez and Lapunzina, 
2007).  
 
1.5.3 Genotoxic events in clinical trials via vector integration  
 
1.5.3.1 Acute lymphoblastic leukaemia in SCID and WAS clinical trials by 
vector-mediated IM 
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The first report of adverse events in a gene therapy clinical trial was the SCID-X1 
trials in Paris and London using GRV with intact LTR (Hacein-Bey-Abina et al., 
2008; Howe et al., 2008). Notwithstanding the successful immune reconstitution 
by the gene therapy, five of the total treated 20 patients developed T cell 
leukaemia two to 5.5 years after the treatment. When the expanded leukemic 
clones were examined, integration sites of GRV were identified in oncogenes 
LMO2 or CCND2 and those genes were up-regulated by the enhancer-mediated 
IM mechanism. In addition, other genetic abnormalities were observed possibly 
contributing to the leukaemogenesis, such as SIL-TAL1 fusion transcripts, a 
deletion of CDKN2A tumour suppressor gene, a gain of function mutations in 
NOTCH1, or a translocation of the TCR-ß region of the SIL-TAL1 locus. In the 
follow-up study, longitudinal pyrosequencing analysis was carried out using 
eight patients from the Paris SCID-X1 trial (Wang et al., 2010). Interestingly, four 
patients (two patients (P1, P2) without leukaemia development) had integration 
sites near CCND2. This resulted in a clonal expansion in those two healthy 
patients, suggesting that this integration event does not inevitably lead to 
leukaemia. In the same study integrations near HMGA2 were observed in P1 
and P7. Vector integration was found between exon 3 and 4 of HMGA2 which 
generated host cell-virus fusion mRNA with truncation of exon 4 and 5. The lack 
of let-7 microRNA binding sites, the negative regulator of this gene coded in 
exon 5, stabilised the gene product and upregulated it. The same mechanism of 
IM via integration into HMGA2 was also observed in the LV-mediated clinical 
trial of ß-TM (Cavazzana-Calvo et al., 2010) 
 
In WAS clinical trials, a first phase I/II study was conducted with 10 patients. 
They were treated by GRV with intact LTR that drives WASP expression (Boztug 
et al., 2010) (Braun et al., 2014). Nine out of 10 patients who received the HSCT 
showed successful engraftments of transduced autologous HSCs and improved 
clinical symptoms by sustained expression of WASP. Nevertheless, seven 
patients developed acute leukaemia. Although the comprehensive analysis of 
the latest patient is currently ongoing, GRV integration was commonly found 
within or near LMO2 in the six patients, MDS1 for two patients or MN1 for one 
patient. High throughput integration site identification without a restriction 
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enzyme (nrLMA-PCR) identified the four most targeted gene loci (MDS1-EVI1, 
PRDM16, LMO2, and CCND2) in all treated patients. These sites were observed 
in the clonal expiation of other GT clinical trials. 
 
1.5.3.2 Myelodysplasia in CGD clinical trial by vector-mediated IM 
 
Two adult patients treated with nonmyeloablative bone marrow conditioning 
received an infusion of peripheral blood CD34+ cells transduced by a GRV 
carrying gp91phox (SF71gp91phox) whose transcription was driven by SFFV-LTR 
(Ott et al., 2006). Treated patients had reconstitution of NADPH oxidase function 
in peripheral blood leukocyte and granulocyte and had improvement of 
antibacterial activity. Three months after the treatment, clones harboring 
integrations in MDS1-EVI1, PRDM16, or SETBP1 were expanded in both 
patients and an elevated level of MDS1-EVI1 expression was found in bone 
marrow cells and peripheral blood leucocytes. This clonal expansion was 
regarded as the contributor for the treatment at the time. However, longer 
follow-up of those patients showed the development of bone marrow disorders, 
myelodysplasia, owing to the increased expression of fusion transcripts 
MDS1-EVI1 and EVI1 via GRV integrations (Stein et al., 2010). Chromosomal 
aberration (monosomy 7; a loss of a copy of chromosome 7), possibly 
associated with clonal dominance, was also found in both patients. They also 
found that EVI1 overexpression was dominantly contributing to centrosomal 
aberrations chromosomal instability. This study indicated that clonal expansion 
can lead to malignant myelodysplasia, thus long-term follow-up on treated 
patients is required to test if multi lineage populations have remained in patients’ 
bodies.  
 
1.5.3.3 Clonal expansion caused by virus integration: clonal dominance in 
ß-thalassaemia clinical trial by vector-mediated IM 
 
In the case of ß-TM, clinical trials have been mainly performed with LVs and 
there are no reported malignancies to date. However, clonal dominance was 
reported as a first potential cancerous risk of using LVs for ß-thalassaemia 
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(Cavazzana-Calvo et al., 2010). In this trial, patients were infused with bone 
marrow CD34+ cells, transduced by SIN lentiviral vector encoding ß-globin cDNA, 
driven by the human ß-globin locus control region with chicken hypersensitive 
site 4 (cHS4) insulators in the deleted 3’ U3. In the dominant clones, a single 
vector integration in the same orientation as HMGA2 was detected and the 
integrated vector lost one of the two copies of cHS4 insulators. The mechanism 
of the up-regulation of the gene was due to loss of the negative control region 
(let-7 microRNA binding sites) in HMGA2-vector transcripts by exon-skipping. 
The follow-up study reported the disappearance of the dominant clone and the 
clonal expansion did not cause malignancy (Leboulch, 2013).  
 
1.5.4 Studies to understand the mechanisms of IM  
 
1.5.4.1 Cell line-based assay 
 
Murine cells are a robust tool to investigate IM mechanisms. The reason why 
mouse cells are chosen over human cells is that they can be immortalised at a 
higher frequency owing to a higher functional activity of telomerase (Rangarajan 
and Weinberg, 2003). To isolate mutants and assess the IM mechanisms, 
murine cytokine dependent cell lines have been exploited for a fast and 
quantitative tool. In our lab, mutant isolation was carried out by IL-3 dependent 
Baf3 (Palacios and Steinmetz, 1985) and its derivative clone with Bcl-2 
overexpression Bcl15 cells (Collins et al., 1992) by RV integration. Both cell lines 
are IL-3 dependent and mutant isolation was successfully performed under the 
IL-3 starvation. With regard to the robustness of cells, Bcl15 cells are more 
advantageous than the parental Baf3 because Bcl-2 overexpression makes 
Bcl15 more resistant to apoptosis and a higher number of mutant recovery is 
expected in the protocol. Using those cell lines, our group established the in vitro 
quantitative IM assay and we studied the molecular mechanism by which 
isolated mutants gained growth advantage in an aspect of vector integration 
(Bokhoven et al., 2009). The vector integration sites were assessed by 
ligation-mediated PCR (LM-PCR) or inverse PCR and the expression of chimeric 
transcripts between cellular and viral sequences was confirmed by qRT-PCR 
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and 5’ RACE. This assay system discovered that LV integration-derived mutants 
had integration in Ghr locus and the virus-host fusion mRNAs from vector SD to 
the host cellular SA at Ghr exon 2. In contrast, GRV-derived mutants were 
generated by integration into retroviral vector common integration sites (CIS) 
and upregulation of oncogenes listed in RTCGD. In a later study from our team, 
the safety of the vector component was also examined in this assay system by 
comparing the number of generated mutants by LV integration (Knight et al., 
2010). All used LV vectors have intact LTR. The tested vector components 
include SFFV, ubiquitin (UBIQ) promoter, and an SFFV vector counterpart 
without WPRE element at the 3’ side of the vector. The LV with SFFV promoter 
generated mutants at a high rate and the deletion of WPRE did not affect mutant 
generation. Intriguingly, there were no mutants by UBIQ vector transduction. 
These results suggested that SFFV promoter could increase or enhance 
transcription initiation from 5’ LTR. qRT-PCR demonstrated transcription 
initiation from 5’ LTR of the vector but the comparison date for the UBIQ vector is 
required to confirm this hypothesis. Furthermore, in the search of a promoter 
replaceable to a commonly used promoter such as CMV or SFFV promoter, 
Ubiquitous Chromatin-Opening Element (UCOE) element was raised as a 
candidate because of the resistance to gene silencing in a position independent 
manner (Antoniou et al., 2003). Therefore, UCOE element within LV was 
optimised to achieve the safest candidate with the low mutant formation (Knight 
et al., 2012). In IM assay, splice sites in the original UCOE sequence caused 
aberrant splicing. The vector candidate MA1082 and its derivatives that have 
mutations at both known and cryptic splice sites could abrogate aberrant splicing 
and result in a reduced number of mutants. These studies demonstrated that 
possible IM mechanisms of LVs can be assessed in the well-established murine 
cytokine independent cell-based assay and this assay can be further used to 
optimise vector safety. 
 
In another study, to address the quantitative measurement of IM by mutant 
generation and molecular mechanism of IM in a relevant cell type, a protocol for 
re-plating cell assay was developed using lineage-negative (Lin-) bone marrow 
(BM) cells (Modlich et al., 2006). In the protocol, Lin- BM cells were derived from 
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C57B16/J mice and transduced by test vectors twice. The transduced cells were 
then expanded for two weeks and cells were re-plated at a density of 100 
cell/well in 96-well plates and cultured for another two weeks. Based on the 
number of wells with proliferated clones, the frequency of mutagenesis was 
calculated. To validate the mechanism of the growth advantage of the 
transformed cells, LM-PCR and linear amplification–mediated PCR (LAM-PCR) 
were exploited. Using this model, vector safety was compared between SIN 
GRV and wild-type (WT) GRV (with intact LTR), showing a reduction in 
transformation risk by SIN GRV (Modlich et al., 2006). In expanded clones both 
vectors had integration in the EVI1 locus in reverse-orientation relative to the 
Evi1 transcription direction. This suggests that the clonal expansion by 
upregulation of EVI1 was enhancer-mediated by WT GRV and was possibly 
aberrant-splicing by SIN GRV. Importantly, those results can draw the 
conclusion that enhancer/promoter-mediated IM has a stronger affect for mutant 
generation than splicing-mediated IM by SIN GRV. Later, from the same 
research group, LVs with different physiological promoters or with varieties of 
deletion in the U3 of the LTR were tested in the same assay system (Modlich et 
al., 2009). It revealed that SIN LVs with physiological promoters have a lower 
risk of cell transformation compared to SIN LV with SFFV promoter, suggesting 
the choice of promoter is important for the design of a safer vector. 
 
1.5.4.2 Murine models 
 
As a pre-clinical assessment of HSC gene therapy, the murine model has been 
used to validate the feasibility of the tested vector and find the potential risk of IM 
mechanisms via vector integrations (Montini et al., 2009). Mutagenicity of tested 
vectors was measured by the occurrence of clonal expansion or malignancies of 
transduced cells in transplanted mice. One example is the transplant of the 
transduced Lin- cell derived from the BM of tumour prone Cdkn2a-/- mice by 
retroviral vectors (GRVs and LVs) with different designs into lethally irradiated 
wild-type FVB mice. Retroviral vectors with SFFV enhancer/promoter region in 
the LTR or SIN vectors with an SFFV internal promoter were assessed for 
genotoxic potential. This study showed that an active LTR is the major 
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determinant of genotoxicity in the recipient mice and LV with SFFV LTR required 
a 10-fold higher integration load to obtain the same genotoxic risk than GRV with 
SFFV LTR. The mechanism of IM by LV with SFFV LTR was examined by a 
further transplant of tumours generated by the vector into secondary recipient 
mice to obtain biological replicates. One transplanted myeloid tumour showed 
LV-Braf chimeric transcripts. The fusion transcripts were initiated from an SD in 
the 5’ LTR and spliced out to the SA in the exon 13 of Braf (splice-out). The 
transcripts generated a truncated Braf molecule, which led to constitutive kinase 
activity. In addition, one myeloid and one lymphoid tumour showed NSD1 
haploin-sufficiency by the reduction of the product by about 40 %. 
 
In contrast to cell-based assay, the mouse-based IM model is costly and 
time-consuming. However, the pre-clinical vector should be actually tested in 
vivo to confirm that the vector can work in the same manner as in vitro and no IM 
events are detected. The combinational use of both assay systems would not 
only assess the vector precisely and rapidly but also contribute to reducing the 
number of experimental animals. 
 
1.5.4.3 Analysis of vector integration loci and chimeric transcripts 
between host and vector sequences  
 
When the cause of vector-mediated IM is studied, firstly vector integration sites 
are identified, if such sites have hits in RTCGD, so that potential integration sites 
that could be the cause of IM would be narrowed down. One of the common 
methods uses restriction enzyme digestion such as inverse PCR (Carteau et al.) 
or LM-PCR (Wu et al., 2003). Digested gDNA is ligated with linker 
oligonucleotides, which allows us to obtain the host genome sequence next to 
the vector sequence using vector- and linker-specific primers. These techniques 
are sufficient to analyse monoclonal samples. However, to characterise complex 
samples with multiple target sequences another sensitive method, LAM-PCR 
(Schmidt et al., 2007), was developed. Prior to restriction enzyme digestion, the 
target vector-host junctions are amplified using 5’ biotinylated primers, allowing 
for immobilisation on the solid phase and magnetic selection. The amplified DNA 
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is then digested by four-cutter enzymes and ligated to linker oligonucleotides. 
However, some studies argue that the use of a restriction enzyme creates a bias 
of retrieving integration sites (Harkey et al., 2007) (Wang et al., 2008b). 
Alternatively, nrLAM-PCR was invented (Paruzynski et al., 2010), which does 
not use restriction enzyme digestion. Nowadays it is increasingly common to 
combine LAM/nrLAM-PCR with next-generation sequencing technology to 
obtain a large number of sequence reads and analyse quantitatively.  
 
Regarding the analysis of host-vector chimeric transcripts, rapid amplification of 
cDNA ends (RACE) is exploited for cDNA-based vector-host junction 
amplification of 5’ or 3’ mRNA (Frohman et al., 1988). Ligation of linker 
oligonucleotide to 3’ cDNA or priming reverse transcription by oligo dT primers 
allows reading of the unknown host cDNA region fused to the vector sequence. 
The cDNA is ligated in a circular form, or concatemers, and the vector host 
boundary sequence is read by vector- and the linker/oligo dT specific primers. 
Another method recently proposed is cLAM-PCR (Cesana et al., 2012) whose 
protocol is based on LAM-PCR (Schmidt et al., 2007). mRNA is reverse 
transcribed by oligo dT primers and a biotinylated primer is used for linear PCR 
based on cDNA. Magnetic selection and digestion steps are the same in 
LAM-PCR. The shotgun cloned products are sequenced by next generation 
sequencing. 
 
1.5.5 LV integration profile as solution for the treatment of cancer or 
infectious diseases 
 
We highlighted retroviral vector-mediated IM as an adverse event in the previous 
section. However, IM can provide the genes of altered expression by integration 
as beneficial information to discover the strategies to treat cancer (Ranzani et al., 
2014) or infectious diseases like AIDS (Maldarelli et al., 2014) (Wagner et al., 
2014).  
 
1.5.5.1 Cancer-related gene discovery 
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LV-mediated IM was firstly applied to the oncogene screen in hepatocyte as the 
model of liver cancer (Ranzani et al., 2013). They established the IM model to 
induce human hepatocellular carcinomas (HCC) in three different mouse 
models: tumour prone Cdkn2-/-ifnar1-/- mice with higher permissiveness of 
transduction, Pten liver-null mice as a model of chronic liver oxidative damage, 
and wild type mice with CCl4 treatment as a model of chronic liver injury. The 
tested LV in this model has enhanced transthyretin, hepato-specific 
enhancer-promoter sequences in the LTR, to induce tumours in the mice. 
Integration site analysis of cancer tissues by LAM-PCR found that Fign, Braf, 
Sos1, and Dlk1-Dio3 were highly targeted integration sites whose expression 
was upregulated. All those loci had vector integration in the same direction as 
transcriptional direction. In the analysis of chimeric transcripts by RT-PCR, 
transcriptions start from the 5’ LTR and are spliced in from the vector HIV major 
splice donor (SD) to the acceptor (SA) in each gene. In the case of Fign, Braf, 
and Sos1, the lack of N-terminal domain by vector integration contributed to the 
gene upregulation. Integration of the Dlk1-Dio3 generated fusion transcript with 
full-length Rtl1 caused Rtl1 upregulation. 
 
LV IM was also exploited in a model of breast cancer. Using two subtypes of 
HER2+ breast cancer cell lines (SKBR3 and BT474), LV integration sites 
contributed to discover the genes involved in resistance to anticancer therapy 
(Ranzani et al., 2014). LV with SFFV enhancer/promoter in the LTR was 
transduced, followed by lapatinib (a tyrosine kinase inhibitor) selection. Cells 
with growth advantage gained by vector transduction can survive this drug 
selection step. The amplified vector-host sequence boundaries by LAM-PCR 
were sequenced by next generation sequence and PIK3CA and PIK3CB were 
identified as CIS. PIK3CA had integration in the first intron of the gene in the 
sense strand. PIK3CB had integration upstream of the gene in the sense 
integration by 87 %. The vector promoter-mediated IM overexpressed those 
genes; overexpression of those genes by SIN LV conferred the resistance to 
lapatinib. In the same study, they attempted to apply the same LV IM platform to 
discover novel drug-resistance genes in the context of pancreatic cancer. The 
LV integration in SOS1 was isolated as a drug resistance gene to erlotinib 
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(clinically used EGFR inhibitor) in the pancreatic cell line. The overexpression of 
this gene was achieved in the integration of the intron 8 of the gene in the sense 
orientation, which led to truncation of the gene product. 
 
1.5.5.2 HIV latency and the relation to virus integration sites 
 
The HIV latency in AIDS patients is a barrier to eradicate infected cells under 
combinational antiretroviral therapy (ART). HIV in the latent stage is not affected 
by the ART and, once the treatment is stopped, the suppressed virus loads 
easily to increase to the level before the ATR is initiated because of the virus 
production from latent reservoirs (Weinberger and Weinberger, 2013). In order 
to understand the mechanisms of virus latency in regard to targeted gene locus 
within the infected cells, HIV integration sites in cells from AIDS patients under 
the ART were studied (Maldarelli et al., 2014) (Wagner et al., 2014). To test 
whether identical sequences are found in the HIV genome, single genome 
sequencing was performed (Kearney et al., 2008). This particular sequencing 
method permits individual cDNA molecules of a defined portion of the genome to 
be PCR amplified. As a result of genome analysis of HIV infected individuals, 
interestingly, clonally expanded cells were observed in plasma or peripheral BM 
cells of the five tested patients (Maldarelli et al., 2014). Integration analysis of 
CD4+ T cells was performed in one patient who underwent 11.4 years of 
combinational ART prior to the cell collection. This revealed the characteristic 
virus integration in the intron 4 or 5 of Bach2 (Liu et al., 2009) and in the intron 4 
of MKL2 (Ma et al., 2001) in the sense orientation to the transcriptional direction. 
HIV promoter-mediated IM possibly dysregulated those gene expressions and 
contributed to clonal expansion. Separately, they performed HIV integration site 
analysis in HeLa cells and CD34+ cells. Because HIV did not have a preference 
of integration into Bach2 and MKL2, those sites in the expanded clones were 
selected overtime. These novel findings revealed that HIV wisely uses gene loci 
that could be related to cell survival by disrupting the gene transcripts by 
integration. Overall, the cells with such integration can expand and persist 
without being affected by ART, and therefore contribute to achieving latency in 
patients.  
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1.6. Splicing 
 
In my PhD project, we investigated the possible mechanism of LV-mediated 
insertional mutagenesis. Our focus is to look into host-vector fusion mRNAs 
expressed in LV-transduced cells that were isolated in an IM assay. The 
formation of such chimeric mRNAs is mediated by splicing. Therefore, the basic 
knowledge of splicing, the essential step for producing mRNA for gene 
expression, is crucial for understanding and estimating potential splicing 
patterns of host-vector chimeric mRNAs. For the formation of such various 
transcripts, use of different splice sites is related and the generation of multiple 
RNAs from one transcript is called alternative splicing. In this section, I start with 
the history of splicing and cover the basic knowledge of splicing including the 
chemistry and alternative splicing. 
 
1.6.1 Genome composition of eukaryotic cells  
 
Eukaryotic genes comprise both exons, expressed in the final mRNA, and 
introns which contain regulatory elements of gene expression. The density and 
size distribution of introns and exons vary between species (Zhu et al., 2009). In 
vertebrates, exons are relatively shorter and introns are longer.  
 
The evolution of exon-intron structure and the evolutionary property of introns 
have been discussed in the context of the “introns-early” vs. “introns-late” debate 
(reviewed in (Rogozin et al., 2012)). The intron-early hypothesis proposes that 
(nearly) all introns present in eukaryotic cells were inherited from prokaryotic 
ancestors. In this theory, the difference in gene structure among homologous 
eukaryotic genes is due to differential intron loss (Gilbert, 1987). The intron-late 
hypothesis proposes that introns emerged during evolution (Logsdon, 1998). 
Comparative studies between different eukaryotic organisms were performed to 
see conserved intron positions, or loss of introns, and elucidate which theory 
could be correct. However, intron gain is not easy to detect and a defined 
mechanism of intron evolutions is yet to be proved. 
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1.6.2 Discovery of splicing 
 
The discovery of splicing, the process which turns the nuclear primary transcript 
RNA to cytoplasmic RNA, was based on the availability of techniques to study 
unstable RNA and accumulation of knowledge about RNA (reviewed in (Darnell, 
2013)). In the late 1950s, RNA labelling with isotopes in nucleated cells 
illustrated that RNA synthesis in the nucleus was not followed by a transfer of 
these RNA species to the cytoplasm because of their instability (Harris, 1959). 
To understand the process between nuclear and cytoplasmic RNA, the study of 
unstable nuclear RNA was challenged. In 1971-12, a 3′ unitary-sized polyA 
segment was observed in polyribosomal RNA (Darnell et al., 1971) which was 
shown to be added by polyA polymerase (Edmonds and Abrams, 1960). A few 
years later, a 5′-methylated GpppXmp cap (p:phosphate; X: methylated base) at 
the 5′ end of animal virus mRNA was reported (Shatkin, 1974). Finally in 1977, 
electron microscopic (EM) analysis of adenovirus type 2 (Ad2) infection 
uncovered RNA splicing (Berget et al., 1977) (Berk, 2016). Many completed 
different late cytoplasmic Ad2 mRNAs were bound to Ad2 DNA at the same 
three regions close to the transcription start site and also to distant genomic 
segments. Thus the groundbreaking idea of splicing was born from the 
observation of the reduction in length from large primary Ad2 RNAs to shorter 
cytoplasmic RNAs (Bachenheimer and Darnell, 1975). In addition, the EM photo 
revealed Ad2 mRNAs with different lengths from each single large adenovirus 
pre-mRNA, whose event is called alternative splicing (Chow and Broker, 1978) 
(Nevins and Darnell, 1978).  
 
1.6.3 Key factors and sequences for splicing 
 
When splicing is carried out, the interaction between cellular sequences and 
proteins is required (reviewed in (Rogozin et al., 2012)). There are four key 
factors involved in splicing: splice sites located at both ends of the intron, a 
branch point in an intron, a polypyrimidine tract in an intron, and small nuclear 
ribonucleoproteins (snRNPs).  
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The splice site at the 5’ and 3’ ends of introns are defined as identical 
dinucleotides. The 5’ dinucleotides in introns are known as splice donors (SDs) 
and the 3’ dincleotides as splice acceptors (SAs). Intron removal is processed 
using those splice signals (see more details in 1.6.4). Splice site consensus 
sequences vary by species. For instance, for human (Churbanov et al., 2006) 
consensus sequence at a SD is (A/C)AG|GU (3’ exon and a SD at the 5’ intron 
underlined are indicated on the left or right of the vertical line, respectively), 
while, that at a SA is (C,U)AG|G (a SA at the 3’ intron underlined and 5’ exon are 
indicated on the left or right of the vertical line, respectively). The branch point 
locates anywhere from 18 to 40 nucleotides upstream of a SA and its sequence 
is YNYYRAY (Y: pyrimidine; N: any bases; R: purine; A: adenine) (Tazi et al., 
2009). The reactive adenosine in the branch point is involved in the formation of 
the lariat-like structure, by the attachment of the cleaved 5’ end of the intron to a 
branch point in the splicing intermediate. A polypyrimidine tract (C or U) that 
locates between the branch site and an SA plays an important role for an SA 
recognition via host protein U2AF (Sickmier et al., 2006). snRNPs catalyze the 
splicing reaction by recognising those crucial sites above and forming 
spliceosomes, then orchestrating the site-specific transesterification reaction 
(Clancy, 2008). Five snRNPs are known to form a spliceosomal complex; U1, U2, 
U4, U5, and U6. 
 
In most Eukaryotes, the vast majority of spliceosomal introns contain GU at the 
SD and AG at the SA (Churbanov et al., 2006) and the splicing of such 
universally conserved U2-type introns is mediated by the listed five snRNPs 
above, a U2 spliceosome. However, atypical introns with distinct dinucleotides 
have also been discovered: AT at the SD and AC at the SA (Jackson, 1991) 
(Hall and Padgett, 1994). Splicing of this minor class of U12-type intron is 
processed by a specific spliceosome that includes low-abundant snRNPs, called 
a U12 spliceosome (reviewed in (Turunen et al., 2013)). The U2 and U12 
spliceosomes share U5 snRNP and, especially, the U12 spliceosome contains 
U11, U12, U4atac, and U6atac as possibly equivalent to U1, U2, U4, and U6 of 
U2 spliceosome, respectively. 
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There are two principle machineries of splicing signal recognition: exon definition 
and intron definition (reviewed in (Ast, 2004)) (Fig.1-6). This theory describes 
that splicing is initiated either by recognition of exon or intron first. Both 
mechanisms are mediated by cis-elements either in the exon or intron. Here I 
describe the two recognition systems using exonic splicing enhancers (ESEs) 
that enhance the inclusion of exons with ESE (Ibrahim et al., 2005) as an 
example. Binding of serine/arginine (SR) protein to ESE on an exon recruits U1 
to the downstream SD and U2 auxiliary factor (U2AF) to the upstream SA on the 
different introns, respectively, followed by recruiting U2 to the branch site 
(Robberson et al., 1990). As a result, the formation of the cross-exon recognition 
complex is promoted and the exon with the ESE is included in spliced mRNAs. 
This splicing signal recognition is called exon definition (Berget, 1995). 
Alternatively, intron definition can be explained by U1 being recruited to the 
upstream SD and U2AF/U2 to the downstream SA and the branch site on the 
same intron, respectively (Romfo et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1-6 Exon and intron definition 
(a) Exon definition. SR protein (purple) binding to exonic splicing enhancer (blue) 
enhances snRNPs binding on the 3’ (U2: green; U2AF: orange) and 5’ (U1) splice sites. 
This induces the recruitment of additional snRNPs subsequently to complete splicing. (b) 
Intron definition. 5’ and 3’ splice sites on the same intron are recognised by snRNPs. 
Figure reprinted from (Ast, 2004). 
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1.6.4 Splicing machinery 
 
Splicing removes intron sequences between exons and joins the exons together 
via interaction with spliceosomal proteins. A few steps of a chemical reaction are 
required to complete splicing (Fig.1-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1-7 The process of splicing  
(Top) The first transesterification for the formation of the lariat structure. From the left of 
figure 5’ exon, intron and 3’ exon are illustrated, the region of which is divided by 5’ or 3’ 
splice sites. The dashed arrow indicates the attack of the hydroxyl group to 5’ splice site. 
(Middle) The second transesterification. The dashed arrow indicates the attack of the 
hydroxyl group to 3’ splice site. (Bottom) The joining of 5’ and 3’ exons and the release of 
the lariat structure. Figure reprinted from (Brow, 2002). 
 
 
Firstly, with the aid of binding of the U1 snRNP to the downstream 5’ splice site, 
the cleavage at the 5’ end of the intron in pre-mRNA occurs (Siliciano and 
Guthrie, 1988). The cleaved end of the 5’ intron then attaches to a branch point 
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by pairing with guanine and adenine nucleotides to form a looped structure that 
is known as “lariat” (Berget et al., 1977). This attachment reaction occurs by 
attacking a hydroxyl group on a carbon atom of the adenosine residue of the 
branch point to the phosphorus atom of guanine nucleotide at the downstream 5’ 
splice site. This chemical reaction is called transesterification. 
 
U1/5’ splice site base-pairing is weakened in an ATP-dependent manner (Staley 
and Guthrie, 1999) and this allows U2 binding to the branch point. U4/U5/U6 
try-snRNPs are further recruited to the pre-spliceosome. The 3’ hydroxyl group 
of the released 5’ exon then attacks the phosphodiester bond of guanine of the 
upstream 3’ splice site. As a result, the lariat structure is removed and the5’ and 
3’ exons are joined together to form mRNA. 
 
1.6.5 Alternative splicing 
 
Alternative splicing increases the diversity of gene expression (Ponting, 2008), 
for example in the IgM locus (Early et al., 1980), therefore alternative splicing is 
an essential process in the development and differentiation of cells. This 
explains the expression of over 90,000 proteins from approximately 23,000 
genes (Hernandez-Lopez and Graham, 2012). 95 % of human pre-mRNA is 
estimated to undergo alternative splicing in different human tissues (Johnson et 
al., 2003) (Wang et al., 2008a). Throughout the eukaryotic evolutionary tree, 
alternative splicing is more prevalent in higher eukaryotes than lower eukaryotes 
and the number of genes that undergo alternative spicing is larger in vertebrates 
than invertebrates (Alekseyenko et al., 2007) (Artamonova and Gelfand, 2007). 
By alternative splicing, several forms of mRNAs can be generated by the 
following mechanisms: exon skipping, alternative splice site (3’ or 5’) selection, 
intron retention, mutually exclusive exons, alternative promoter usage, and 
alternative polyadenylation (Hernandez-Lopez and Graham, 2012) (Fig.1-8).  
 
 
 
 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1-8 Patterns of alternative splicing 
(a) Exon skipping. A cassette exon is spliced together with surrounding introns. (b) 
Alternative 3’ or (c) 5’ splice site selection. Two or more splice sites are recognised in the 
same exon. (d) Intron retention. An intron is retained in mRNA. (e) Mutually exclusive 
exons. Clustered internal exons are spliced in a mutually exclusive manner. (f) 
Alternative promoter usage. The generated transcripts have different 5′ untranslated 
regions (UTR) or open reading frames (ORF). (g) Alternative poly (A). The generated 
transcripts have different 3’ UTR. Constitutive (blue) and alternatively spliced (purple) 
exons are illustrated in the figure. Introns are shown by a solid line. Dashed lines are 
splicing options. Figure reprinted from (Keren et al., 2010). 
 
 
The first three mechanisms of alternative splicing are the major patterns and the 
rest is rare and more complicated (Keren et al., 2010). Exon skipping and 
alternative 3' splice site selection account for the major alternative splicing 
events in higher eukaryotes (Alekseyenko et al., 2007) (Sugnet et al., 2004), 
while intron retention is the most prevalent alternative splicing events in plants, 
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fungi, and protozoa (Kim et al., 2008). 
 
In addition, alternative splicing can also introduce stop codons that can be 
targeted as a prematurely terminated gene product and degraded by 
nonsense-mediated decay (NMD) (Lewis et al., 2003). In this regard, alternative 
splicing can negatively regulate gene expression. In some cases, non-functional 
gene products generated by alternative splicing can be a cause of disease as 
introduced in the next section 1.6.6 (Cooper et al., 2009) (Tazi et al., 2009) 
(Scotti and Swanson, 2016).  
 
1.6.6 Alternative splicing in disease and therapy 
 
1.6.6.1 Neuronal disease 
 
One example for alternative splicing as a cause of diseases is spinal muscular 
atrophy (SMA) characterised by degeneration of alpha motor neurons in the 
brain stream and spinal code (Wirth et al., 2006) (Tazi et al., 2009). SMA is the 
second most common autosomal recessive disorder and a leading genetic 
cause of infant mortality. The genetic cause of this disease is a homozygous 
loss of the survival motor neuron 1 (SMN1) gene. The human genome encodes 
SMN2, almost identical to SMN1; however, SMN2 has a C to T change at 
position 6 in the exon 7, which leads to exon-skipping of the exon 7. As the result, 
the SMA2 protein is less stable and probably non-functional. Therefore it cannot 
be compensated for the loss of the SMN1 protein. The therapeutic approach for 
SMA focuses on increasing the expression level of functional SMA2 by including 
the SMA2 exon 7 by antisense oligonucleotides (AONs) that target the splicing 
silencer (Spitali and Aartsma-Rus, 2012).  
 
Secondly, Duchenne muscular dystrophy (DMD) is a severe muscle-wasting 
disorder caused by mutations in the DMD gene encoding dystrophin that links 
the cytoskeleton to the extracellular matrix of muscle fibers. Point mutations and 
frame-shifting deletions insert stop codon in the exon 51, resulting in the 
formation of a premature dystrophin protein. In order to restore reading fame, 
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AON targeting the exon 51 is applied to hide it from the splicing machinery and 
skip the exon in pre-mRNA (Spitali and Aartsma-Rus, 2012). 
 
Finally, Hutchinson-Gilford progeria syndrome is a rare autosomal-dominant 
disease characterised by accelerated ageing, growth impairment, and shortened 
life span (Spitali and Aartsma-Rus, 2012). Most patients carry a mutation in exon 
11 of the LMNA gene encoding lamin A [a C-to-T transition in the LMNA coding 
region at the nucleotide position 1824 but no putative change in the protein 
sequence], which introduces a cryptic SD, and the protein lacks the region 
coded in exon 11 (Osorio et al., 2011). This shortened protein is called progerin 
and is expressed during normal ageing, albeit at a lower level. Reduction in 
progerin production by targeting exon 10 SD and the mutation in exon 11 with 
phosphorodiamidate morpholino oligomers (PMOs) were proven in the 
LMNAG609G knock-in mouse model, resulting in an improvement in survival rate 
compared to untreated knock-in mice (Osorio et al., 2011). 
 
1.6.6.2 Cryptic splicing as a cause of ß-thalassaemia 
 
The majority of ß-thalassaemia patients have mutations in cryptic splice sites in 
the ß-globin gene (Busslinger et al., 1981). This mutation activates the cryptic 
splice sites, which causes aberrant splicing of the gene and subsequent 
generation of nonfunctional transcripts, leading to defective ß-globin expression. 
As a treatment option, 2’-O-methyl RNA AONs were developed in a pre-clinical 
model to target the cryptic splice sites in ß-globin to block the access of 
spliceosomes to those sites and restore cryptic splicing (Dominski and Kole, 
1993) (Svasti et al., 2009). However, the treatment for ß-thalassaemia by AONs 
is not clinically established yet and viral vector-mediated treatment is being 
further developed to be more durable (Arechavala-Gomeza et al., 2014). 
 
1.6.6.3 Alternative splicing and cancer 
Abnormalities of alternative splicing were reported in cancer (reviewed in (Tazi 
et al., 2009)). Tumour generation is related to a mutation in cis- or trans-acting 
splicing regulatory factors including RNA binding heterogeneous nuclear RNP 
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(hnRNP) and SR proteins. Changes in the concentration, localisation, 
composition, or activity of such regulatory proteins alter the splicing site 
selection. For instance, a splicing isoform of the tyrosine kinase receptor for the 
Macrophage-stimulating protein Ron is related to breast and colon cancer (Zhou 
et al., 2003). The exon 11 (147 nucleotides) skipping form of Ron (ΔRon) is 
constitutively active and abnormal accumulation correlates with a metastatic 
phenotype. The inclusion or exclusion of exon 11 is controlled by two regulatory 
sequences, an enhancer and silencer, in the exon 12 and by the level of SR 
protein SF2/ASF that binds to those elements (Ghigna et al., 2005). Mutations 
that affect splice site selection can also produce non-functional tumour 
suppressor transcripts. In colorectal cancer (Markowitz and Bertagnolli, 2009) 
mutations in regulatory elements of adenomatous polyposis coli (APC), the 
tumour suppressor gene, affect exon skipping of the exon 4 (Neklason et al., 
2004) or a single nucleotide deletion at the beginning of the exon 8 (Kurahashi et 
al., 1995).  
 
In contrast, alternative splicing could produce isoforms that prevent 
tumorigenesis. For instance, persistent phosphorylation of STAT3, a 
transcription factor implicated in cytokine and growth factor signalling, was found 
in the majority of human cancer (Spitali and Aartsma-Rus, 2012). STAT3 has 
two isoforms: the full-length STAT3-alpha, and a shorter STAT3-beta. The 
STAT3-beta is produced by a cryptic SA within the exon 23, resulting in a lack of 
C-terminal transactivation domain. The STAT3-beta downregulates the 
expression of genes involved in proliferation and cancer and promotes apoptosis 
(Caldenhoven et al., 1996). This idea was utilised as a strategy to anti-cancer 
therapy by applying a PMO targeting the cryptic SA in exon 23 to increase the 
production of STAT3-beta (Zammarchi et al., 2011). Similarly to STAT3, 
production of a short form of anti-apoptotic protein Bcl-x, called Bcl-xS, is known 
to lead to apoptosis in different cancer cell lines (Sumantran et al., 1995) 
(Lindenboim et al., 2000) (Hossini et al., 2003) (Singh et al., 2016). The selection 
of an SD proximal to exon 2 results in Bcl-x, while an SD distal to the exon 2 
results in Bcl-xS formation.  
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1.6.6.4 Alternative splicing and HIV replication 
 
Alternative splicing is a key mechanism that is used by most DNA viruses and 
nuclear replicating RNA viruses including HIV (reviewed in (Karn and Stoltzfus, 
2012)). HIV has three classes of transcripts distinguished by the length (1.8, 4 
and 9 kb) that are produced by alternative splicing from its polycistronic 
pre-mRNA (Tazi et al., 2010) (Fig.1-9). These transcripts are produced by the 
combinational use of different splice sites on the genome. On the HIV genome 
there are four splice donors (D1, D2, D3 and D4) and eight splice acceptors (A1, 
A2, A3, A4a, A4b, A4c, A5 and A7) which result in more than 40 different spliced 
mRNA species (Karn and Stoltzfus, 2012). In addition, cis-acting elements, 
namely exonic/intronic splice silencer (ESS, ISS) and exonic/intronic splice 
enhancer (ESE, ISE), further regulate the splicing of transcripts negatively or 
positively.  
 
In general, HIV-1 SAs are relatively inefficient compared to constitutive cellular 
SAs (Martin Stoltzfus, 2009). However, those splicing controlling cis-acting 
elements make a difference in the relative abundances of each viral mRNA 
species. For instance, two ESS elements within the first tat coding exon repress 
A3 SA (Jacquenet et al., 2001). This results in a reduction in the level of both 
incompletely and completely spliced tat mRNA. In contrast, a 
guanosine-adenosine-rich ESE element within the exon 5 facilitates splicing at 
weak SAs (A4a, A4b, A4c, and A5) to increase the level of incompletely spliced 
env/vpu and completely spliced nef and rev mRNAs (Purcell and Martin, 1993). 
In addition, mutations in splice sites also affect viral infectivity by altering the 
relative amount of each transcript. For instance, 5’ splice site D2 mutation 
decreases the affinity of U1 snRNP and the inclusion of exon 2, therefore the 
level of vif mRNA and the protein is also reduced (Madsen and Stoltzfus, 2006). 
The produced virus with low Vif protein expression would be more sensitive to 
APOBEC3G inhibition than wild-type HIV (1.2.16).  
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Fig.1-9 The location of splice sites, elements, and the variations of spliced HIV 
transcripts  
(Top) HIV RNA genome. LTR is divided into three elements, U3 (grey), R (black), and U5 
(blue), respectively. The position of RRE is indicated by the red rectangle. (Middle) 
Three classes of HIV transcripts. The first nine kb transcripts are unspliced mRNAs. 
Splice sites (D with red bars: splice donor; A with black bars: splice acceptor) are 
indicated. The second 4 kb transcript is an incompletely spliced mRNA. The third 1.8 kb 
transcript is a completely spliced mRNA. The use of splice sites and genes encoded on 
each transcript are on the left or right of the first rectangle, respectively. Each form of 
spliced transcripts is illustrated on the right. (Bottom) The known HIV regulatory 
elements. Splicing enhancers or silencers are designated by vertical green or red bars, 
respectively. Each rectangle corresponds to each numbered exon. Figure reprinted from 
(Karn and Stoltzfus, 2012). 
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1.7 Aims of thesis 
 
To obtain more knowledge of IM by LV, we aimed to establish the model LV to 
investigate splice-in fusion mRNAs. This splicing form is generated by splicing 
from a host cellular SD to a vector SA as in the first report of mutagenic potential 
of LV (Cavazzana-Calvo et al., 2010). To investigate this particular type of 
splicing, we introduced a strong SA into a LV sequence for inducing splice-in 
efficiently. In addition, the model LV is promoterless to make marker gene 
express from a host promoter and in a chimeric form by splice-in. The 
construction of the model LV and the vector function in respect of vector titration 
was tested in Chapter 3. We then employed an IM assay established by our 
research group to test mutagenicity of the model vector and generated a mutant 
likely caused by integrations of the model LV. We took an approach of 
interrogating integration sites and characterisation of fusion mRNAs to 
understand the mechanism of the cellular transformation in Chapter 4. Because 
of the lack of information about host gene sequences in Chapter 4, next 
generation sequencing in mRNA was utilised. In the same assay, we used bulk 
transduced cells from a step before mutant isolation (STEP 4) by pooling 
recovered cells after IL-3 addition to see skewed gene expression that could 
lead to cell survival and transformation. 
 
Throughout the experiments presented in the result chapters, we also aimed to 
find some further modification in this model LV and the flow of mutant isolation to 
make the assay system optimal. This model vector could be used to assess the 
mutagenicity of future clinical vectors by comparing the frequency of mutant 
generation and expression of fusion mRNAs via splice-in. 
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2 Materials and Methods 
 
2.1 Cell culture  
 
2.1.1 Cell lines used in this PhD project 
 
HEK293T, WEHI3B, and Bcl15that were used in this study were a kind gift from 
Dr. Sean Knight. HEK293T cell line is immortalised by the expression of SV40 
largeT antigen (Thomas and Smart, 2005). WEHI3B cell line originated from 
Balb/c mouse mylomonocytic leukemia cells (Ymer et al., 1985) that have 
intracistarnal A particle (IAP) insertion in two locations, IL-3 and HoxA loci. 
These insertions maintain continuous IL-3 secretion and its immortalisation, 
respectively. Bcl15 cell line originated from Baf3 cells; that is, Balb/c mouse 
pro-B cell lines with the expression of B220 surface antigen not being expressed 
on mature B/T cells and monocytes (Palacios and Steinmetz, 1985). Bcl15 cells 
are apoptosis resistant by the continuous expression of human Bcl2 (Collins et 
al., 1992). 
 
Through this PhD project, HEK293T cells were used for transient virus 
production and LV transduction. Bcl15 cells were used for LV vector 
transduction and insertional mutagenesis assay. WEHI3B cells were used for 
harvesting the supernatant to support parental Bcl15 cell growth. In the routine 
culture, HEK293T and WEHI3B cells were cultured in D10 medium which is 
DMEM (Dulbecco’s Modified Eagle Medium) with Glutamax (Gibco, Carlsbad, 
CA, USA) supplemented with 50 U/ml Penicillin 50 µg/ml Streptomycin (Gibco) 
and 10 % Fetal bovine serum (FBS) (Labtech.com, Uckfield, UK) at 37 oC in 
10 % CO2. Bcl15 cells were also cultivated in the same condition with an 
additional supplement of 10 % WEHI3B supernatant in the culture medium. 
WEHI3B supernatant was harvested four days after the initial culture condition at 
1 x 105 cells/ml of cell density in 120 ml in a T175 flask (Corning, St Louis, MO, 
USA). The supernatant was filtrated with a 0.45 µm filter and stored at -20 oC. 
HEK293T cells are adhesive. At the cell passage, HEK293T cells were firstly 
trypsinized with 1 ml 25 % trypsin-EDTA (Gibco) by incubation for a few minutes 
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in 5 % CO2 and then the reaction was neutralised by adding 1 ml fresh D10 
medium. The 1:4 cells were seeded in a new flask, while WEHI3B and Bcl15 
cells were suspension cells. 1:4 and 1:20 cells, respectively, were seeded into a 
new flask every three to four days. 
 
Cell stocks were prepared by centrifugation followed by resuspending in FBS 
with 10 % DMSO (Sigma, St Louis, MO, USA). They were aliquoted into a 
cryotube (Corning) and stored at -80 oC in an isopropanol container. 
 
 
2.1.2 Cell viability/proliferation assay 
 
Cell viability/proliferation assay was performed for three purposes in this PhD 
study. Firstly, cell viability of the Bcl15 cell under different puromycin 
concentration was measured by trypan blue staining (Gibco) to decide the 
critical puromycin concentration that kills off the majority of parental Bcl15 cells. 
3.4 x 104 Bcl15 cells were cultured in duplicate wells (24-well plates) under 
different puromycin concentrations (0.1-1 µg/ml) for seven days. The cell 
number was counted on a hemocytometer. 10 % WEHi3B supernatant was kept 
in the culture. 
 
Secondly, cell viability/proliferation assay was performed to test if the isolated 
IL-3 independent clone (the IL-3I clone) secretes autocrine factors in the 
supernatant. We tested cell viability of parental Bcl15 cells cultured in the 
supernatant from WEHI3B cells or the IL-3I clone. For this purpose, two 
techniques were employed independently: trypan blue staining (Gibco) and 
colorimetric assay CTK-8 (Dojindo, Munich, Germany). The supernatant from 
both WEHi3B cells and the IL-3I clone was harvested 24 h after seeding cells at 
5 x 105 cells/ml. 3.4 x 104 cells were seeded in 1 ml in a 24-well plate in 
duplicates. We tested 20 and 100 % of the IL-3I clone supernatant and 0.01, 
0.05, 0.1 (the concentration used only in Fig.4-3B), 0.5, 1 and 10 % of WEHi3B 
supernatant. The cell number was counted on a hemocytometer every 24 hours 
by trypan-blue staining. Cell expansion was estimated by the absorbance of the 
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culture at 450 nm by MultiskanTM FC Microplate Photometer (Thermo Scientific, 
Wilmington, DE, USA) that was measured after the reagent was added and 
incubated for 4h. The absorbance was monitored every 24 hours from when 
cells were initially seeded. The absorbance number over the experimental 
period was normalised by the absorbance number obtained on Day 0. The 
absorbance in empty wells was considered as background absorbance and was 
subtracted from the other test wells with cells. All experimental conditions were 
performed in duplicate wells. 
 
Finally, cell viability/proliferation assay was performed to see the difference 
between cell density and the rate of cell proliferation of the Il-3I. Three initial cell 
densities (5.6 x 104 (low), 1.7 x 105 (medium), and 5 x 105 (high)) were prepared 
in duplicate wells (24-well plates). Cell proliferation was measured by 
colorimetric assay CTK-8 (Dojindo) every 24 hours up to three days. The method 
of measurement was as described in the previous paragraph. 
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2.2 Construction of lentiviral vectors for splice-in study 
 
pSIN-BX-IRES-Em (pSFFV-Em in this thesis) 
The splice-in model vector plasmid used in this study, pGhr IRES-Em, was 
constructed based on pSIN-BX-IRES-Em that was kindly provided by Dr. Y 
Ikeda. pSIN-BX-IRES-Em was used as a positive control vector for Em 
expression at FACS. It contains a spleen focus-forming virus (SFFV) promoter, 
followed by internal ribosomal entry site (IRES) to drive the expression of 
Emerald (Em) (Demaison et al., 2002)). This vector also contains the woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) to enhance gene 
expression (Zufferey et al., 1999). The 3’ LTR of the vector has a deletion in 
promoter/enhancer sequence in the U3, thus this SIN vector theoretically has no 
transcriptional initiation from the 5’ LTR. The restriction enzyme sites important 
for other vector construction in this thesis are indicated in Fig.3-2. EcoRI locates 
upstream of SFFV. BamHI and XhoI locate between SFFV and IRES. NcoI 
locates between IRES and Em. NotI locates between Em and WPRE. 
 
pUBIQ-Puro 
This construct is a kind gift by David Escors (Escors et al., 2008). The vector 
encodes a ubiquitin promoter to express a puromycin resistant (puroR) gene; 
therefore, it was used as a positive control for puro drug selection of transduced 
cells by puro construct. 
 
pGhr IRES-Em/Puro 
In order to construct a vector model that can induce splice-in insertional 
mutagenesis (IM), a strong splice acceptor (SA) derived from Ghr exon 2 was 
introduced. The SA of the Ghr exon 2 was detected as a dominant SA site that 
was used in virus-host cellular transcripts expressed in IL-3 independent 
mutants to support its survival without IL-3 supply into the culture (Bokhoven et 
al., 2009). Using the gDNA of parental Bcl15 cells (2.4.2), the growth hormone 
receptor (Ghr) locus was amplified by PCR primers (Ghr Fw and Ghr Rc, Table 
2-1) which includes 150 nt of the intron 1 and 56 nt of exon 2, followed by three 
stop codons in three translation frames to separate the marker protein from the 
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host-vector fusion protein. The synthetic stop codons are located between 
BcmHI and XhoI. The DNA fragment of Ghr exon 2 with three stop codons was 
replaced with the SFFV promoter in pSIN-BX-IRES-Em by EcoRI and XhoI. 
pGhr IRES-Puro was constructed by replacing the Em with puro that was 
amplified on pUBIQ-Puro by PCR primers (Puro Fw and Puro Rc, Table 2-1) and 
replaced by BspHI (compatible restriction enzyme site of NcoI) and NotI.  
 
pIRES-Em/Puro 
The derivative vectors of pGhr IRES-Em/Puro, pIRES-Em/Puro, were 
constructed to test background transgene expression compared to that from 
pGhr IRES-Em/Puro. In order to remove the introduced sequence of the Ghr 
exon 2 locus, but leave the synthetic three stop codons, the PCR-amplified 
fragment 5’ NruI-RRE-cPPT-BamHI 3’ (1591 nt) by primers NruI RRE F and 
BamHI cPPT Rc was replaced with the corresponding region of the vector.  
 
pGhr IRES-Em/Puro SV40 rev 
Another derivative vector of pGhr IRES-Em/Puro, pGhr IRES-Em SV40 rev, has 
a reverse-oriented region within the vector as described (Fig.3-2E) to test its 
mutagenicity. Initially, SV40 late polyA signal flanked by 5’ NotI and 3’ EcoRI 
was introduced at the downstream of the transgene. pGhr IRES-Em/Puro has 
another EcoRI restriction enzyme site at 152 nt upstream of SA of the Ghr exon 
2. The sequence flanked by the EcoRI sites was digested and ligated again. The 
vector with the reverse orientated fragment was screened by sequencing.  
 
All PCR-amplified DNA fragments during vector construction, were initially 
subcloned into a pJET1.2/blunt cloning vector (Thermo Scientific) and 
sequenced using the commercial pJET1.2 forward/reverse sequencing primer 
(pJET Fw/Rv, 10 µM) to confirm if any mutation was not inserted (Table 2-1). In 
order to confirm that a final vector construct upon DNA ligation was valid, 
diagnostic DNA digestion, as well as the confirmation of vector sequence of the 
boundary of each ligated fragment, was performed if any mutations or deletions 
occurred. The obtained sequences were analysed using DNAdynamo 
(http://www.bluetractorsoftwa re.co.uk/). 
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Table 2-1 Primers used for vector construction 
 
Primer name Primer sequences (5’ to 3’) 
Ghr Fw CTCGGAATTCTGAAGTCTGAGGC 
Ghr Rc CAGTCTCGAGCTAGTTATTCAGGATCCCTGGTGACTGCCAGTGC
CAA 
Puro Fw AGTCTCATGACCGAGTACAAGCC 
Puro Rc ATGCGGCCGCTAATTCCCTCGAGTCA 
NruI RRE F GGGAGAATTAGATCGCGATG 
BamHI cPPT Rc TCAGGGATCCGATATCAAGCTTATC 
SV40 F NotI GACTAGCGGCCGCAGCTTATAATGGTTACA 
SV40 RC ACTCCGCGGGAATTCCAGACATGATAAGATAC 
pJET Fw CGACTCACTATAGGGAGAGCGGC  
pJET Rv AAGAACATCGATTTTCCATGGCAG  
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2.3 Molecular cloning 
 
2.3.1 Polymerase chain reaction (PCR) 
 
General PCR on DNA was employed for vector cloning, semi-quantitative mRNA 
expression (RT-PCR), vector integration site identification (2.5.5), and detection 
of host-vector fusion transcripts (2.5.6). Different polymerases were used for 
different purposes as described below. 
 
For plasmid cloning (2.2), or sample preparation for RNAseq (2.6), high fidelity 
KOD polymerase (Novagen, Gibbstown, NJ, USA) was used to minimise the 
occurrence of mutations in target sequences. For colony screening after 
bacterial transformation with cloning vectors (2.3.8), GoTaq G2 Hot Start Green 
Master Mix (Promega, Madison, WI, USA) was used to test if the target DNA 
fragment was successfully inserted. GoTaq G2 Hot Start Green Master Mix 
contains the high-performance GoTaq G2 DNA polymerase that binds to a 
proprietary antibody that blocks polymerase activity; hence, the pre-incubation at 
94 or 95 oC before PCR reaction is required to restore the polymerase activity. 
Ligation-mediated PCR (LM-PCR) (2.5.5) and 5’ RACE (2.5.6) was performed 
by Taq polymerase (Qiagen, Hilden, Germany). This polymerase was chosen 
because the reaction needs amplification with sufficient fidelity, but not too high.  
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Table 2-2 Composition of reactions for KOD polymerase PCR 
 
Components Concentration Amount per 
reaction (µl) 
10 x Buffer 10 x  5 
MgSO4 25 mM 3 
dNTPs 2 mM each 5 
Primer (Forward) 10 µM 1.5 
Primer (Reverse) 10 µM 1.5 
KOD polymerase - 1 
Nuclease-free H2O - Up to 50 µl 
Template DNA 1 to 50 ng (plasmid DNA) X** 
Total amount (µl)  50 
X; valuable amount 
 
 
Table 2-3 Cycle conditions for KOD polymerase PCR 
 
Temperature (oC) Time Cycle number 
95 2 mins 1 
95 20 sec 
20-40 X 10 sec 
70 Y sec*/kb 
70 7 mins 1 
* Annealing temperature X is decided as -3 to -5 oC of the melting temperature (Tm) of a 
primer. The elongation time Y depends on the length of the fragment. If the fragment 
length is less than 500 bp, the elongation time is 10 s/kb. If the length of the amplicon is 
500 to 1000 bp, 1000 to 3000 bp, or more than 3000 bp, the elongation time is 15 s/kb, 
20 s/kb, or 25 s/kb respectively. 
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Table 2-4 Composition of reactions for GoTaq G2 DNA polymerase PCR 
 
Components Concentration Amount per  
reaction (µl) 
GtoTaq G2 Hot Start Green MasterMix 2 x 12.5 
Primer (Forward) 10 µM 2.5 
Primer (Reverse) 10 µM 2.5 
Bacteria colony 1 colony - 
Nuclease-free H2O - 7.5 
Total amount - 25 
 
 
Table 2-5 Cycle conditions for GoTaq G2 DNA polymerase PCR 
 
Temperature (oC) Time Cycle number 
95 2 mins 1 
95 30 sec 
30 50 45 sec 
72 1 min 
72 5 mins 1 
 
 
2.3.2 Restriction enzyme digestion for plasmid cloning 
 
This technique was used for cutting out a DNA fragment in a vector and cloning 
it into another vector or diagnostic purpose. The digestion reaction was 
performed in 50 µl total reaction volume for plasmid cloning, followed by gel 
excision and purification (2.3.5), while in 20 µl for diagnostic digestion to test 
whether a size of DNA fragment is as expected. 
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Table 2-6 Experimental components and conditions for restriction digestion 
 
Component Diagnostic purpose  Cloning purpose 
10 x Buffer* 2 5 
100 x BSA** 0.2 0.5 
DNA  200-500 ng >1 µg 
Nuclease-free water Determined by the amount 
of DNA and RE 
Determined by the 
amount of DNA and RE 
Restriction enzyme 
(RE, Promega) 
Enzyme unit*** number for 
the amount of input DNA 
Enzyme unit number for 
the amount of input DNA 
Total volume (µl) 20  50 
Incubation 
temperature (oC) 
According to enzyme 
(e.g.37 oC) 
According to enzyme 
(e.g.37 oC) 
Incubation time 1 to 2 hours a few hours to overnight 
10 x buffer*; according to the choice of restriction enzyme, the company-suggested 
buffer was chosen, BSA**, Bovine Serum Albumin, to stabilise enzymes in the reaction 
mix, Enzyme unit***; one enzyme unit can digest 1 µg DNA in an hour. 
When using different REs in one reaction mix, the amount of RE was adjusted according 
to the enzyme efficiency in the chosen buffer (e.g. if the enzyme efficiency is 50 %, twice 
the amount was added). The digested product was electrophoresed for the diagnostic 
test or for gel purification. 
 
 
2.3.3 Agarose gel electrophoresis 
 
In order to prepare 1 % of agarose gel for instance, 1.0 g agarose (Sigma) was 
prepared in 100 ml 1 x Tris base, acetic acid, and ethylenediaminetetraacetic 
acid (EDTA) (TAE) buffer (the stock concentration: x 50). This mixture was 
heated in a microwave until all the agarose particles were dissolved 
homogenously in the 1 x TAE. Once the gel had cooled down, ethidium bromide 
(Dutscher Scientific, Essex, UK) was added to the final concentration at 0.25 
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µg/ml. The agarose gel was poured into a tray with an appropriate size and a 
good comb was inserted. Once the gel was solidified, the gel was set inside an 
electrophoresis tank (BIO-RAD, Dublin Ireland) filled with 1 x TAE. Upon 
electrophoresis, samples were mixed with 6 x loading buffer (Thermo Scientific) 
to make the final concentration at 1 x and load in each well. 1 kb plus DNA 
ladder (Invitrogen, Carlsbad, CA, USA) was run in parallel to indicate the DNA 
size. When better band separation was required, a gel with higher concentration 
(2 %) was used. The electrophoresis was performed with an electric current of 
100 V from 45 minutes to 1 hour for DNA fragments to migrate to an anode. In 
order to visualise the DNA fragments the gel was exposed to UV light in the 
GelDoc-It®e Imaging System (UVP, Cambridge, UK). 
 
 
2.3.4 Purification of electrophoresed PCR product  
 
When a PCR product was used for cloning, 5 µl was loaded in “a reference well” 
and 45 µl in “an excision well”. After the electrophoresis, the reference well was 
exposed to UV light on High Performance Transilluminators (UVP) to confirm the 
location of the DNA band to be excised in the excision well that was not exposed 
to UV light. Using a blade, the corresponding part in the excision well was 
excised. The excised agarose gel was purified by a Gel Extraction Kit (Qiagen) 
according to the manufacturer’s protocol. The final eluted sample was used for 
ligation or cloning. The concentration of the purified DNA was measured by 
Nanodrop 3300 spectrophotometer (Thermo Scientific). The sample was kept at 
-20 oC. 
 
 
2.3.5 DNA dephosphorylation treatment for plasmid cloning 
 
Upon plasmid cloning, DNA dephosphorylation was performed to avoid the 
self-ligation of a DNA fragment that was digested by the one restriction enzyme 
at both ends. Calf intestinal alkaline phosphate (CIAP, Promega) was used to 
remove phosphate groups from both 5’ termini. The CIAP (1 u/µl) was used by 
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1:100 dilution up to 10 pmol of 5’ ends of DNA. The reaction was performed by 
incubation at 37 oC for 30 minutes, twice, by adding the same amount of CIAP 
before the second round of the incubation. For the following purpose, such as 
ligation, this reaction mix was purified by the Gel Extraction Kit (Qiagen) to get 
rid of any inhibitory compounds in it. 
 
 
2.3.6 DNA ligation for vector cloning 
 
T4 DNA ligase (Promega) was used to ligate a DNA fragment with another piece 
that has compatible ends to be ligated. The general condition for ligation was set 
up in 10 µl according to the manufacturer’s instructions. 10 x ligation buffer that 
was provided by Qiagen was added to the reaction mix at the final concentration 
of 1 x. In general condition, 1:3 molar ration of backbone to insert was used. 
0.1-1 u of ligase (3 weiss unit/µl, the original enzyme stock) was used for 100 ng 
DNA vector. Nuclease-free water was used to adjust the reaction mix to 10 µl. 
Ligation reaction mix was incubated overnight at 4 oC. The ligation mix was 
stored at -20 oC. 
 
 
2.3.7 Subcloning digested/amplified fragments in pJET cloning vector  
 
Subcloning in this study was performed using CloneJET PCR Cloning Kit 
(Thermo Scientific). pJET1.2/blunt cloning vector was designed for the 
subcloning of blunt-ended DNA such as DNA amplified by KOD polymerase. 
Even DNA has sticky end by restriction enzyme digestion or PCR amplification 
by Taq polymerase. DNA blunting enzyme (thermostable DNA blunting enzyme 
from E.coli with proofreading activity) can make the sticky ends blunt end prior to 
ligation. Firstly, 2 x reaction buffer was added to make the final concentration at 
1 x into the reaction mix with the DNA template. This reaction mix was incubated 
at 70 oC for 5 minutes and immediately placed on ice. Secondly, the blunted 
DNA fragment was ligated into the multiple cloning sites in a pJET1.2/blunt 
cloning vector (50 ng) with T4 DNA ligase. The reaction mix was incubated at a 
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room temperature (22 oC) for five minutes to complete ligation. 5 µl of the 
reaction mix was used for bacterial transformation (2.3.8). 
 
 
2.3.8 Bacterial transformation by heat shock method 
 
XL1-blue competent bacteria (Invitorgen) were used to incorporate foreign 
vector plasmids and transform them to produce and purify the plasmids. 
XL1-blue competent bacteria that were stored at -80 oC were thawed on ice for 
15 minutes, followed by inoculation of an aliquot of ligation mix (5 µl) or DNA 
plasmid (100 ng). This XL1-blue bacteria and DNA mix were incubated on ice for 
20 minutes, allowing them to take up the exogenous DNA in the meantime. In 
order to enclose the DNA into the competent bacteria, heat shock was given at 
37 oC for two minutes precisely. Immediately after the heat shock, the bacteria 
and DNA mix were incubated on the ice again for a few minutes and seeded on 
an LB agarose plate with ampicillin. The plate was incubated at 37 oC overnight 
to obtain bacterial colonies that potentially carry target DNA plasmids. Before 
preceeding those plasmids to 2.3.10, colony PCR was performed to identify 
which colony carries the target plasmid. 
 
 
2.3.9 Antibiotics selection of transformed bacteria  
 
Ampicillin (Sigma) was used to screen transformed bacteria that have a plasmid 
with an ampicillin-resistant gene. The ampicillin-resistant gene catalyses the 
hydrolysis of the ß-lactam ring of ampicillin to detoxify, thus bacteria which have 
DNA plasmid with an ampicillin resistant gene can survive in the 
ampicillin-containing culture. In order to purify plasmids, bacteria were cultured 
in LB medium with ampicillin (2.3.10). 
 
 
2.3.10 Plasmid purification in cultured bacteria 
Seeding the colonies obtained in 2.3.8, bacteria were cultured with a vigorous 
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shake at 37 oC for 14 to 16 hours in 2 ml (miniprep) or 50 - 100 ml (midiprep) LB 
medium with ampicillin at 100 µg/ml. Pelleted bacteria were lysed and then 
column-purified by the Qiagen Miniprep Kit or Midiprep Kit (Qiagen). The 
concentration of purified DNA was measured by a Nanodrop 3300 
spectrophotometer (Thermo Scientific). The purified plasmid was digested with a 
restriction enzyme to confirm that the purified DNA was the target product. 
 
 
2.3.11 In silico splice site identification of our test vectors 
 
Prior to the vector virus titration, test vectors including pGhr IRES-Puro, 
pIRES-Puro, and pGhr IRES-Puro SV40 rev were analysed by the NetGene2 
splice sites identifier (http://www.cbs.dtu.dk/services/NetGene2/) (Brunak et al., 
1991) (Hebsgaard et al., 1996). Each proviral sequence was used as input. 
Splice sites were identified on both strands with nucleotide position and 
confidence that defines the likeliness of the site used (where 1 = a consensus 
splice site).  
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2.4 Gene transfer to Mammalian cells 
 
2.4.1 Transient lentiviral vector (LV) production by three plasmids on 
HEK293T cells 
 
The all virus supernatant used in this project was produced by transient 
transduction by three plasmids in HEK293T cells. The vector genome plasmids 
were p8.91 (packaging plasmid encoding gag-pol) and pMDG (VSV-G 
envelope-coding plasmid) as described previously (Zufferey et al., 1997). On 
day one, 2 x 106 HEK293T cells were seeded in 12 ml D10 medium in a 100 
mm2 dish (Corning) and cultured in 10 % CO2 overnight. On day two, 
premixed-vector components of 1.5 µg of vector plasmid and 1 µg each of p8.91 
and pMDG were then mixed with 200 µl Optimem (Gibco) and 10 µl FuGene 6 
(Promega) and incubated at room temperature for 15 minutes. Meanwhile, the 
old medium was replaced with 8 ml fresh DMEM. Then, the incubated mixture 
was added onto the HEK293T cells. Cells were cultured at 37 oC in a 10 % CO2 
incubator. At 24 hours post-transfection, the medium was replaced with 8ml 
fresh D10 medium. At 48 and 72 hours post-transfection, virus supernatant was 
harvested and filtrated with a 0.45 µm filter and cryopreserved at -80 oC. Those 
supernatants were used for transduction to titrate it (2.4.3). 
 
 
2.4.2 Genomic DNA (gDNA) extraction to obtain vector copy number in 
transduced cells 
 
Extracted genomic DNA (gDNA) was used for vector titration to determine the 
vector copy number in transduced cells and for identification of vector integration 
sites by ligation-mediated PCR (LM-PCR). Generally, 1 x 106 cells (the 
maximum cell number: 5 x 106) that were counted by trypan blue staining were 
used for gDNA extraction using the DNeasy Blood and Tissue Kit (Qiagen). 
When the number of cells was harvested, cells were washed a few times with 1 x 
PBS to remove DMEM and centrifuged to make cell pellets. The supernatant 
was discarded and the gDNA was extracted according to the manufacture’s 
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protocol. The concentration of the eluted sample was measured by Nanodrop 
3300 spectrophotometer (Thermo Scientific). The sample was kept at -20 oC 
until its use. 
 
 
2.4.3 Vector titration to estimate vector infectivity to host cells 
 
2.4.3.1 The vector titration of EmGFP vectors by fluorescence activated 
cell sorting (FACS) 
 
HEK293T cells have higher vector infectivity in comparison to Bcl15 cells 
according to the previous research carried out by our group. Therefore, virus 
titration experiments were performed onto both HEK293T cells and Bcl15 cells. 
Firstly, HEK293T cells were prepared at the concentration of 2 x 106 cells/ml in 
D10 medium that contained 8 µg/ml polybrene (Sigma). Separately, serial 
dilutions (1:5 reduction serially, four points for SA and SA-less vector, and four 
points for the positive control vector) of test virus supernatant were prepared 
with 8 µg/ml polybrene. Secondly, 300 µl of cell-contained D10 medium (6 x 105 
total cells) and 200 µl viral supernatants were added into 12-well plates 
(Corning). When cells were plated, the cell number was measured again to 
obtain the accurate cell number to use for a more accurate calculation of titre. 1 
ml of fresh D10 medium was added 24 hrs post-transduction to dilute polybrene 
and avoid any of its inhibitory effects on cell growth.  
 
Using the similar protocol with HEK293T cells, Bcl15 cells (24-well plates) were 
re-suspended in D10 medium with 8 µg/ml polybrene to make the cell 
concentration of 105 cells/ml. Separately, serial dilutions (1:5 reduction serially, 
four points for an SA and an SA-less vector, and five points for a positive control 
vector) of test virus supernatant were prepared with 8 µg/ml polybrene. When 
cells were plated, the cell number was measured again to obtain the accurate 
cell number to use for a more accurate calculation of titre. The transduced cells 
were scaled up in a T25 flask to 10 ml four hrs post-transduction.  
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FACS was performed 48 hrs post-transduction. Before processing transduced 
cells to measure the fluorescence, they were fixed. Firstly, HEK293T cells were 
trypsinized. Then, HEK293T and Bcl15 cells were re-suspended in 0.5 ml 2 % 
paraformaldehyde (PFA, Sigma) and transferred into a FACS tube (FALCON, St 
Louis, MO, USA). Gene expression in the transduced cells was detected by BD 
FACSCalibur™ (BD Biosciences, San Jose, CA, USA) and analysed by 
CellQuest Pro software (BD Biosciences). 
 
The titre for Emerald GFP (EmGFP, the further enhanced eGFP) vectors was 
estimated using the following formula. 
Titre (IU/ml) = the number of cells exposed to virus (initial cell number) x 
proportion of GFP positive cells (%) x dilution factor* 
* Virus dilution factor was calculated by dividing the virus input (µl) by 1000 
 
 
2.4.3.2 The measurement of vector titration by quantitative PCR (qPCR) 
 
In addition to titre measurement by FACS, vector titre was estimated based on 
the vector copy number transferred into the host genome. Using the same 
transduced cells that were processed by FACS, an aliquot of HEK293Tor Bcl15 
cells were kept passed for seven to 10 days for gDNA extraction. When cells 
were harvested, the cell number was counted by trypan blue (Gibco) staining 
and 1 x 106 cells were processed by gDNA extraction. After cells were washed 
once with 1 x PBS (Gibco) to remove culture medium, gDNA was extracted via 
column-purification by the Qiagen DNeasy Blood and Tissue kit (Qiagen) 
according to the manufacturer’s protocol. SYBR green dye (Qiagen) was chosen 
for quantitative PCR (qPCR). The qPCR was performed by 7500 Fast Real-Time 
PCR System (Applied Biosystems, Warrington, UK) and analysed with 7500 
Software version 2.0.6. The analysis software calculated the correlation 
coefficient (r2) of the standard curve, standard deviation of triplicates, and copy 
number of samples based on the standard curve. Standard curves were 
accepted as an efficient reaction when r2 was >0.98 and the slope of the 
standard curve was between -3.2 and -3.9. 
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Primers for HIV-1 leader sequence were routinely used to obtain the total 
number of vector integrations into the host cellular genome, while human beta 
actin (HEK293T cells) or mouse beat actin (Bcl15 cells) were also used to 
normalise the vector copy number (Table 2-7).  
 
 
Table 2-7 The primer list for SYBR green-based qPCR 
 
Amplification 
target 
qPCR primer 
name 
Primer sequence (5’ to 3’) Standard 
plasmid 
HIV leader 
sequence 
GT248 TGTGTGCCCGTCTGTTGTGT SIN pHV 
GT249 GAGTCCTGCGTCGAGAGAGC 
Human beta 
actin 
HB-actin-F TGGACTTCGAGCAAGAGATG pJET-HB 
actin HB-actin-RC TTAAGTAGGCCGTCTTGCCT 
Mouse beta actin MB-actin F AGAGGGAAATCGTGCGTGAC pJET-mB 
actin MB-actin Rc CAATAGTGATGACCTGGCCG 
 
 
Table 2-8 Reaction components for SYBR green-based qPCR 
 
Components Concentration 
Standard 
samples (µl) 
Test 
samples (µl) 
SYBR green master mix 2 x 12.5 12.5 
Primer (forward) 20 µM 0.5 0.5 
Primer (reverse) 20 µM 0.5 0.5 
Nuclease-free H2O - 6.5 X 
Standard vectors 
gDNA 
10n copies/µl 
100 ng 
5 Y 
Total (µl) - 25 25 
 
 
Reaction was set up in an optical 96-well plate (Applied Biosystems). The top of 
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the plate was sealed by an adhesive sheet (Applied Biosystems) and centrifuged 
briefly before loading the plate on the machine 7500 Fast Real-Time PCR 
System (Applied Biosystems).  
 
 
Table 2-9 Cycle conditions for SYBR green-based qPCR  
 
Temperature (oC) Time Cycle number 
95 15 mins 1 
95 (denature) 15 sec 
40 55 (annealing) 30 sec 
72 (extension) 30 sec 
Melting curb analysis 
Data retrieval was automatically set at the extension step by the machine. 
 
 
In order to calculate titre from the obtained vector copy numbers, per sample, 
the cell number to 100 ng gDNA was calculated using the molecular weight of 
double stranded DNA as follows. The length of the haploid human genome per 
cell is 3,099,734,149 bp (http://www.ncbi.nlm.nih.gov/projects/genome 
/assembly/grc/hum an/data/). HEK293T cells are hypotriploid cells, containing 
less than three times the number of chromosomes compared to a normal human 
haploid cell (Lin et al., 2014). Hence, the total genome length per cell was three 
times the haploid genome length. The single DNA mass (675 Da per bp) was 
applied to convert the unit of bp to Da. Total DNA mass (Da) was converted into 
g using 1.66 x 10-27 kg per Da. 100 ng of gDNA was used for each sample, which 
theoretically contains 9594 cells. Multiplicity of infection (MOI) is defined as the 
vector copy numbers per single cell. Therefore, MOI was obtained by dividing 
the raw vector DNA copy number by the cell number to 100 ng gDNA. The 
length of the haploid mouse genome is 2,803,568,840 bp 
(http://www.ncbi.nlm.nih.gov/assembly/GCA000001635.6). Bcl15 cells are 
diploid; therefore the total genome length per cell was twice the size of the 
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haploid genome length. According to the conversion of bp to the cell number, as 
used in HEK293T cells, 100 ng of samples were assumed to be derived from 
15911 cells. 
 
In order to draw a standard curve to obtain the vector DNA copy number in test 
samples, SIN pHV plasmid (lentiviral vector with SIN LTR, a kind gift from Dr. 
Sean Knight) (Knight et al., 2010), that contains the HIV-1 leader sequence, was 
serially diluted (10, 102, 103, 104, 105 copies per µl). The target copy in each 
sample was proportional to test sample amplification that was shown by Ct value. 
Vector titre was defined by the following formula. 
 
Titre (IU/ml) = the number of cells exposed to virus (initial cell number) x MOI 
(raw vector copy number that was divided by cell number in 100 ng gDNA) x 
dilution factor* 
* Virus dilution factor was calculated by dividing virus input (µl) by 1000 
 
 
2.4.3.3 The measurement of vector titration of puromycin vector by 
puromycin selection 
 
Transduction of puromycin vectors was also performed on HEK293T and Bcl15 
cells. In the case of HEK293T cells, on day 1, 2 x 105 cells were seeded in a 
12-well plate in 2 ml D10 medium per well. On day two, one well was chosen to 
trypsinize HEK293T cells to obtain the cell number as the initial cell number for 
titre calculation later. Virus dilutions were serially made (1:5 reduction serially, 
four points for SA and SA-less vector, and five points for positive control vector) 
in D10 medium with 8 µg/ml polybrene (Sigma). The old culture was removed 
and 500 µl of the diluted virus supernatant was added into each well. 24 hours 
later, in order to select puromycin resistant transduced cells, a quarter of the 
cells (2 x 105) were transferred into 6-well plates onto three ml D10 medium that 
contains 1 µg/ml puromycin. Separately, an aliquot of the rest of the cells were 
passaged in a 12-well plate for seven to 10 days without puromycin to use for 
qPCR. Cell growth in the puromycin culture was kept monitored under a 
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microscope for 10 to 14 days. Half of the culture medium was changed every 
three to four days to keep puromycin in the culture.  
 
1 x 105 Bcl15 cells in D10 medium with WEHI3B (D10WEHI20%) supernatant 
and 8 µg/ml polybrene were transduced with virus supernatant (1:5 reduction 
serially, four points for SA and SA-less vector, and five points for positive control 
vector) containing 8 µg/ml polybrene in a 24-well plate. At 24hr post-transduction, 
cells were diluted at 1:100 with D10WEHI10% containing 1 µg/ml puromycin and 
seeded into a 96-well plate. At the preliminary stage, when pruomycin 
concentration was decided, different concentrations were tested (0.5 to 1 µg/ml) 
to culture transduced cells by pGhr IRES-Puro. Positive control cells transduced 
by pUBIQ-Puro were cultured in 0.6, 0.8, 1 µg/ml puromycin. The rest of the cells 
were passaged in D10WEHI10% without puromycin for seven to 10 days to use 
for qPCR. The cell growth in the puromycin culture was kept monitored under a 
microscope for 10 to 14 days. Half of the culture medium was changed every 
three to four days to keep puromycin in the culture. 
 
Toward the end of the monitoring period in both cell lines, cell colonies (foci) for 
HEK293T and cell expansion in wells for Bcl15 were observed. Especially, in 
order to count the number of foci, the supernatant was completely removed from 
each well and wells were dried briefly under the clean bench. The number of foci, 
or wells, was considered as the number of single puromycin resistant (puroR) 
clones. Using this number, “transduction rate” is the ratio of puroR number 
against the total cell number seeded at puromycin selection. The transduction 
rate was obtained by dividing the obtained puroR clone number by the total cell 
number seeded when puromycin selection started (Table 2-10).  
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Table 2-10 The method of calculating titre based on the number of puroR cells 
 
Steps Cell number 
A: Initial cell number at 
transduction 
87,500/well 
B: Cell number 24 hrs 
post-transduction 
350,000/well 
Make 1:100 cell dilutions and 100 µl was plated in each well 
C: Initial cell number at the 
start of puro selection 
14,000/20 wells 
 
 
Puromycin titre was calculated using the formula below. 
Titre (IU/ml) = the number of cells exposed to virus (initial cell number) x 
(transduction rate)/(virus dilution factor*)  
*Virus dilution factor was calculated by dividing virus input (µl) by 1000 
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2.5 Insertional mutagenesis (IM) assay to obtain IL-3 
independent clones that could be caused by expression of 
splice-in fusion mRNAs 
 
2.5.1 IM assay protocol 
 
IM assay used in this study was based on the previously reported protocol that 
was established by our group (Bokhoven et al., 2009). The vector model in this 
study has a puromycin-resistant gene. Therefore, puromycin selection was 
performed to provide a better chance of screening potential IM events caused by 
splice-in. The virus supernatant used in the IM assays was primarily titrated 
before applying it. In order to achieve the aimed puroR clone number, a cell 
number and volume of the virus supernatant were determined based on this 
preliminary titration. 
 
On day one, Bcl15 in D10WEHI10% medium cells was transduced by pGhr 
IRES-Puro with 8 µg/ml polybrene in a t175 flask at 37 oC in 10 % CO2. 24 hrs 
post-transduction, the same number of cells with the transduction were 
transferred into a new t175 flask. Puromycin was added to make the final 
concentration at 1 µg/ml and kept cultured for three days. On the same day, 
puromycin selection of cells was performed using an aliquot of transduced cells 
to measure vector titre. The cells were seeded in 100 µl medium in 96-well 
plates with 1:2 serial cell dilutions from 2000 cells/well down to 62.5 cells/well. 
The leftover cells that were not used for any downstream experiments were 
cryopreserved as a backup. 
 
On day five, IL-3 that was kept in the culture was removed (IL-3 starvation). In 
order to remove IL-3 from the culture medium, cells were washed thrice with D10 
medium with the interval of 15-minute incubation at 37 oC. The washed cells 
were again re-suspended in D10 medium that contains puromycin (1 µg/ml) and 
seeded at 1-1.4 x 105 cells per well in 24-well plates with 1:3 cell serial dilutions. 
This IL-3 starvation was performed for two weeks, monitoring cell condition 
under the microscope. Because this step is known as being harsh to transduced 
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cells, preventing them with proliferation, then potential cell populations that could 
expand without IL-3 were rescued by adding WEHI3B to make the final 
concentration at 10 %. The cells were kept until cell proliferation was observed 
(up to one month). In order to verify whether the expanded cells were IL-3 
independent, IL-3 starvation was performed again in a t25 flask without IL-3 
supplement for two weeks to a month. The isolated IL-3 independent clone 
underwent the downstream analysis to examine integration site identification 
and fusion mRNAs expressed in the clone. 
 
 
2.5.2 RT-PCRon puromycin transcript to see if splice-in between the 
introduced Ghr exon 2 SA and an upstream SD is a major event 
 
Total RNA was extracted by the Qiagen RNeasy mini kit (Qiagen) from 1.5 x 106 
Bcl15 cells transduced by pGhr IRES-Puro. cDNA was synthesised by reverse 
transcription on the 1 µg total RNA by the Quantiscript Reverse Transcription kit 
(Qiagen) (M.M 2.3.3). PCR was performed with two different forward primers 
paired with a reverse primer on the synthesised single-stranded cDNA as a 
template. RT-PCR was carried out by GoTaq G2 DNA polymerase (Promega). 
The amplified samples were run in 1 % agarose gel and electrophoresed for 
DNA band detection. 
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Table 2-11 The list of primers to test splice-in the introduced Ghr exon 2 SA with an 
upstream SD 
 
Amplicons Forward primers (5’ to 3’) Reverse primers (5’ to 3’) 
Ghr (upstream of the 
Ghr SA) 
TCAGGTCTTCTTAACCTTGG
CA 
ACACCTTGCCGATGTCGAG 
 
Ghr (downstream of 
the Ghr SA) 
CTCGGAATTCTGAAGTCTGA
GGC 
ACACCTTGCCGATGTCGAG 
 
Puro  AGTCTCATGACCGAGTACAA
GCC 
ATGCGGCCGCTAATTCCCTC
GAGTCA 
 
 
2.5.3 Analysis in the IL-3 independent clone (the IL-3I clone) about the 
expression of IL-3 mRNA as an autocrine factor 
 
3 x 106 cells (the maximum cell number: 1 x 107) were washed with 1 x PBS and 
pelleted by centrifugation for total RNA extraction. Total RNA was extracted by 
following the manufacturer’s protocol of the Qiagen RNeasy Mini Kit using the 
column purification method (Qiagen). The concentration of extracted total RNA 
was measured by a Nanodrop 3300 spectrophotometer (Thermo Scientific). The 
rest of the extracted total RNA was kept at -80 oC to avoid its degradation.  
 
1 µg of total RNA of the IL-3I clone was reverse transcribed by the Qiagen 
Quantiscript Kit (Qiagen) to synthesise complementary DNA (cDNA). Firstly, 
extracted total RNA was treated with a gDNA wipe-out buffer to eliminate the 
gDNA contamination in RNA samples. This reaction is performed in 14 µl. Then, 
the gDNA-free template was reverse transcribed using the optimised cocktail of 
oligodT and random primers to increase the yield of the cDNA from all regions of 
RNA transcripts. This reaction is performed in 20 µl. The recombinant reverse 
transcriptase that contains the RNase inhibitor has three enzyme activities; 
RNA-dependent DNA-polymerase activity, RNaseH activity, and 
DNA-dependent DNA polymerase activity. Therefore, the final product can be 
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used directly in the next step without treating the sample with additional 
RNaseH. 
 
According to the manufacturer’s suggestion, 2 µl of the reverse transcribed 
product was used for RT-PCR and qRT-PCR to detect IL-3 mRNA. Both 
reactions were performed in 20 µl. As control samples, two negative controls 
(water control at PCR and from reverse transcription), WEHI3B cells, parental 
Bcl15 cells, and two step four survivors from the first IM assay were tested. 
WEHI3B and parental Bcl15 cells were tested as positive and negative controls, 
respectively, for IL-3 mRNA detection. In both RT-PCR and qRT-PCR, the 
amplification of mouse beta actin was tested as a standard control. In RT-PCR, 
amplified samples were run in 1 % agarose gel and electrophoresed for DNA 
band detection.  
 
 
Table 2-12 The list of primers used for RT-PCR and qRT-PCR in the IL-3I clone for IL-3 
mRNA detection 
 
Amplicons Forward primers (5’ to 3’) Reverse primers (5’ to 3’) 
IL-3 mRNA IL-3 Fw TATCCCGGGAATGGTTCTTGCCAGC 
IL-3 R GTCGACTTAACATTCCACGGTTCC 
Mouse beta actin MB-actin F AGAGGGAAATCGTGCGTGAC 
MB-actin Rc CAATAGTGATGACCTGGCCG 
 
 
2.5.4 Ligation mediated PCR (LM-PCR) to identify integration sites on 
gDNA 
 
This technique was employed to identify vector integration sites in transduced 
cells as previously described (Wu et al., 2003). Firstly, gDNA was extracted by 
the Qiagen DNeasy Blood and Tissue Kit from the isolated IL-3 independent 
clones (106 cells). 1 µg gDNA was digested by a four-cutter enzyme, Nlalll 
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(5’-CATG^-3’), overnight at 37 oC. The reaction mix was column-purified to 
remove any inhibitory agents within samples by a Gel Extraction Kit (Qiagen) for 
downstream use. A pair of linkers with Nlalll overhang sequence (100 pmol 
each) was synthesised by incubation at 95 oC for five mins then by cooling down 
to 15 oC (1 oC decrease/min). 0.5 pmol of the annealed linkers and 10 µl of 
digested gDNA were ligated by T4 DNA ligase (Promega) at 15 oC overnight. 
The reaction mix was again column-purified by the Gel Extraction Kit (Qiagen). 
This purified product was subjected to the first round of PCR. 1 µl of the first 
round of the PCR product was used in a nested PCR. HotStart Taq polymerase 
(Qiagen) was used for both PCRs. Primers used in this experiment are listed 
below. 
 
 
Table 2-13 The list of primers used for LM-PCR 
 
Purpose Primers Primer sequence (5’ to 3’) 
Linker generation Linker positive GTAATACGACTCACTATAGGGCTCCGCTT
AAGGGACTACATG 
Linker negative TAGTCCCTTAAGCGGAG 
1st PCR 3'LTR-F AGTGCTTCAAGTAGTGTGTGCC 
Linker F GTAATACGACTCACTATAGGGC 
Nested PCR Nested 3'LTR GTCTGTTGTGTGACTCTGGTAAC 
Nested F AGGGCTCCGCTTAAGGGAC 
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Table 2-14 Composition of reactions for HotStart Taq polymerase PCR for LM-PCR 
 
Components Concentration Amount per 
reaction (µl) 
10 x PCR buffer (contains 15 
mM MgCl2) 
10 x 10 
dNTPs  10 µM each 2 
Primer Fw 10 µM 5 
Primer Rv 10 µM 5 
Template DNA ≤1 µg/100 µl reaction 30 
Nuclease-free water - Up to 100 
HotStart Taq polymerase 2.5 units/reaction 0.5 
 
 
Table 2-15 Cycle conditions for HotStart Taq polymerase PCR for LM-PCR 
 
Temperature  
(oC) 
Time 
Cycle 
number 
95 15 mins 1 
94 45 sec 
30 50 30 sec 
72 1 min 
72 10 mins 1 
 
 
The final PCR products were electrophoresed on 2 % agarose gel containing 
ethidium bromide (Dutscher Scientific) and the excised DNA fragments were 
column-purified by the Gel Extraction Kit (Qiagen). The purified fragments were 
ligated into pJET1.2 cloning vectors (Thermo Scientific). The ligated vectors 
were transformed into XL1-Blue competent cells. The obtained bacterial colony 
was seeded and propagated in ampicillin-containing 2 ml LB medium. The 
sample plasmids were column-purified by Qiagen miniprep kit (Qiagen) and 
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sequenced with pJET commercial primers (Table2-1) by University College 
London sequencing service, Beckman or GATC Biotech. Obtained sequences 
were analysed by DNAdynamo (http://www.bluetractorsoftware.co.uk/) and 
vector and host cellular genome sequences were annotated. The defined host 
cellular sequence was analysed by BLAT (https://genome.ucsc.edu/cgi-bin/ 
hgBlat?command=start) to validate the location of the sequences on mouse 
genome (chromosome coordinate). The region of the chromosomal number and 
position obtained by BLAT were used as input in Ensembl 
(http://www.ensembl.org/index.html) to gain the information of genes 
surrounding the integration sites in 1 mega base (Mb) window. 
 
 
2.5.5 Rapid amplification of 5’ cDNA ends (5’ RACE) to identify host 
cellular sequence adjacent to vector sequence on fusion puromycin 
mRNAs 
 
5’ RACE was performed to identify host cellular sequences that make splice-in 
fusion transcripts with vector sequences. Total RNA was extracted by the 
Qiagen RNeasy mini kit (Qiagen) from puroR clones isolated in the IM assay. 1 
µg of the RNA was reverse transcribed by the Quantitect reverse transcription kit 
(Qiagen). RT primers in this kit were the optimised cocktail of oligo-dT and 
random primers. In order to remove any possible inhibitors in the sample, cDNA 
was purified by ethanol precipitation. The purified cDNA was ligated by T4 RNA 
ligase (TaKaRa, New York, NY, USA) at 15 oC for 15 to 18 hours. 1 µl of the 
ligated cDNA was used for the first round (1:10 dilution of the sample from the 
previous reaction) and nested PCRs. HotStart Taq polymerase (Qiagen) was 
used for both PCRs. Primers used in this experiment are listed below. The first 5’ 
RACE targeted the transcript with a puromycin resistant gene. The second 5’ 
RACE was primed further upstream compared to the first trial, 44 nt downstream 
of 5’ LTR. We aimed to obtain the host cellular sequence next to the viral 
sequence more easily at the later trial. 
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Table 2-16 Primers used for rapid amplification of 5’ cDNA ends (5’ RACE) at the first trial 
 
Purpose Primer name Primer sequence (5’->3’) 
Reverse transcription 
(5’phos) 
RT PURO ACACCTTGCCGATGTCGAG 
1st PCR PCR1 PURO F ATGACCGAGTACAAGCCCAC 
PCR1 SA ATTCAGGATCCCTGGTGACT 
Nested PCR Nested PURO F GTCACCGAGCTGCAAGAAC 
Nested SA Rc GCCAGTGCCAAGGTTAAGAA 
 
 
Table 2-17 Primers used for rapid amplification of 5’ cDNA ends (5’ RACE) at the second 
trial 
 
Purpose Primer name Primer sequence (5’->3’) 
Reverse transcription 
(5’phos) 
GT249 (5'Phos) GAGTCCTGCGTCGAGAGAGC 
1st PCR GT248 TGTGTGCCCGTCTGTTGTGT 
PCR1 R RC GAAGCACTCAAGGCAAGCTTTA 
Nested PCR U5 Nested F GAAAATCTCTAGCAGTGGCG 
DelU3 Nested Rc or 
R Nested RC 
AGCAGATCTTGTCTTCGTTGG 
or CCAGGCTCAGATCTGGTCTA 
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Table 2-18 Composition of reactions for HotStart Taq polymerase PCR (5’ RACE) 
 
Components Concentration Amount per reaction (µl) 
10 x PCR buffer (contains 15 
mM MgCl2) 
10 x 10 
dNTPs  10 µM each 2 
Primer Fw 10 µM 5 
Primer Rv 10 µM 5 
Template DNA ≤1 µg/100 µl 
reaction 
1 (1:10 sample dilution of 
the previous reaction) 
Nuclease-free water - Up to 100 
HotStart Taq polymerase 2.5 units/reaction 0.5 
 
 
Table 2-19 Cycle conditions for HotStart Taq polymerase PCR (5’ RACE) 
 
Temperature  
(oC) 
Time 
Cycle 
number 
95 15 mins 1 
94 45 sec 
30 50 30 sec 
72 1 min 
72 10 mins 1 
 
 
The final PCR product was column-purified by the Gel Extraction Kit (Qiagen) 
and the purified DNA fragments were cloned into the pJET1.2 cloning vector 
(Thermo Scientific). The obtained bacterial colony was seeded and propagated 
in ampicillin-containing 2 ml LB medium. The sample plasmids were 
column-purified by the QIAprep spin miniprep kit (Qiagen), and sequenced with 
pJET commercial primers (Table2-1). Obtained sequences were analysed by 
DNAdynamo (http://www.bluetractorsoftware.co.uk/) and vector and host cellular 
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genome sequences were annotated. This allowed us to exhibit splicing form 
within fusion transcripts. Host cellular sequences were identified by BLAT 
(https://genome.ucsc.edu/cgi-bin/hgBlat?command=start) and further 
information of host cellular genes, such as the composition of genes and gene 
function, was obtained by Ensembl (http://www.ensembl.org /index.html). 
 
Based on the identified three genomic sequences (Ch4, 7 and 17, respectively) 
by the second 5’ RACE trial, we tested whether those were genuine integration 
sites. We designed primer pairs for those three sites as listed in Table 2-20. 
Initially, the primer pairs were tested on gDNA to amplify those genomic 
sequences properly. Then, using primer annealing to 5’ and 3’ side of the 
sequence of pGhr IRES-Puro we performed PCR on gDNA of the IL-3I clones by 
GoTaq G2 DNA polymerase (Promega) (see 2.3.1 for PCR protocol). PCR 
negative control, PCR water control, Bcl15, and a step 4 survivor from the first 
IM were tested.   
 
 
Table 2-20 The list of primers to confirm vector integration sites based on the second 5’ 
RACE 
 
Purpose Primer name Primer sequence (5’->3’) 
Ch4 Fw GACTCCAATATGATGGTCTT 
Rc GAGCACGAAGCAACATAGTG 
Ch7 Fw CAGGATCACCATAGATACAC 
Rc CCAACAATTTAGCGGCAATC 
Ch17 Fw AGAGTCTGTGTTCTTGCCTC 
Rc GTGAAGGAATCTCTGATGAC 
Vector 5’ GT249 GCTCTCTCGACGCAGGACTC 
Vector 3’ WPRE Fw CTCAGACGAGTCGGATCTC 
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2.6 Next generation sequencing (NGS) by Illumina Miseq to 
identify host cellular genes on fusion puromycin transcripts 
and characterise its splicing form 
 
2.6.1 The work flow to run Illumina Miseq 
 
The workflow of the next generation sequencing is based on 16S Metagenomic 
Sequencing Library Preparation revision B issued by Illumina (http://suppor 
t.illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.ht
ml). This protocol includes RNA sample preparation through to the initial 
analysis of the raw sequence. 
 
 
2.6.2 mRNA sample preparation; mRNA extraction using oligotex beads 
from total RNA and direct cell lysis   
 
For mRNA extraction from total RNA, initially 2 x 108 transduced Bcl15 cells 
were pelleted and lysed for total cytoplasmic RNA extraction by an RNeasy Midi 
Kit (Qiagen) according to the manufacturer’s protocol. This resulted in 600-1200 
µg of total RNA yield. Then, 300 µg of total RNA was used to extract mRNA by 
Oligotex mRNA Kits (Qiagen). Oligotex suspension is an affinity reagent to 
detect nucleic acids containing polyadenylic acid sequences. dC10T30 
oligonucleotides are covalently linked to the surface of the component of oligotex 
suspension, polystyrene-latex particles via condensation reaction. After 
capturing mRNA by the beads, mRNA was dissociated and eluted in RNase-free 
H2O.  
 
The step of total RNA extraction can be omitted and mRNA can be extracted by 
direct lyses of cells. I used 2 x 107 cells for the direct lysis, and the total yield of 
mRNA was 400 to 2000 ng. 10 ng of this mRNA was directly used as I prepared 
for NGS samples; however, on the 1 % electrophoresed gel unexpectedly higher 
background DNA bands were observed in untransduced Bcl15 cells at nested 
PCR (Fig.5-4). In addition, the direct mRNA extraction from cells requires a 
 129 
greater amount of oligotex beads and this is not cost-effective. Therefore, the 
RNA samples processed in the next generation sequencing were extracted from 
total RNA. 
 
 
2.6.3 Reverse transcription (RT) with a vector specific RT primer with an 
overhang tag sequence 
 
Using the vector-specific RT primer i5_R1_SA27 (SA1), reverse transcription 
was performed by the SuperScript ○R III First-Strand Synthesis System 
(Invirtogen) according to the manufacturer’s protocol. Reaction mix (mRNA, the 
RT primer and 10 mM dNTP mix) was prepared in 10 µl and mRNA was heated 
at 65 oC for five minutes to denature unwanted secondary structures. cDNA 
synthesis mix that contains reverse transcriptase was added into the reaction 
mix that contains mRNA, and was incubated at 50 oC for 50 minutes followed by 
incubation at 85 oC for five minutes to terminate the reaction. In order to degrade 
mRNAs in the sample, RNaseH (2 U/µl) was added and incubated at 37 oC for 
20 minutes. 
 
 
Table 2-21 Condition of reactions for reverse transcription by SuperScript○R III reverse 
transcriptase: elimination of unwanted RNA secondary structure 
 
Components Amount per reaction (µl) 
Poly(A)+ RNA X (1 pg-500 ng) 
Gene specific primer (2µM) 1 
10 mM dNTP mix 1 
DEPC-treated water To 10 
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Table 2-22 Condition of reactions for reverse transcription by SuperScript○R III reverse 
transcriptase: cDNA synthesis 
 
Components Amount per reaction (µl) 
10 x RT buffer 2 
25 mM MgCl2 4 
0.1 M DTT 2 
RNaseOUT TM (40 U/µl) 1 
SuperScript®III (200 U/µl) 1 
 
 
2.6.4 Optimisation of NGS sample preparation: choosing an optimal RT 
primer 
 
Among three RT primers, SA1 was designed initially. In order to test the function 
of primers, PCR was performed on gDNA from transduced and untransduced 
Bcl15 cells. The gDNA extracted from Bcl15 cells and the IL-3I clone was serially 
diluted (1:5 dilution, 5 points) starting from 100 ng gDNA. Three primer pairs 
were tested to detect the amplification of the region in the puromycin gene, the 
Ghr locus, and vector backbone sequence. PCR was performed by GoTaq G2 
DNA polymerase (Promega). 
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Table 2-23 Primers used for PCR on gDNA to test the function of SA1 RT primers 
 
Target Primer Primer sequence 
Puro Puro Fw TGACCGAGTACAAGCCCAC 
Puro Rc CTTCCATCTGTTGCTGCGC 
The Ghr locus Ghr Fw CTCGGAATTCTGAAGTCTGAGGC 
SA1 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
GCCAGTGCCAAGGTTAAGAA 
Vector 
sequence 
RRE-cPPT GAGACAGATCCATTCG 
SA1 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
GCCAGTGCCAAGGTTAAGAA 
 
 
As next optimisation, SYBR green qPCR (Qiagen) was performed using three 
RT primers, including the SA1, to detect amplification in the region downstream 
of the Ghr exon 2, puromycin gene, and mouse beta actin. Prior to SYBR green 
qPCR, the mRNA extracted from Bcl15 cells and Bulk-Puro was reverse 
transcribed by the SuperScript○R III First-Strand Synthesis System (Invirtogen).  
 
 
Table 2-24 Candidate RT Primers for next generation sequencing 
 
RT Primer 
name 
The distance 
from the Ghr 
exon 2 SA (nt) 
Primer sequence 
SA1 47 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
GCCAGTGCCAAGGTTAAGAA 
SA2 77 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
CGAGCTAGTTATTCAGGAT 
IRES 119 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
CTTCGGCCAGTAACGTTAG 
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Table 2-25 Primers used for SYBR green qPCR to choose an optimal RT primer for NGS 
 
Target Primer Primer sequence 
The region downstream 
the Ghr exon 2 SA 
Ghr exon 2 Fw GTCTCAGGTATGGATCTTTGT 
Tag primer  TCGTCGGCAGCGTC 
Puro Puro Fw TGACCGAGTACAAGCCCAC 
Puro Rc ACACCTTGCCGATGTCGAG 
Mouse beta actin MB-actin F AGAGGGAAATCGTGCGTGAC 
MB-actin Rc CAATAGTGATGACCTGGCCG 
 
 
2.6.5 Double-stranded DNA synthesis by a random octamer 
 
In order to flank the amplified target cDNA with a known sequence, 
double-stranded cDNA synthesis was initiated using a primer with random 
octamers with a tag sequence. This second strand cDNA was synthesised by a 
large fragment of DNA polymerase I (Invitrogen). 10 µl of the previous reaction 
mix that contains cDNA (2.4.3) was used. The following incubation cycle was 
used for the reaction. 
 
 
Table 2-26 Condition of reactions for the second strand cDNA synthesis by Large 
fragment of DNA polymerase I 
 
Component Amount per reaction (µl) 
RACT2 Buffer 5 
dNTPs (10 mM) 0.75 
Primer (100 µM) 1 
Reverse transcribed product 10 
Klenow Large fragment (3-9 U/µl) 1 
Nuclease-free water Up to 50 
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Table 2-27 Incubation conditions for the second strand cDNA synthesis by Large 
fragment of DNA polymerase I  
 
Temperature 
(oC) 
Time 
(minutes) 
15 10 
20 10 
25 10 
37 60 
75 20 
 
 
2.6.6 Amplification of target fusion transcripts 
Since the synthesised double-stranded DNA has the tag sequences at both 
ends, the target fusion transcripts were amplified using them by KOD 
polymerase (Novagen) with a cycle number of 22. 
 
 
Table 2-28 Primers used for RNA sequencing 
 
Purpose of use Primer name Primer sequence 
Reverse transcription i5_R1_SA27 
(SA1) 
TCGTCGGCAGCGTCAGATGTGTATA
AGAGACAGGCCAGTGCCAAGGTTAA
GAA* 
The second strand 
cDNA synthesis  
i7_R2_N8 
(a random octamer) 
GTCTCGTGGGCTCGGAGATGTGTAT
AAGAGACAGNNNNNNNN 
Tag PCR i5_R1 (a tag primer) TCGTCGGCAGCGTC 
i7_R2 (a tag primer) GTCTCGTGGGCTCGG 
*Vector specific sequence 
 
 
The PCR-amplified products were indexed to distinguish each sample replicate 
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by Nextera XT Index Kit v2 set C (Illumina, San Diego, CA, USA), followed by a 
purification step by Ampure XP beads (Beckman, Brea, CA, USA) according to 
the manufacturer’s protocol. The concentration and size distribution of the 
purified product was assessed by a Qubit 2.0 fluorometer (Invitrogen) and 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
Sequencing was run on the DNA libraries using a 500-cycle paired-end 
sequencing reagent kit (Illumina). This sequencing generated the average read 
length of 250 pb. Low quality sequencing tails were trimmed by Phred quality 
score of 30 suing trimmomatic (http://www.usadellab.org/cms/?page=tr 
immomatic). Separately, to analyse host-vector fusion transcripts, all forward 
sequence reads were filtered with vector-specific 47 nt sequence (5’ 
GTCTCAGGTATGGATCTTTGTCAGGTCTTCTTAACCTTGGCA CTGGC 3’) by 
trimmomatic to confirm that analysed sequence reads are genuine fusion 
transcripts between the host and vector sequences. Those experimental steps 
were kindly helped by Dr, Edward T. Mee (NIBSC) and initial sequencing 
analysis by Dr. Mark Preston (NIBSC) (Table 5-3 and 5-4).  
 
I then performed the later study to identify the host sequence on fusion mRNAs. 
Initially, the extracted forward sequences with 47 nt vector sequence were 
clustered by a multiple sequence alignment tool, Clustal X (Jeanmougin et al., 
1998). A representative sequence in each cluster was selected and was blasted 
to the mouse genome (GRCm38.p4) using Ensembl (http://www.ense 
mbl.org/index.html) to obtain the information of host sequences. Reverse 
sequences of the selected forward sequences were blasted against the mouse 
genome (GRCm38.p4) in Ensembl. Separately, all forward sequences were 
blasted in NCBI nucleotide blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PRO 
GRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) to find new 
host cellular sequences that could not be identified by forward sequence screen.  
 
In addition, the biological and molecular function of each identified gene was 
extracted from the Universal Protein Resource called UniProt (http://www. 
uniprot.org/), a comprehensive resource for protein sequence and data 
annotation (Consortium, 2010). 
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2.7 Buffers 
 
Purpose of use Reagent name Component 
Fixing solution for FACS 2 % paraformaldehyde 
(PFA) 
1 x PBS, 37 wt. % in H2O 
paraformaldehyde (Sigma) 
Electrophoresis gel running 
buffer and gel making 
Tris-acetate EDTA (TAE) 40 mM Tris (pH 7.8), 20 mM 
sodium actate, 1 mM EDTA 
Electrophoresis sample 
loading 
6 x loading dye 0.25 % bromophonol blue, 
0.25 % xylene cyanol FF, 
30 % glycerol in water (pH 
6.8) 
Preparation for competent 
bacteria cells (for 
resuspension) 
Transformation buffer 
(TFB)-I 
30 mM potassium acetate, 
100 mM rubidium chloride, 10 
mM CaCl2, 50 mM MgCl2, 
15 % glycerol, acetic acid to 
pH 5.5 
Preparation for competent 
bacteria cells (for final 
resuspension) 
TFB-II 10 mM MOPS, 75 mM CaCl2, 
15 % glycerol, KOH to pH 6.5 
Bacterial colony formation Luria-Bertani (LB) Agar LB broth, 15 g/L bacto-agar 
(pH.7.5) 
Bacterial culture for plasmid 
purification 
Luria-Bertani (LB) Broth 1 % bacto tryptone, 0.5 % 
bacto yeast, 0.5 % NaCl (pH 
7.5) 
Elusion buffer for extracted 
gDNA  
AE 10 mM Tris-HCl (pH 9.0). 0.5 
mM EDTA 
Elusion buffer for purified 
DNA plasmids/fragments 
EB 10 mM Tris-HCl (pH 8.5) 
gDNA extraction  lysis buffer (ATL) 10 mM Tris-Cl (pH 7.4), 10 
mM EDTA, 10 mM NaCl, 
0.5 % SLS, 1 mg/ml 
Proteinase K 
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Total RNA extraction  lysis buffer (RLT buffer) 
1 % ß-mercaptoethanol) 
RLT buffer composition 
(confidential by Qiagen), 1 % 
14.3 M ß-mercaptoethanol 
(Sigma) 
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Chapter 3 
 
Characterisation of a lentiviral 
vector to study splice-in fusion 
transcripts  
 138 
3.1 Introduction 
 
Insertional mutagenesis (IM) caused by vector integration and the subsequent 
alteration of the host cellular gene splicing pattern is a potential concern in the 
clinical use of lentiviral vectors. Several in vitro studies demonstrated that LV 
could disrupt cellular gene splicing. The paper from our group by Bokhoven et al 
(Bokhoven et al., 2009) showed gene upregulation by splicing out from the LV 
(see below). Moiani et al used a splice trap vector, without an internal promoter 
but using an internal ribosomal entry site (IRES) for transgene expression, and 
also a clinical candidate beta-globin vector (Moiani et al., 2012) and detected a 
variety of fusion transcripts, including read-through, splice-in and splice-out. 
Cesana et al (Cesana et al., 2012) performed a similar study with a vector 
carrying the PGK promoter driving GFP expression, detecting read-through 
transcripts and a number of cryptic splice donors and splice acceptors. The 
potential risk of splicing alteration by a lentiviral vector was also reported in a 
clinical trial for beta thalassaemia (Cavazzana-Calvo et al., 2010). The vector 
integration contributed clonal expansion of myeloid cells by truncation and 
activation of transcription factor-associated gene, the high mobility group 
AT-hook 2 (HMGA2) (Modell and Darlison, 2008). This dominant clone 
disappeared after 6 years of clinical follow-up (Leboulch, 2013). The safety risk 
of this single clinical event is hard to estimate. On the one hand the expanded 
clone contributed to beta-globin expression in the patient allowing them to attain 
transfusion independence, however such expanded clones might ultimately 
become leukaemic after additional mutations.  
 
Since the splicing event that caused a clonal expansion in the ß thalassaemia 
clinical trial was a splice-in, using an SA in the LV, we decided to develop a 
vector design to study splice-in. We assumed that the insertion of a potent splice 
acceptor (SA) upstream from an IRES driving a marker gene could increase the 
chance of inducing splicing by splice-in, as in the study of Moiani et al (Moiani et 
al., 2012).  
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3.1.1 Selection of a potential SA  
 
Previously, our research group discovered distinct mechanisms of cell 
transformation to IL-3 independence caused by integration of gammaretroviral 
vectors (GRVs) or lentiviral vectors (LVs) respectively (Bokhoven et al., 2009) 
(Knight et al., 2010). In these studies, LV integrated into the Ghr locus, at sites 
identified by inverted PCR and LM-PCR (Fig.3-1A). Those vector integrations 
altered not only the original Ghr transcriptional pattern by inclusion of vector 
sequence in the transcript (Fig.3-1B), but also mRNA and protein expression, 
which was detected by 5’RACE, qRT-PCR (Fig.3-1C) and immunoblotting. The 
novel transcripts used a splice donor (SD) within the vector specific and the Ghr 
exon 2 SA (Fig.3-1B). Based on this finding, we hypothesised that the Ghr exon 
2 SA could be a potential strong SA that can be introduced in this novel splice-in 
vector design to induce and detect splice-in splicing.  
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Fig.3-1 The identification of the Ghr locus as the mechanism by which LV make 
Bcl15 cells IL-3 dependent by splice-out fusion mRNA, which is described in 
(Bokhoven et al., 2009) (Knight et al., 2010). 
(A) LV integration sites were clustered in the Ghr locus in the IL-3 independent mutants 
caused by LV integration. Each vertical line shows the integration site of an individual 
mutant, identified by inverse PCR. (B) mRNAs that were expressed in mutants were 
examined using a different set of primers to classify patterns of transcript formation. (C) 
Each form of fusion mRNAs that is shown in B was examined in a quantitative manner by 
q-RT-PCR. The splice acceptor (SA) of the Ghr exon 2 was used frequently with the 
HIV-1 major splice donor (MSD) site for virus-host fusion transcripts that were expressed 
in the isolated IL-3 independent mutants. This bar graph shows the relative copy number 
normalised by the number of mouse beta actin copy number. 
 
  
A 
B C 
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3.2 Aims 
 
1. Construction of a novel LV with a strong splice acceptor (SA) site 
introduced upstream of an IRES-transgene in a promoterless 
self-inactivating (SIN) vector.  
2. Measure the titre of this vector, both by detection of transgene expression 
and by vector genome integration in the host genome, these parameters to 
be compared with a control vector with an internal promoter driving 
transgene expression. The prediction would be that both vectors would 
have similar titre measured by genome integration, but the test vector would 
have a much lower titre when transgene expression is measured. This is 
because such expression will only occur in the small number of integrants 
adjacent to a cellular promoter, driving expression of a fusion transcript.  
3. Optimal puromycin culture condition for selection of puromycin resistant 
clones that may transform into cytokine-independent in the IM assay (see 
Chapter 4). 
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3.3 Results 
 
3.3.1 Construction of splice-in lentiviral vectors 
 
All vector constructs in this study are shown in Fig.3-2 (Materials and Methods 
(M.M) 2.2) and the splice-in model vector is pGhr IRES-Em/Puro (Fig.3-2C), 
designed to express a marker gene by splice-in.  
 
pGhr IRES-Em came from pSFFV-Em (Fig.3-2A) (Demaison et al., 2002). This 
original vector is a bicistronic vector that contains a spleen focus forming virus 
(SFFV) promoter, followed by IRES downstream to control transcription of Em 
(Emerald, Em, mutation-enhanced GFP). The SIN design in its backbone was 
used to construct pGhr IRES-Em. In order to make the vector promoter-less, the 
SFFV promoter was removed. Then the Ghr exon 2 locus (150 nt of intron 1 
upstream of exon 2 and 56 nt of the beginning site of exon 2) was amplified by 
PCR from genomic DNA (gDNA) of Bcl15 cells and was introduced with the 
three stop codons, followed by IRES. This vector design has the potential strong 
SA site in the SIN LV backbone. A marker gene Em or Puro (puromycin resistant 
gene)) within the vector is located downstream of the Ghr exon 2 SA. The 
marker gene expression is under the control of an internal ribosomal entry site 
(IRES). Theoretically, the marker gene may be expressed when there is a host 
promoter upstream of vector integration site in the same orientation relative to 
the direction of the integrated vector. Under this condition, the marker gene can 
be expressed and a host SD can select an SA within the vector to generate a 
fusion mRNA. Between the introduced Ghr exon 2 and the IRES, three stop 
codons to cover three reading frames were introduced. It is assumed that the 
separation of host gene open reading frame (ORF) from the marker gene ORF 
by introducing these stop codons might avoid any host-vector fusion protein. The 
final construct was sequenced by primers (Ghr Fw: CTCGGAATTCTGAAG 
TCTGAGGC, BamHI Ghr Rc: CTCGGAATTCTGAAGTCTGAGGC, Ghr Rc: 
CAGTCTCGAGCTAGTTATTCAGGATCCCTGGTGACTGCCAGTGCCAA). 
pGhr IRES-Em was utilised to construct pGhr IRES-Puro by replacing Em with a 
PCR fragment encoding the puromycin resistance gene. The final construct was 
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sequenced by the primer (Puro Fw: AGTC TCATGACCGAGTACAAGCC, Puro 
Rc: ATGCGGCCGCTAATTCCC TCGAGTCA). 
 
 
 
 
 
 
 
 
 
 
Fig.3-2 The lentiviral vector constructs that were used in the PhD project.  
The provirus form of each vector is shown. All vectors have self-inactivating long 
terminal repeats (SIN-LTRs) with deletions in the U3 (the promoter and enhancer 
regions). (A) pSFFV-Em has a spleen focus-forming virus (SFFV) promoter to express 
Emerald GFP (Em) that was used as a positive control for Em expression. Restriction 
enzyme sites important to construct other model vectors (C, D, E) are indicated on the 
vector in blue. (B) pUBIQ-Puro has a ubiquitin promoter to express puromycin 
resistance gene (puroR) and was used as a positive control for puromycin expression 
A A 
B 
C 
D 
E 
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(Escors et al., 2008). (C) pGhr IRES-Em/Puro is a derivative vector of pSFFV-Em. In 
order to allow gene transcription by an upstream host promoter, pGhr IRES-Em/Puro 
does not have an internal promoter, but an internal ribosomal entry site (IRES) that 
controls the marker protein translation. The Ghr exon 2 splice acceptor (SA) with its 
surrounding genomic sequence was introduced upstream of the IRES (150 nt of intron 
1 upstream of the exon 2 and 56 nt of the beginning site of the exon 2). (D) 
pIRES-Em/Puro is a derivative vector of pGhr IRES with deletion of the Ghr exon 2 
SA. This vector was used to observe background gene expression by a 
post-transcriptional mechanism that was unrelated to the Ghr exon 2 SA. (E) pGhr 
IRES-Em/Puro reverse is another derivative vector of pGhr IRES. This vector has 
reverse-oriented sequence from downstream the central polypurine tract (cPPT) to 
upstream of the vector 3’LTR. This vector design has a potential to investigate different 
chimeric transcripts compared to the pGhr IRES vector.  
 
 
SFFV, spleen focus forming virus; LTR, long terminal repeat; IRES, internal 
ribosomal entry site; WPRE, Woodchuck Hepatitis Virus Posttranscriptional 
Regulatory Element; SIN-LTR, self-inactivating LTR; RRE, rev response 
element; polyA, polyadenylation signal; α−GT, alpha-galactosyltransferase.  
 
To confirm the function of the SA introduced to increase transgene expression in 
pGhr IRES-Em/Puro, pIRES-Em/Puro was designed as a control vector based 
on pGhr IRES-Em/Puro. This vector does not contain the Ghr exon 2 SA 
(Fig.3-2D). We hypothesised that this SA-less vector would express a marker 
gene less than the SA vector because less host-vector fusion mRNAs would be 
generated by splice-in. Additionally, this SA-less vector might give an insight into 
the background expression of a marker gene that is not related to the Ghr exon 2 
SA, such as splice-in via cryptic SAs in the vector backbone or read-through 
transcripts without splicing. The final construct was sequenced by primers 
(DelSA F：GCAGTTAATCCTGGCCTG、BamHI cPPT Rc：TCAGGGATCCGA 
TATCAAGCTTATC) for its confirmation. 
 
pGhr IRES-Em/Puro reverse was designed based on pGhr IRES-Em/Puro, as 
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another candidate vector to study splice-in (Fig.3-2E). The vector sequence 
flanked by two EcoRI sites, the downstream of cPPT to upstream of 3’LTR is 
reversed. This vector had a potential to test the effect of the reversed vector 
sequence on fusion mRNA generation with host sequence and marker gene 
expression. Initially, the SV40 late polyA signal was introduced downstream of a 
marker gene to terminate the transcript as well as introducing another EcoRI site. 
This intermediate vector was then digested with EcoRI to obtain the vector with 
the reverse-oriented vector sequence. The final construct was sequenced by 
primers (Em Fw: ATGGTGAGCAAGGGCGAG, Puro Fw: AGTCTCATGACCG 
AGTACAAGCC, Ghr Rc: CAGTCTCGAGCTAGTTATTCAGGATCCCTGGTG 
ACTGCCAGTGCCAA) for its confirmation.  
 
 
3.3.2 In silico prediction of splice sites within model vectors showed the 
introduced Ghr exon 2 SA was a potential strong SA  
 
The provirus sequence of each promoter-less puromycin vector was tested in 
the in silico programme NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) 
to confirm that the Ghr exon 2 SA was a possible dominant SA site in the vector 
provirus sequence (Fig.3-3) (M.M 2.3.11). The number of predicted SA and SD 
sites in each vector was counted and summarised (Fig.3-3A). The number of SA 
sites is relatively larger than that of SD sites in each test vectors. When looked at 
each predicted SA, the Ghr exon 2 SA was predicted as the strongest SA in the 
provirus sequence of pGhr IRES-Puro. The Ghr exon 2 SA showed the highest 
confidence number (0.69) out of other 21 SA candidate sites (Fig.3-3B). On the 
other hand, the pIRES-Puro vector does not contain any outstanding SA sites (< 
0.33). pGhr IRES-Puro reverse showed the introduced SA as the strongest SA in 
the negative strand of the provirus sequence, as expected.  
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Fig.3-3 in silico prediction of the Ghr exon 2 SA as a potential strong SA in vector 
provirus sequence.  
Using the NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), potential splice sites 
(SD and SA) on both DNA strands were detected on the provirus sequences of pGhr 
IRES-Puro, pIRES-Puro and pGhr IRES-Puro reverse. (A) The predicted total number of 
SA and SD of each vector was summarised. S, a sense strand; AS, an antisense strand 
(B) The top three SAs with a highest confident number of each vector were extracted. 
The row that is highlighted in red is the Ghr exon 2 SA. 
 
 
3.3.3 The constructed promoterless vectors were characterised by 
measuring vector infectivity and marker gene expression 
 
Prior to the test of vector infectivity by measuring vector DNA transfer and 
transgene expression in transduced cells, a VSV-G pseudotyped virus 
containing promoter-less vector genome was produced by HEK293T cells by 
transient transfection of three plasmids (M.M 2.4.1). RNA genome of this model 
vector is driven by a cytomegalovirus (CMV) promoter that leads the robust Em 
A 
B 
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expression, which was confirmed in the virus producer cells of pSFFV-Em, pGhr 
IRES-Em and pIRES-Em at 72 hours post-transfection (Fig.3-4). 
 
 
 
Fig.3-4 FACS analysis of vector producer cells  
Virus producer cells (HEK293T) of pSFFV/pGhrIRES/pIRES-Em were analysed by 
FACS 72 hours post-transfection (M.M 2.4.1). The histogram shows the distribution of 
Em expression intensity of transfected cells by each vector. X axis shows Em expression, 
and Y-axis shows the number of live cells being analysed. Each colour in the histogram 
indicates the transfection result of each vector as listed in the small table next to the 
histogram. The Cells were fixed in 2 % PFA prior to the detection by FACS.  
 
 
The scheme of vector titration was described in the Fig.3-5. The serially diluted 
virus supernatant was transduced on HEK293T or murine pro-B cell line, Bcl15 
cells (M.M 2.4.3). HEK293T have higher transduction efficiency than Bcl15 cells. 
The vector infectivity was tested by two titration methods: the titre based on 
vector DNA transfer and marker gene expression. Depending on the marker 
gene in the vector, the method to measure the protein expression differed. For 
an Em vector construct, fluorescence activated cell sorting (FACS) was 
employed to measure the transgene expression at 48 hours post-transduction 
(M.M 2.4.3.1). On the other hand, for a puromycin vector construct, drug 
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selection of transduced cells (1 µg/ml puromycin) was performed (M.M 2.4.3.3). 
Choosing in the linear range of the number of puroR clones under certain virus 
inputs (µl), the occurrence of puroR cells per virus dose was calculated as a titre 
of puromycin vectors.  
 
The marker gene expression of the promoter-less vector would rely on the 
presence of a host cellular promoter upstream of vector integration. Therefore, 
the FACS-based titre of the promoter-less construct would be expected to be 
much lower than the titre estimated by vector genome transfer detected by 
SYBR green qPCR (Qiagen) (M.M 2.4.3.2). For this measurement, in order to 
eliminate unintegrated episomal vector DNA transduced cells were kept cultured 
for 7 to 10 days post-transduction, then gDNA was extracted. The vector copy 
number of 100 ng gDNA was estimated by a standard curve of HIV-1 leader 
sequence of SIN pHV. Five points of known vector copy numbers of SIN pHV 
are plotted against the corresponding Ct values (Fig.3-6, top). Using the 
standard curve, experimentally detected amplification of each sample estimates 
a vector copy number. As a representative result of vector transduction 
efficiency measured by qPCR, the similar efficiency of vector DNA transfer was 
achieved among the tested vectors (Fig.3-6, bottom). 
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Fig.3-5 The experimental protocol of vector titration in HEK293T or Bcl15 cells for 
estimating virus infectivity.  
pSFFV-Em and pGhr IRES-Em or pUBIQ-Puro and pGhr IRES-Puro  were titrated to 
estimate the efficiency of vector genome transfer by qPCR and transgene expression 
following the successful gene transfer by FACS or puromycin selection (M.M 2.4.3). The 
serially diluted virus supernatant was transduced. In Bcl15 cells, 24 hrs after the 
transduction, puromycin selection was initiated on transduced cells by 1:100 dilution. 
The cells were kept cultured in puromycin medium (1 µg/ml) for 2 to 3 weeks to obtain 
puro-resistant clones in 96-well plates. For Em vectors, Em expression was detected by 
FACS 48-hour post-transcription. Prior to the detection, cells were fixed in 2 % 
paraformaldehyde (PFA) solution (Materials and Methods). Upon both vector 
transduction, genomic DNA (gDNA) was extracted from transduced cells that were 
cultured for 7 to 10 days post-transduction to avoid the detection of non-integrated 
episome DNA by SYBR green qPCR (Qiagen). The experimental condition specific for 
HEK293T cells was highlighted in blue. 
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Fig.3-6 Titration of vector based on measuring gene transfer by SYBR green 
qPCR.  
The standard curve was drawn by plotting Ct value for amplification of HIV-1 leader 
sequence on the Y axis against the known copy numbers of the SIN pHV plasmid on the 
X axis (M.M 2.4.3.2). The standard curve allows the calculation of the vector copy 
number of each test sample according to an amplification result shown in Ct values. 
Once the raw vector copy number was obtained, the cell number corresponding to the 
gDNA input (100 ng) was estimated based on genome size (bp) of a mouse. Using the 
estimated cell number in 100 ng gDNA and the raw copy number of pHV, the vector copy 
number per cell was calculated and defined as a multiplicity of infection (MOI). Using the 
transduction condition of each sample (virus input (µl) and an initial cell number), the 
vector titre was calculated.  
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3.3.4 Promoter-less SIN LV-Em vectors expressed lower levels of marker 
genes  
 
In order to characterise the marker gene expression, the vector was titrated on 
HEK293T cells. As a positive control, pSFFV-Em with a strong promoter driving 
constant expression of Em was used.  
 
The percentage of live cells with Em expression was detected by FACS 
(Fig.3-7A). The percentage increases in a dose-dependent manner for all three 
vectors, though that with pSFFV-Em is highest. The mean fluorescence intensity 
(MFI) of marker gene expressing cells was also compared to the three vectors 
(Fig.3-7B). The MFI in transduced cells by pSFFV-Em was much higher than 
that of promoter-less vectors at each virus dose (µl) as expected.  
 
As also described in Fig.3-6 on Bcl15 cells, vector integration upon transduction 
was similar in HEK293T cells for both promoter-less Em vectors and pSFFV-Em 
(Fig.3-7C). However, the titre measured by GFP expression was much lower for 
the two promoterless vectors. Nearly 85-fold reduction in the FACS titre was 
observed in transduction of pGhr IRES-Em compared to pSFFV-Em (Fig.3-7D). 
Transduction of pIRES-Em showed a further reduction in the FACS titre 
compared to pSFFV-Em (116-fold) (Fig.3-7D). 
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Fig.3-7 Vector transduction in HEK293T cells to estimate virus infectivity  
(A) Using a virus harvest of pSFFV/pGhrIRES/pIRES-Em by transient transfection on 
HEK293T cells, each virus was titrated on HEK293T cells. Em positive cells (%) in live 
cells in comparison to mock-transduced cells were calculated by FlowJo software 
(http://www.flowjo.com/). (B) Mean fluorescent intensity (MFI) of Em positive cells in 
each virus dilution was analysed by FlowJo software (http://www.flowjo.com/). The shift 
of MFI of each vector was compared. (C) Each vector titre based on vector copy number 
in genome detected by qPCR was compared. (D) Each vector titre based on Em protein 
expression detected by FACS was compared. Each experiment was performed in 
duplicate. Error bar in each bar graph shows the standard deviation of between 
duplicates (FACS) or triplicate (qPCR) in a single experiment. 
 
A B 
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3.3.5 Bcl15 showed lower marker gene expression than HEK293T cells, 
however the same trend of vector DNA transfer and marker gene 
expression 
 
Bcl15 cells were transduced by the same vector constructs tested in HEK293T 
cells in 3.3.4 because this cell line was to be used for screening transduced cells 
with marker gene expression in the future assay described in Chapter 4. This 
cell line is known for having lower transduction efficiency compared to HEK293T 
cells (Bokhoven et al., 2009), accordingly, reduced marker gene expression in 
Bcl15 cells was also expected in our experiment.  
 
The percentage of cells with Em expression was detected by FACS (Fig.3-8A). 
The percentage increases in a dose-dependent manner in all three tested 
vectors. When the MFI at highest virus dose among test vectors was compared, 
pSFFV-Em showed 55-fold higher than pGhr IRES-Em, and 44-fold higher than 
pIRES-Em (Fig.3-8B).  
 
As it was observed in the Fig.3-6 (bottom), the promoterless vectors showed a 
high qPCR titre (1.09 x 106 (IU/ml) for pGhr IRES-Em and 9.95 x 105 (IU/ml) for 
pIRES-Em) similar to that of pSFFV-Em (1.77 x 106 (IU/ml)) (Fig.3-8C). Also, 
similarly to HEK293T cells, Bcl15 cells transduced by pGhr IRES-Em showed 
lower Em expression (34-fold reduction) compared to that of pSFFV-Em 
(Fig.3-8D). In addition, the Em expression by transduction of pIRES-Em was 
also lower than that of pSFFV-Em (20-fold reduction) (Fig.3-8D). The 
observation of lower marker gene expression of promoter-less vector compared 
to the positive is consistent with the results in HEK293T cells. While, a difference 
of Em expression between pGhr IRES-Em and pIRES-Em was not as distinct as 
transduction in HEK293T cells. 
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Fig.3-8 Vector titration in Bcl15 cells to estimate virus infectivity  
(A) Using the same virus harvested used in HEK293T cells (Fig.3-6), the virus was 
titrated on Bcl15 cells. Em positive cells (%) in live cells in comparison to 
mock-transduced cells were calculated by FlowJo software (http://www.flowjo.com/). (B) 
Mean fluorescent intensity (MFI) of Em positive cells in each virus dilution was analysed 
by FlowJo software (http://www.flowjo.com/). The shift of MFI of each vector was 
compared. (C) Each vector titre based on vector copy number in genome detected by 
qPCR was compared. (D) Each vector titre based on Em protein expression detected by 
FACS was compared. Each experiment was performed in duplicate. Error bar in each 
bar graph shows standard deviation between duplicates (FACS) or triplicate (qPCR) in a 
single experiment. 
A 
 
A B 
C D 
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3.3.6 Puromycin drug concentration optimisation in Bcl15 cells 
 
We proposed screening potential splice-in fusion mRNAs being a cause of 
mutagenesis in transduced cells. We thought that selection of transduced cells 
with fusion mRNAs by the addition of drug into the culture medium would be an 
easier method than cell sorting for Em expression. Therefore, puromycin drug 
selection was performed on cells transduced by puromycin constructs. An 
optimal puromycin concentration should be sufficient to eliminate all 
untransduced parental Bcl15 cells. In addition, this elimination of untransduced 
background parental cells might reduce the number of spontaneous mutants 
that were irrelevant to vector integrations (Bokhoven et al., 2009). To decide 
optimal puromycin concentration, initially, 3.35 x 104 parental Bcl15 cells were 
treated with puromycin at different concentrations (0.1 to 0.8 µg/ml) and cell 
growth was monitored under a microscope. Live cell number was counted by 
trypan blue staining (Gibco) on day 7 after the drug treatment was initiated 
(Fig.3-9). The bar graph showed that 0.5 µg/ml puromycin concentration killed 
most of the background cells compared to lower puromycin concentrations (0.1 
to 0.4 µg/ml). 
 
We then tested the puromycin concentration required for selection of vector 
transduced clones. Puromycin vectors (pGhr IRES-Puro and pUBIQ-Puro) were 
titrated by culturing transduced cells under a range of puromycin concentration 
(0.5 to 1 µg/ml) (Fig.3-10A). The positive control vector pUBIQ-Puro was titrated 
at three puromycin concentrations, 0.6, 0.8 and 1 µg/ml. At the 0.6 µg/ml 
puromycin concentration, the number of puroR clones of pGhr IRES-Puro 
transduction was more than 10 times less than that of pUBIQ-Puro. The number 
of puroR clones generated by transduction of pUBIQ-Puro did not change 
largely over the tested puromycin concentrations (0.6, 0.8 and 1 µg/ml) 
(Fig.3-10A). The number of puroR clones generated by pGhr IRES-Puro showed 
a decrease in the number of clones as the puromycin concentration increased. 
qPCR performed on transduced cells without puromycin selection showed that 
vector DNA transfer was similarly efficient on both pGhr IRES-Puro and 
pUBIQ-Puro (Fig.3-10B). 
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Fig.3-9 Bcl15 cells cultured in different concentrations of puromycin.  
3.35 x 104 Bcl15 cells were cultured in puromycin at a series of concentrations (0.1-0.8 
µg/ml). The live cell numbers were counted on day 7 using trypan blue (Gibco). The X 
axis of the bar graph shows puromycin concentration and the Y axis shows cell 
concentration (cells/ml). Cell culture was performed in duplicate per puromycin 
concentration. Error bar in each bar graph shows standard error of mean (SEM) between 
two independent experiments. The live cell number below the detection limit (104) is not 
shown in the graph.  
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Fig.3-10 Vector titration of puromycin constructs by various puromycin 
concentrations (0.5-1 mg/ml).  
(A) Vector titration based on puromycin resistance was carried out in Bcl15 cells (M.M 
2.4.3.3). The X axis of the bar graph shows the puromycin concentrations (µg/ml) and 
the Y axis shows the titre calculated based on the number of puromycin resistant (puroR) 
clones that were emerged in each puromycin culture. The positive control (pUBIQ-Puro) 
was tested in the three puro concentrations (0.6, 0.8, 1 µg/ml). (B) Separately, vector 
infectivity was estimated by qPCR. Error bar represents standard error of mean (SEM) of 
duplicate (puro selection) and triplicate (qPCR) between two independent experiments. 
 
 
3.3.7 Transduction by promoterless puromycin vectors resulted in 
efficient vector DNA transfer but lower puromycin expression  
 
Puromycin vectors were then titrated on both HEK293T (Fig.3-11A, B) and Bcl15 
cells (Fig.3-11C, D) using the vector titration protocol as described in the Fig.3-5. 
and 1 µg/ml puromycin for selection. Upon transduction of different cell lines, the 
vector genome titre was very similar for the three vectors, though higher in the 
HEK293T cells (Fig.3-11A and C, blue bars). HEK293T cells transduced by the 
promoterless vectors showed the reduced number of puroR clones, which 
resulted in lower puroR titre compared to that of pUBIQ-Puro: 145-fold reduction 
in pGhr IRES-Puro, and 545-fold in pIRES-Puro (Fig.3-11B). When those puroR 
constructs were titrated on Bcl15 cells, the puroR titre of pGhr IRES-Puro 
A B 
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showed 570-fold reduction and the puro titre of pIRES-Puro showed 5412-fold 
reduction compared to that of pUBIQ-puro (Fig.3-11D). These results are 
consistent with the result obtained by transduction of Em vector constructs 
(Fig.3-7C, D).  
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Fig.3-11 Puromycin vector titration on HEK293T or Bcl15 cells to estimate the 
vector infectivity  
Puromycin vectors were titrated in HEK 293T (A, B) cells and Bcl15 (C, D) cells based on 
puromycin selection (B, D) and qPCR (A, C) to observe the difference in 
puromycin-resistant protein expression and vector gene transfer into host cells. qPCR 
was performed in HEK293T and Bcl15 cells, respectively. The error bar on each bar 
graph represents standard error of mean (SEM) of duplicate (puro selection) and 
triplicate (qPCR) between three (HEK293T cells) or two (Bcl15 cells) independent 
experiments. An error bar could not be drawn in pIRES-Puro (D) because one 
experiment did not generate any puroR cells in the assay protocol. 
  
A B 
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3.4 Discussions 
 
This chapter tested the virus infectivity and transgene expression of our model 
vectors to see if they functioned as we expected. Transgene expression in 
promoterless vectors relied on the presence of host cellular promoter therefore 
we hypothesised that most transduced cells would be silent for transgene 
expression, which was observed in transduction experiments (Fig.3-7D, 
Fig.3-8D, and Fig.3-11B, D). Titration of promoter-less vectors (pGhr 
IRES-Em/Puro and pIRES-Em/Puro) along with positive controls (pSFFV-Em 
and pUBIQ-Puro) on HEK293T and Bcl15 cells showed consistent results 
independent of a marker gene, or cell lines. As a next step, we focused on 
transduced cells with marker gene expression to investigate the mechanism of 
potential genotoxic events via splice-in in the future mutagenesis assay. Vector 
transduction by puroR vector constructs was the most relevant experiment for 
the next chapter because the selected puroR cells could generate 
cytokine-independent mutants. We postulated that puroR cells with strong 
puromycin resistance could potentially transform into cytokine-independent cells. 
Such selection was achievable under a high concentration of puromycin. The 
vector titration on the Bcl15 cells with various puromycin concentrations showed 
that 1 µg/ml was an optimal puromycin concentration to select puroR cells with 
strong puromycin resistance. 
 
 
3.4.1 The Ghr exon 2 SA was detected as a potential strong SA  
 
The promoter-less vector designed for inducing host-vector chimeric transcripts 
via splice-in was successfully constructed (Fig.3-2). The initial assessment for 
the designed promoterless vectors was performed by NetGene2 in silico splice 
site finder. Using this sequence-based splice site prediction, the Ghr exon 2 SA 
derived from Bcl15 cellular sequence was shown as the strongest SA in each 
promoter-less vector provirus sequence (Fig.3-3B). Other splice sites, either 
known or cryptic, also includes splice sites that play an important role for 
structural and accessory gene expression in HIV-1 replication such as HIV-1 
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major splice donor SD1 (343) and the known SA downstream of RRE sequence 
SA7 (1507) (see 1.6.6.4, the main introduction). These splice sites can 
potentially function as a splice site with a host cellular sequence to generate 
fusion transcripts and alter exogenous gene and even protein expression as 
observed in the HMGA2 case (Cavazzana-Calvo et al., 2010). The actual use of 
the identified splice sites by NetGene2 can be confirmed by examining the 
sequence of fusion mRNAs expressed in transduced cells. Therefore, the 
presence of those listed splice sites should be also inspected in isolated 
host-vector chimeric transcripts in the later study (Chapter 5 and 6). If any of 
those cryptic splice sites are mainly used in the fusion transcripts, they can be 
mapped and mutated for instance to test that occurrence of fusion mRNAs will 
be reduced as reported previously (Cesana et al., 2012) (Moiani et al., 2012). 
Such sites can be ranked by the number of use on fusion mRNAs. This can 
indicate the strength of each identified splice site by times of use and be 
compared with the in silico result (Fig.3-3). 
 
 
3.4.2 Reduced transgene expression in transduced cells by the 
promoterless model vector  
 
In all transduction results of promoterless vectors reproducibly showed efficient 
vector DNA delivery on host cells and low marker gene expression because of 
the promoterless design. One possible explanation for this is the low frequency 
for the integrated promoterless vector to encounter a host cellular promoter 
upstream in the same orientation relative to the transcriptional direction 
(Fig.3-7D, Fig.3-8D, and Fig.3-11B, D). The relatively random distribution of 
lentiviral vector integration sites (Berry et al., 2006) would also contribute to this 
effect. In addition, in the host cell nonsense-mediated decay pathway senses 
premature termination codons and degrades products (Chang et al., 2007). This 
could be another possible cause to keep the level of host-vector fusion mRNA 
low, which was shown in the assay using the inhibitor of degradation by the 
pathway in the context of ß Thalassaemia gene therapy (Moiani et al., 2012). 
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Although the molecular mechanisms of this transgene expression cannot be 
concluded from these titration results, it is postulated that the chimeric 
transcripts expressed in transduced cells may contain both splice-in and 
read-through forms (Cesana et al., 2012) (Moiani et al., 2012) (Knight et al., 
2010) and contribute to marker gene expression. Even splice-in with a host SD 
at a different SA within the model vector could be observed. This aspect was 
investigated in the following Chapter 5 and 6 by identifying the fusion transcripts 
expressed in transduced cells. 
 
 
3.4.3 The introduced Ghr exon 2 SA may enhance transgene expression  
 
Upon vector transduction, the pGhr IRES vector was tested to see whether it can 
increase marker gene expression in comparison to pIRES vector. Indeed, the 
SA vector showed enhancement in marker gene expression over the SA-less 
vector, based on the number of emerged puroR cells (Fig.3-7D and Fig.3-11B, 
D). While transduction of both pGhr and pIRES vector on Bcl15 cells did not 
show a clear difference in Em expression (Fig.3-8D). This could be due to less 
efficient transduction efficiency than HEK293T cells and for instance small 
difference in experimental condition might affect Em gene expression. However 
reproducible data about the small reduction of titre by transduction of pIRES 
vector than pGhr vector was demonstrated in different cell lines and different 
marker gene constructs. Therefore this is the most likely the trend about marker 
gene expression. The only difference between pGhr and pIRES vector is the 
sequence of the Ghr locus. Hence, this suggests that the presence of the 
introduced strong SA of Ghr exon 2 affects the formation of fusion transcripts by 
certain mechanisms, for instance, enhancing the interaction between the Ghr 
exon 2 SA with a host SD and induce splice0in between them.  
  
 
3.4.4 Transduction of pGhr IRES-Puro generated puroR cells with various 
levels of puromycin resistance 
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When puroR titre at 0.5 µg/ml and 1 µg/ml by pGhr IRES-Puro transduction were 
compared, there was a nearly 100-fold reduction in the number of puroR clones 
(Fig.3-10A). This shows that the majority of puroR cells have a weak to 
moderate puromycin resistance. Then what possibly decides the strength of 
puromycin resistance of transduced cells? One possibility is the strength of a 
host promoter upstream of vector integration. If the host promoter is highly active 
in transcription, the expression level of fusion mRNAs could be relatively higher 
than other fusion RNA species transcribed by relatively lower active promoters. 
Another possibility is a vector integration site that could affect the molecular 
function of gene transcripts such as stabilising or enhancing expression as 
fusion forms. Such chimeric mRNA can persist in the transduced cells and could 
be a driving force of cell transformation.  
 
However, this experiment lacks a possible negative control for pGhr IRES-Puro 
and that could be pIRES-Puro. Based on the result shown in Fig.3-11D, slightly 
lower titre based on puromycin selection by pIRES-Puro may be expected at 
higher puromycin concentration compared to the tire by pGhr IRES-Puro. A 
certain concentration of puromycin could separate puroR cells generated 
specifically by the Ghr exon 2 SA in pGhr IRES-Puro by testing pIRES-Puro in 
one experiment?? If such concentration exists, the more optimal puromycin 
concentration could be selected, which could be beneficial to investigate 
splice-in fusion mRNAs. Therefore, generated puroR cells by transduction of 
pGhr IRES-Puro discussed above can contain host-vector fusion mRNAs 
irrelevant to the effect of the Ghr exon 2 SA such as read-through or splice-in 
with another SA located upstream of the Ghr exon 2 SA.  
 
As a next step, we decided to use the promoter-less vector to generate puroR 
cells at first and then cytokine-independent mutants from the puroR cells. The IM 
assay performed previously in the literature used a lentiviral vector with intact 
LTRs with GFP marker gene and mutagenesis was quantitatively measured 
based on the number of mutants that had been transformed by vector integration 
and aberrant splicing. However, our study used SIN lentiviral vector with the 
puroR gene. This difference in the experimental condition made it difficult to 
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expect the number of mutants from a certain number of puroR cells. Therefore, 
based on the titre by puromycin selection (Fig.3-11B, D), the experimental 
conditions of IM assay (multiplicity of infection (MOI) and virus volume (µl)) were 
decided to obtain more than 104 puroR clones and initially focused on the 
isolation of IL-3 independent mutants. 
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Chapter 4 
 
Insertional mutagenesis assay   
 166 
4.1 Introduction 
 
A number of methods have been developed to test the mutagenic potential of 
integrating viral vectors. Ideally, such a method needs to produce a quantitative 
measurement of the risk of host gene activation or silencing, so that vectors can 
be modified to reduce this. An early method involved the transduction of 
haematopoietic stem cells from tumour-prone Cdkn2a-/- mice by GRVs or LVs, 
followed by bone marrow transplant and quantification of tumour type and 
frequency (Montini et al., 2006). However, the time and expense of this assay 
then prompted an in vitro assay measuring plating efficiency and proliferation of 
mouse primary bone marrow cells (Modlich et al., 2006). Our group then 
developed a third assay using the IL-3 dependent mouse pre-B cell line BAF3 
and its derivative Bcl15, which is engineered to express the survival gene Bcl2 
(Bokhoven et al., 2009). The principle of this assay is that a vector insertion into 
a gene that allows survival or proliferation of the cells allows them to grow in the 
absence of IL-3. Use of a cell line rather than primary cells makes the assay 
cheaper and more reproducible. Bcl15 cells proved more robust upon IL-3 
removal than the parental BAF3 cells and allowed the isolation of more mutants. 
The mechanism of LV mutagenesis in this assay was an insertion into the 
growth hormone receptor (ghr) gene first intron leading to upregulation of Ghr 
expression allowing cells to proliferate in growth hormone. The LV produces a 
fusion transcript encoding ghr using known, cryptic or introduced splice donor 
sites in the vector. So it was possible to use this assay to test clinical candidate 
vectors for the presence of splice donor sites and eliminate them when 
necessary (Montiel-Equihua et al., 2012) (Knight et al., 2012). During these 
experiments several IL-3 independent clones were isolated from Bcl15 cells that 
were not transduced with the vector. These “background” mutants all secreted 
IL-3 (Bokhoven et al., 2009). 
 
The reported clinical trial using a LV to treat ß-thalassaemia found that a LV had 
caused expansion of a dominant hematopoietic cell clone by activating HMGA2 
expression (Cavazzana-Calvo et al., 2010). In this case expression was 
activated by the production of a truncated HMG2A fusion transcript which splices 
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into a cryptic SA in the mutated U3 of the LV, this removes a 3’ regulatory 
sequence from the HMG2A mRNA. My aim was to adapt the Bcl15 cell assay to 
detect any “splice in” fusion events that could make the cells IL-3 independent. If 
successful this could provide a quantitative measurement for clinical candidate 
vectors allowing the detection and elimination of splice acceptor sites, thereby 
improving their safety.  
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4.2 Aims 
 
1. To use the vector pGhr IRES-Puro to transduce Bcl15 cells, then starve 
them of IL-3 followed by rescue with IL-3 re-addition to identify IL-3 
independent mutants  
2. To assess whether any IL-3 independent clones secrete IL-3 as this was 
previously identified as a common mechanism of background mutants 
3. To identify vector integration sites in any IL-3 independent clones 
4. To identify host-vector fusion transcripts in any IL-3 independent clones 
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4.3 Results 
 
4.3.1 Insertional mutagenesis assay isolated an IL-3 independent mutant 
from transduced cells with a pGhr IRES Puro vector 
 
To isolate IL-3 independent mutants generated by a “splice-in” from a host gene 
to the pGhr IRES Puro vector, Bcl15 cells were transduced, selected in 
puromycin then starved of IL-3 followed by an IL-3 rescue (M.M 2.5.1). Any cells 
that then appeared were once again starved of IL-3 to confirm IL-3 
independence (Fig.4-1A). Initially Bcl15 cells transduced by pGhr IRES-Puro 
were cultured in bulk in 1 µg/ml puromycin for three days to select puromycin 
resistant (puroR) cell population. Such puromycin resistance should come from 
“splice in” from a cellular gene. To isolate IL-3 independent mutants from the 
puroR bulk populations, cells were washed then incubated at a maximum 
density of 1 to 1.4 x 105 cells/well in 24-well plates. This selection method was 
chosen because an estimated frequency similar to that of our previous “splice-in” 
assay would ensure that each well contained at most a single IL-3 independent 
cell (Bokhoven et al., 2009). To rescue potential IL-3 independent mutants 
WEHI3B supernatant was re-added to the culture medium after 14 days of IL-3 
starvation. The rescued potential clones at this step (step 4 survivor) were used 
for testing up-regulation of IL-3 mRNA and 5’ RACE analysis for fusion 
transcripts. Once cells were expanded, IL-3 was washed away again and 
incubated to identify truly IL-3 independent mutants.  
 
Two rounds of IM assay were performed and the results are summarised in 
Fig.4-1B. During the IM assay, a small aliquot of transduced cells was used for 
puromycin selection using a limiting dilution experiment in order to calculate the 
number of puroR clones generated by each transduction. 9.7 x 106 cells or 5 x 
107 cells challenged with the vector yielded 1.13 x 104 or 8.3 x 104 puroR clones 
respectively in the two experiments. The number of isolated puroR clones from 
puromycin titration at the first and the second IM assay was 5 or 6 at the highest 
cell dilution, respectively. The five puroR clones from the first IM assay was used 
in Fig.4-2. At the rescue step by IL-3 re-addition, a 24-well plate was used for 
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each cell dilutions (1, 1:3 and 1:9). More than 50 % of the well became 
recovered when plated at 1.1 x 104 cells per well and the accurate number of 
IL-3 survivors of each IM assay is unknown. If the number of survivors had been 
accurately titrated, the number of IL-3 independent mutants would be estimated. 
However in the IM assays the cell density was not enough to obtain recovered 
wells in a linear range. 
 
 
 
Fig.4-1 The overview of the experimental plan and the results of Insertional 
Mutagenesis (IM) assay.  
(A) The flow of IM assay is drawn. Since the transducing vector carried a puroR gene, 
cells were selected for puromycin resistance (puroR) (STEP 2). Puromycin was then 
kept in the culture through the following steps for mutant isolation (from STEP 2 to STEP 
5). (B) The experimental conditions, the number of puroR clones and IL-3 mutants are 
summarised by each round of experiments. pGhr IRES-Puro virus harvest with known 
A 
B 
A 
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infectivity determined by Q-PCR of the genome (2.64 x 106 (the first IM), 1.53 x 106 (the 
second IM) (IU/ml)) was used to transduce Bcl15 cells. Virus volume (ml) for 
transduction was designed to obtain 1 x 104 (the first IM) or 5 x 104 (the second IM) 
puromycin resistant (puroR) clones, based on preliminary titrations based on the 
selection of puroR cells under 1 µg/ml puromycin in the culture medium. At 24 hours 
post-transduction, cells were subjected to puromycin selection (1 µg/ml) for 3 days to 
select puroR cells. Under this puromycin selection, untransduced parental Bcl15 and 
weak puroR cells are susceptible to the puromycin concentration and are eliminated. On 
the day when the puromycin selection started, aliquots of transduced cells were plated in 
96-well plates and cultured in 1 µg/ml puromycin culture medium to obtain titre based on 
the selection of puroR cells. In addition, an aliquot of transduced cells was cultured for 7 
to 10 days for qPCR to measure the efficiency of the vector DNA transfer into cells as 
presented in titration experiments of Chapter 3. After 3 days of puromycin selection, the 
isolated bulk puroR cells were washed to remove IL-3. The cells were re-suspended in 1 
µg/ml puromycin culture medium and seeded in 24-well plates at 1:3 serial dilutions 
down to 1:9 with a starting cells number of 1 to 1.4 x 105. The cells were kept cultured 
without IL-3 supernatant (IL-3 starvation) for two weeks. In order to encourage the 
expansion of potential IL-3 independent mutants, IL-3 (10 % WEHI3B supernatant) was 
then re-added in the culture. Once cells were expanded, they were then cultured under 
IL-3 starvation again at least for two weeks.  
 
 
Before starting this IM assay, the number of possible IL-3 independent clones 
were unknown, therefore the first trial was performed at a higher MOI (15.5) in 
which we aimed to obtain 104 puroR clones, with a high number of integrants in 
each cell. The first IM assay generated one IL-3 independent mutant (the IL-3I 
clone). To obtain more numbers of IL-3 independent mutants and to compare 
the mechanisms of potential IL-3 independence, another round of IM assay was 
performed. In the second IM assay, we used a lower MOI (4.4) and a larger 
number of cells to give roughly the same number of total integrants but reduce 
the number of integrants per cell. This MOI was chosen so that it would be less 
complex to identify integrants and fusion transcripts leading to IL-3 
independence in any mutants. Although the total number of puroR cells was 
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greater than the first IM assay, this round did not generate any IL-3 independent 
mutants.  
 
 
4.3.2 The Ghr exon 2 SA was not mainly used in mRNA expressed in the 
transduced cells by pGhr IRES-Puro 
 
In Chapter 3, marker gene expressing cells by transduction of pGhr IRES-Em or 
Puro were not examined to see if splice-in using the Ghr exon 2 SA led to marker 
gene expression. To test if splice-in via the Ghr exon 2 SA is actually occurring 
to express puromycin mRNA in transduced cells, RT-PCR was performed 
(Fig.4-2A and B) (M.M 2.5.2). Two different forward primers were designed to 
distinguish splice-in using or not using the Ghr exon 2 SA. This was achieved by 
one forward primer annealing upstream from the Ghr exon 2 SA and the other 
primer annealing the downstream. We used total RNA extracted from the puroR 
clones in the puromycin titration at the highest dilution, some of the step 4 
survivors randomly picked and the IL-3I clone from the first IM assay. A 
previously obtained puroR clone from pUBIQ-Puro transduction and parental 
Bcl15 as a negative control were run in the same reaction in parallel. Both pairs 
of primers showed amplification of DNA bands at the predicted size (the 
upstream of the Ghr exon 2 SA: 1k bp, the downstream of the Ghr exon 2 SA: 
800 bp). While tested, transduced cells including puroR cells, survivors and IL-3I 
and Ubiq showed similar puroR amplification by primers annealing to the puroR 
gene (Fig.4-2C, 629 bp). Ideally a housekeeping gene such as ß-actin should be 
used as a standard, but at least this puroR amplification could be used as a 
control. All tested puroR cells were selected by 1 µg/ml puromycin and this 
threshold regulates the number of puroR cells therefore its puromycin 
expression would be estimated at the similar level as demonstrated in Fig.4-2C. 
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Fig.4-2 RT-PCR on the isolated puro-resistant (puroR) clones and the IL-3I clone 
from the first round IM assay.  
The extracted total RNA was reverse transcribed using optimised blend of oligodT and 
random primers provided by QuantiTect Reverse Transcription Kit (Qiagen) (M.M 2.5.2). 
PCR was then performed on this cDNA template using two different forward primers as 
indicated in the provirus picture on the top. (A) The primer pair to test the presence of 
puromycin mRNA. A forward primer that anneals to the downstream of the Ghr exon 2 
SA was used with a reverse primer that anneals to the puromycin sequence. (B) In order 
to test if the introduced Ghr exon 2 SA is exclusively used for splicing in the potential 
fusion puro mRNAs, a forward primer that anneals to upstream of the Ghr exon 2 SA 
was used with the same puro reverse primer used in (A). (C) Puromycin amplification 
A B 
C 
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(629 bp) was tested as a control for puroR gene-coding vector (pGhr IRES-Puro and 
pUBIQ-Puro). PuroR: puromycin resistant clones; Survivors: step 4 survivors from the 
first IM assay); Ubiq: cells transduced by pUBIQ-Puro; Bcl15: untransduced cells; MM: 
molecular marker. 
 
 
4.3.3 Phenotypic characterisation of the IL-3I clone 
 
In order to investigate the mechanism of IL-3 independence in the IL-3I clone, 
the supernatant in the culture of the IL-3I clone was tested on parental Bcl15 
cells for autocrine factor secretion (M.M 2.1.2). As a control the WEHI3B 
supernatant that was harvested in the same condition with the IL-3I clone 
supernatant was tested at different concentrations. Cell proliferation was 
measured by trypan blue (Gibco) (Fig.4-3A) or a colorimetric MTT assay (Cell 
Counting Kit-8, Dojindo) (Fig.4-3B). Both proliferation assays showed that the 
Bcl15 cells cultured in the 100 % IL-3I mutant supernatant showed cell growth 
similar to those cultured in 0.5 to 1.0 % WEHI3B a concentration that is less than 
1:10 of routine use. Accordingly, the cell growth rate of the 20 % IL-3I clone 
supernatant was not as robust as the 100 %. This demonstrates that IL-3I clone 
do secrete a growth factor, for example IL-3 at a lower level, or a less potent 
factor. 
 
From this data it was possible that the IL-3I clone might have evolved in a culture 
that contained a small sub-population of cells secreting a high level of growth 
factor, which then supported the remaining cells. To test this hypothesis the 
growth rate of the IL-3I clone at a range of initial cell numbers was measured. 
The lowest cell number (5.6 x 104 per well) is the condition at which parental 
Bcl15 cells expand efficiently when 10 % WEHI3B supernatant is supplied in the 
culture. Fig.4-3C shows that IL-3I clone could grow at each cell density, albeit 
with a lag at the lowest cell density.  
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Fig.4-3 Autocrine factors secreted by the IL-3I clone (from the first round of IM 
assay) supported the cell growth of parental Bcl15 cells.  
(A) Parental Bcl15 cells were cultured in the supernatant of the IL-3I clone (20 and 
100 %) in comparison to positive control WEHI3B cell supernatant (0.01, 0.05, 0.1 (the 
concentration used only in B), 0.5, 1 and 10 %) for 6 days (M.M 2.1.2). The cell number 
was counted every 24 hours by trypan blue (Gibco). WEHI3B cells and the IL-3I clone 
supernatants were harvested in the same condition (post 24-hour harvest after seeding 
cell density at 5 x 105 cells/ml). (B) The same cell viability assay was repeated using 
CTK-8 (Dojindo). (C) The cell growth rate of the IL-3I clone at different cell density was 
measured by CTK-8 (Dojindo). Three initial cell numbers were used; 5.6 x 104 (low), 1.7 
x 105 (medium), 5 x 105 (high). Cell proliferation was measured every 24 hours up to 
three days. 
Those experiments were performed in duplicates. The error bar in each graph indicates 
the SEM between two experiments. 
 
 
 
 
A B 
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The previous work of Bokhoven et al (Bokhoven et al., 2009) showed that 
up-regulation of the IL-3 expression was a common mechanism of factor 
independence in “background” cell mutants that had become IL-3 independent 
in the absence of vector integration. Therefore, we initially tested for the 
presence of IL-3 mRNA by RT-PCR (Fig.4-4A) (M.M 2.5.3). WEHI3B cells that 
secrete IL-3 were used as a positive control to compare the strength of IL-3 
expression. IL-3 mRNA amplification by RT-PCR was only detectable in the 
WEHI3B cells, but not in the IL-3I clone. To confirm if this undetectable IL-3 
mRNA expression is due to the absence of the expression in the IL-3I clone or 
not, RT-qPCR was performed (Fig.4-4B) (M.M 2.5.3). RT-qPCR showed that a 
slight up-regulation of IL-3 mRNA in the IL-3I clone but was not as robust as the 
WEHI3B cells. IL-3 mRNA amplification was not detectable in other tested 
samples as in Fig.4-4A such as two step 4 survivors from the first IM assay and 
untransduced Bcl15 cells as expected. 
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Fig.4-4 IL-3 mRNA detection  
(A) Total RNA was reverse transcribed using an optimised blend of oligodT and random 
primers by QuantiTect Reverse Transcription Kit (Qiagen) and IL-3 mRNA expression 
was tested. The expected band size of IL-3 and mouse beta-actin control is 510 bp and 
140 bp, respectively. Total RNA from WEHI3B cell and untransduced Bcl15 cell were 
used as a positive control and a negative control, respectively. Survivior 1 and 2 on the 
gel stands for step 4 survivors. The tested samples were loaded on a 1 % gel and 
electrophoresed. (B) The same sample series in (A) was tested for mRNA copy number 
of IL-3 and mouse beta-actin by SYBR green qPCR. Actin copy number was used to 
normalise the IL-3 copy number. The other samples tested in (A) were run in the same 
qPCR, however had no amplification of IL-3 mRNA, therefore they did not appear in the 
graph. Experiments were performed in triplicates. The error bar indicates the SEM 
between two experiments.   
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4.3.4 Integration site identification in the IL-3I clone by LM-PCR 
 
LV integration sites in the IL-3I clones that link to the IL-3 independence were 
then interrogated. If integration sites near oncogenes as listed in RTCGD or cell 
survival-related genes could be identified, they can be the target for fusion 
mRNA expression by the integrated vector and the cause of IL-3 independence.  
 
Integration sites were identified by ligation-mediated PCR (LM-PCR) (Fig.4-5A) 
(M.M 2.5.4) (Wu et al., 2003). The digested DNA fragments by a 4-cutter 
enzyme, NlaIII were ligated with synthetic oligonucleotide sequences (linkers) 
thereby flanked at both DNA ends. Using a vector primer that anneals in the U5 
of the 3’ LTR and a linker primer vector-host sequences were amplified. 
Amplicon DNAs were then cloned into a pJET1.2 cloning vector for sequencing 
and analysed by UCSC BLAT and Ensembl to find hits of host cellular gene. The 
two rounds of LM-PCR are summarised in Fig.4-5B. Four genes (highlighted in 
red) were found having vector integrations in the same orientation to the 
transcription direction of the host cellular genes.  
 
At this stage I performed a preliminary analysis to see if any of the integration 
sites had been identified in the RTCGD (see Chapter 5, Introduction). Of the 
thirteen integration sites identified by LM-PCR I found that three of them 
appeared more than once in the RTCGD: Sorcs2, Mgmt and Angpt1. In general 
a single hit in this database may easily represent a passenger integrant in a 
multiply infected tumour, but sites appearing more than once have the possibility 
of significance. None of these three genes is classified as “common integration 
sites” (CIS), the gene loci with a proven functional significance in tumour 
formation. 
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Insertion site 
(Chr:integration 
site) 
Genes with 
insertions or the 
nearest gene 
RTCGD 
hits 
Ref 
1:93781343 Atg4b (intron 8-9) 0 (Marino et al., 2003) 
1:9688240 Mybl1 (intron 4-5) 1 (Mettus et al., 1994) 
2:98667291 Gm10800 (exon 1) 0 (Church et al., 2009) 
3:145597269 Znhit6 (intron 8-9) 0 (Francis et al., 2009) 
4:7689360 Car8 (downstream) 1 (Kato, 1990) 
5:36325218 Sorcs2 (Intron 1-2) 3 (Rezgaoui et al., 2001) 
7:54159361 -	  - - 
7:136570830 Mgmt (upstream) 2 (Shiota et al., 1992) 
10:25508756 Epb41l2 (intron 18-19) 0 (Takeuchi et al., 1994) 
11:102559236 Gpatch8 (upstream) 0 (Kai et al., 1997) 
14:14781133 Slc4a7 (intron 20-21) 1 (Okazaki et al., 2002) 
15:42434109 Angpt1 (intron 8-9) 2 (Davis et al., 1996) 
Y:1158993 Uty (intron 14-15) 0 (Mazeyrat et al., 1998) 
B 
A 
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Fig.4-5 Vector integration site identification in the IL-3I clone by ligation-mediated 
PCR (LM-PCR).  
(A) The scheme of LM-PCR (Wu et al., 2003) is explained. Synthesised linker oligo 
nucleotides were then ligated to the digested gDNA. In order to amplify target DNA 
fragments that have host cellular sequence at the 3’ side of vector sequence, linker 
oligonucleotides were ligated. Primers binding to the 3’ U5 and to the linker sequence 
amplify the vector-host genome sequences. The amplified products were 
electrophoresed on a 2 % agarose gel and the DNA bands were excised and 
column-purified. The DNA amplicons were cloned into a pJET cloning vector and 
sequenced. (B) The list of vector integration sites and genes within or near the 
integration sites from two rounds of LM-PCR are summarised. The vector integration site 
is described with the chromosomal number and location (the left and right side of the 
colon). When the integration site is a gene, the location is described either in an exon or 
an intron (between exon numbers). The gene name highlighted in red stands that both 
vector and the gene direction are the same. The number of RTCGD hits was extracted 
from http://variation.osu.edu/rtcgd/. 
 
 
4.3.5 Identification of host cellular sequences in host-vector chimeric 
transcripts by 5’ RACE 
 
LM-PCR identified 13 integration sites and targeted genes respectively, however, 
we need to confirm if they are present on chimeric transcripts expressed in the 
IL-3I clone. We then employed 5’ RACE to identify host cellular genes adjacent 
to 5’ side of vector sequence (Fig.4-6) (M.M 2.5.5). In the 5’ RACE, a reverse 
transcription (RT) primer annealing at the puromycin sequence (193 nt 
downstream of the start site of the puroR gene) was designed to investigate host 
cellular sequences in the chimeric puromycin mRNAs. Theoretically, circularised 
reverse transcribed single-stranded cDNA by T4 RNA ligase can contain a host 
cellular sequence between vector sequences. The DNA amplicons were cloned 
into a pJET1.2 cloning vector and sequenced. I also tested RNA from some of 
the step 4 survivors in this assay, although these were not truly IL-3 independent 
so any detected transcripts would be of unknown significance. 
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As to the IL-3I clone, one identified transcript presented 38 nt of potential host 
cellular sequence, however this did not match any sites on the GRCm38.p4 
mouse reference sequence. In the identified transcripts, various splicing patterns 
were observed using the known SD (343: the HIV MSD), the known SAs (1507, 
1967: the Ghr exon 2 SA)) and the cryptic SDs (1614, 1625). The known SD 343 
and the SA 1507 were also detected in the in silico assay but not the cryptic SDs 
(Fig.3-3B). 
 
One of the step 4 survivors showed splice-in fusion transcripts with myosin 
heavy polypeptide 9, non-muscle (Myh9) on chromosome 15 (Fig.4-6C, (right)). 
Myh9 is also conserved in human and plays an important role in cytokinesis, cell 
motility and maintenance of cell shape (Lalwani et al., 2000). The isolated 
splice-in chimeric transcripts presented two different forms: splice-in from the 
exon 2 SD of Myh9 to the Ghr exon 2 SA or to the HIV-1 major SD (MSD), 
followed by splicing to the Ghr exon 2 SA. Intriguingly, the SA site within 5’ LTR 
(235) is cryptic since it was not detected by NetGene2 in silico analysis (Fig.3-3B, 
Chapter 3), but this SD was also observed in another study (Cesana et al., 2012). 
In both the IL-3I clone and a step 4 survivor, short sequence reads were also 
detected not including host cellular sequences but with different splicing site use 
within the vector (Fig.4-6C,D (left)). Some of the other transcripts detected from 
5’ LTR had various splicing patterns as observed in the IL-3I clones such as 
spliced-in between the HIV MSD with the Ghr exon 2 SA, or between the HIV 
MSD and the known SA 1507. The likelihood of 1507 being used is weaker 
(confidence: 0.26) than the Ghr exon 2 SA (confidence: 0.69) according to 
NetGene2. Other cryptic SD sites at position 1614 and 1625 were not predicted 
by NetGene2 (Fig.3-3B, Chapter 3).  
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Fig.4-6 Detection of host-virus fusion mRNA of the IL-3I clone and a step 4 
survivor by 5’ RACE.  
(A) The scheme of 5’ RACE is visualised (M.M 2.5.5). The extracted total RNA was 
reverse-transcribed using a puroR gene-specific RT primer by QuantiTect Reverse 
Transcription Kit (Qiagen), followed by ligation of the single-stranded cDNA by T4 RNA 
ligase. The first round and nested PCR on the ligated products were performed to enrich 
target sequences. The final products were column-purified and cloned into a pJET 
cloning vector. The cloned fragments were sequenced and analysed. (B) An additional 
38 nt at the 5’ end of the vector was detected in the IL-3I clone, which is assumed to be 
host a cellular sequence. However this could not be mapped to the GRCm38.p4 mouse 
reference genome sequence. (C) The step 4 survivor showed various splicing patterns 
(left) and a fusion mRNA with Myh9 (right). Splice-in from the Myh9 exon 2 to the HIV 
major SD (MSD) or directly to the Ghr exon 2 SA were detected. 
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4.3.6 Further investigation of host cellular sequences in host-vector 
chimeric transcripts by designing the RT primer at further 5’ side of the 
vector sequence 
 
Because the first 5’ RACE failed to obtain host cellular sequence in splice-in 
fusion form (Fig.4-6B), as a second attempt the RT primer was newly designed 
to prime upstream of HIV MSD to detect host cellular sequences in fusion 
transcripts expressed in the IL-3I clone more easily (Fig.4-7A) (M.M 2.5.5). 
Using the same protocol as in Fig.4-6 and the cloned final DNA bands were 
sequenced. As a result three host-cellular genomic sequences were identified 
on chromosomes 4, 7 and 17 (Fig.4-7B). The same integration sites on the 
chromosome 4 and 7 were detected by LM-PCR (Fig.4-5). To verify if they are 
genuine integration sites, PCR on gDNA of the IL-3I clone was carried out. PCR 
primers to amplify the identified genomic regions were designed approximately 
200 nt of downstream and upstream of each integration site (Fig.4-7D, a table on 
the left). Firstly the primer function was tested if they can amplify the target 
genomic sequence (Fig.4-7C (green arrows) and D). Except for the PCR water 
control, all samples presented PCR amplification with the expected DNA length.  
 
Next, using the genomic primers (Fig.4-7C (green arrows)) paired with vector 
primers annealing to 5’ and 3’ side in a vector (Fig.4-7C (orange arrows)) those 
three candidate sites were confirmed by PCR on gDNA. Only the integration site 
on chromosome 4 showed amplification, which is in good agreement with the 
identified vector integration site by LM-PCR (Fig.4-7E). The other two candidate 
sites on chromosome 7 or 17 showed non-specific amplification although the 
integration site was identified on chromosome 7 by LM-PCR (Fig.4-5). 
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Fig.4-7 Another round of 5’ RACE identified the same integration site on 
chromosome 4 that was found in LM-PCR  
(A) The primer binding sites in the next 5’ RACE (M.M 2.5.5) is indicated by arrows; RT 
primer (a white arrow), first PCR (an orange arrow) and nested PCR (a green arrow). 
Two Nested PCR Rc primers were tested on the same amplified sample by the first PCR. 
(B) Three candidate host cellular genomic sequences (on Ch4, 7 and 17) were identified 
and summarised in a table. (C) The primers annealing to the 5’ or 3’ side of vector 
integration site (green arrows) were designed on host genome to confirm the identified 
integration site. When vector integration site was confirmed, the boundary between host 
and vector sequence was amplified by primer pairs (green Fw and orange Rc, and green 
Rc and orange Fw). PCR was performed on gDNA extracted from the IL-3I clone, a step 
4 survivor and parental Bcl15 cells. (D) To confirm the primer function, the paired 
chromosomal primers were tested on gDNA. The PCR-amplified products were run on a 
1 % agarose gel. The same sample order shown in Ch7 is also applied to Ch4 and 17. 
The expected DNA length amplified by each pair of chromosomal primers is summarised 
in the table on the right side. (E) Host genome on each 5’ or 3’ side of the integrated 
vector sequence (indicated 5’ or 3’ on the gel picture) was amplified to confirm vector 
integration sites (M.M 2.5.5). The amplified PCR products were run on a 1 % agarose gel. 
Five samples were tested in each 5’ or 3’ reaction for three sites and the sample order is 
shown on the right side of the gel picture. 
E 
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4.4 Discussion 
 
This project was designed for the identification of host genes that could be 
regulated by “splicing in” to a SA present in a LV. I hypothesised that this assay 
would detect events such as that present in the ß-thalassaemia clinical trial 
where splicing into a LV removed the 3’ end of the HMGA2 transcript 
(Cavazzana-Calvo et al., 2010). The use of the Bcl15 cell line presupposed that 
there would be mRNAs whose expression could be upregulated in this manner 
which then made the cells IL-3 independent. It would also be possible that the 
LV insertion could disrupt expression of one allele of a gene, for example that 
inhibits cell death, and that this could render cells IL-3 independent, however I 
considered this option less likely as such mutants have not been identified in our 
previous work.  
 
By analogy with the previous work in my lab I reasoned that even a single host 
gene that responded in such a manner would be of great value. The study of 
Bokhoven et al showed LV integration into Ghr could upregulate this gene by 
splicing out from the vector (Bokhoven et al., 2009). During the work the assay 
was adapted and an extra growth hormone was added to the assay so that such 
mutants grew more readily. This single locus could then be used to screen and 
eliminate SD sites in clinical candidate vectors (Knight et al., 2012) (Cesana et 
al., 2012). So if I could find a “splicing in” locus and determine its mechanism of 
making Bcl15 cells IL-3 independent, I could potentially adapt the assay to this 
mechanism. 
 
 
4.4.1 pGhr IRES-Puro transduction in IM assay generated one IL-3 
independent clone 
 
Using the functionally characterised pGhr IRES-Puro, I performed two 
mutagenesis assays and isolated one mutant, the IL-3I clone. This occurred at a 
frequency of 1 mutant per 1.5 x 108 integrants. It is not too surprising that the 
frequency of such mutants was so low. The Ghr mutants in the “splice out” assay 
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were more frequent (1 in 4.1 x 107 integrants) but in this case the LV could 
integrate into the 48.3 kb upstream of the second intron of the Ghr gene. If the 
“splice in” targets required integration into a more limited region or regions, far 
fewer mutants would be detected. It remains unclear whether the higher MOI 
used in the first assay was important for isolating the single mutant or whether 
this occurrence in one assay but not the other is a stochastic difference.  
 
Another possible reason contributing to the small mutant number might be a 
strong puromycin selection at the early stage of the IM assay protocol. The initial 
purpose of this selection was to isolate puromycin resistant (puroR) clones 
which have been potentially transformed to IL-3 independent by splice-in events. 
However, this early selection cuts off any other puroR clones with a lower level 
of puroR expression that could be IL-3 independent mutants. A future assay 
could be performed with a lower level of puromycin in the selection medium, or 
with no puromycin selection. 
 
 
4.4.2 The IL-3 independent clone secreted autocrine factor to support cell 
growth 
 
The use of the introduced Ghr exon 2 SA was interrogated by PCR (Fig.4-2). If 
the puromycin resistance of transduced cells were gained exclusively by 
splice-in using the SA of Ghr exon 2, the PCR amplification would be detectable 
using the downstream primer but not the upstream primer. The positive 
amplification by different forward primers can explain read-through transcripts 
without using the Ghr exon 2 SA also contribute to puromycin resistance but the 
frequency of this event is unknown from this experiment. This suggests that 
host-virus chimeric transcripts expressed in these tested samples could be 
generated using any SA sites upstream of the Ghr exon 2 SA or read-through 
from host cellular sequences not mediated by any splicing events. 
 
The IL-3 independent clone showed secretion of a growth factor demonstrated 
by the expansion of parental Bcl15 cell in supernatant from the IL-3I mutant 
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(Fig.4-3A and B). Some level of IL-3 transcript was found in this clone (Fig.4-4B). 
However, the work of Bokhoven et al would have classified this level of IL-3 
mRNA as “background” and did not find significant growth factor secretion by 
clones with this level of IL-3 mRNA (unpublished data). In the work of Bokhoven 
et al, very low levels of IL-3 mRNA (< 103/109 18S rRNA transcripts) were scored 
as negative. This would equate to approximately <103/actin transcript (Bas et al., 
2004), so the clone IL-3I falls within this very low level (Fig. 4-3A and B). It is 
possible that the growth factor secreted by the IL-3I clone is a very low level of 
IL-3, however it also remains possible that another survival factor is secreted, 
which may even act in synergy with a low level of IL-3. In addition, the 
proliferation of the IL-3I clone is enhanced by higher cell density (Fig.4-3C). This 
suggests that the whole population is able to secrete a growth factor and 
proliferate in an autocrine manner. The lag at low density could be explained by 
the cell cycle inhibitory effect of Bcl2 when IL-3 is removed (Marvel et al., 1994). 
 
 
4.4.3 A few integration sites identified had RTCGD hits 
 
In order to identify the mechanism of IL-3 independence in the clone IL-3l I first 
cloned LV integration sites by LM-PCR (Fig.4-5B). As the cells were transduced 
at high MOI it was not surprising to find thirteen sites, and it is not clear whether 
this represents a full list. I performed a preliminary screen of these sites in the 
Retrovirus Tagged Cancer Gene Database (RTCGD) and the full relevance of 
the RTCGD to the Bcl15 assay is described in the introduction to Chapter 5. Of 
the 13 sites 3 appear more than once in the RTCGD; Sorcs2, Mgmt and Angpt1. 
Sorcs2 is a receptor with roles in intracellular vesicle trafficking and neurotrophin 
binding in the nervous system (Lane et al., 2012), Mgmt is a DNA repair enzyme, 
often upregulated as a mechanism of cancer drug resistance (Erickson, 1991), 
and Angpt1 is a growth factor involved in vascularisation, including in cancer 
(Huang et al., 2010). However, integration into these loci does not indicate that 
host gene expression is affected, so I then moved on to attempt to identify fusion 
transcripts in the IL-3I clone by 5’ RACE. Not every integrant will give rise to 
such a transcript that can perturb host gene expression, and those that do are 
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more likely to be associated with IL-3 independence. 
 
 
4.4.4 5’ RACE identified known and cryptic splice sites within a vector 
sequence possibly in fusion mRNA, but failed to identify the host 
sequence itself in the IL-3I clone 
 
This method failed to identify any host gene fusion transcripts in clone IL-3I. Use 
of RNA-Seq for this and the implications of the results are discussed in Chapter 
5. The 5’ RACE did identify splicing patterns within the vector, both in a fusion 
transcript from one of the step 4 survivors with an integrant in Myh9 and from an 
unknown integrant or integrants in the clone IL-3l. As the step 4 survivor is not 
truly IL-3 independent I do not believe that this Myh9 integrant is necessarily of 
any functional significance in IL-3 independence. My in silico analysis showed a 
list of predicted splicing site candidates in the vector provirus sequence 
(Fig.3-3A and B, Chapter 3). I found that the HIV-1 major SD (MSD, 343) or the 
known HIV-1 SA downstream of RRE (1507) were predicted sites and also used 
in the detected transcripts. In addition, novel cryptic SD sites were also observed 
(1614 and 1625). These unpredicted SDs could be mutagenic depending on the 
vector integration site and host chromosomal environment and should perhaps 
be mutated. Short read-through sequence fragments were also detected not 
using the Ghr exon 2 SA. This is in good agreement with the presence of the 
read-through transcripts that resulted in band amplification with the upstream 
primer (Fig.4-2B).  
 
The second 5’ RACE (Fig.4-7), we identified two genomic sequences that match 
with vector integration site detected by LM-PCR (Fig.4-5). One site on 
chromosome 4 was verified as genuine integration site by gDNA PCR amplifying 
host-vector sequence boundary at 5’ and 3’ side of the vector. In LM-PCR 
analysis, a neighbouring gene car8 was found 550 kb downstream of the vector 
integration site on the chromosome 4. Vector integration is in the anti-sense 
relative to the car8 transcription direction and the vector has self-inactivating 
LTR, therefore the possible car8 fusion transcript does not contribute to puroR 
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gene expression in the IL-3I clones. Car8 and the relation to tumourigenesis are 
not known. 
 
In addition, the second 5’ RACE aimed to read a further 5’ host cellular 
sequence adjacent to vector sequence. The RT primer at the 5’ side of the 
vector was designed based on identified spliced transcripts within vector 
sequence and the use of HIV MSD (Fig.4-6B). This design of the RT primer 
could miss fusion transcripts having the direct splice-in between and a host SD 
and the Ghr exon 2 SA or any cryptic SAs between the MSD. This may not lead 
to the recovery of identified vector integration sites by LM-PCR (Fig.4-5) and 
some possible host sequences in fusion transcripts.  
 
Overall, the 5’ RACE results gave some information on splice sites possibly used 
in fusion transcripts that could give rise to puroR expression. One integration site 
on chromosome 4 was confirmed using different techniques (Fig.4-5 and 4-6). 
Because 5’ RACE could not identify and complete a host cellular sequence in 
splice-in fusion form, further mRNA analysis by RNA-Seq was required to the 
identify fusion transcripts in clone IL-3l. We expected that such host sequence 
might be related to IL-3 independence and the results of this analysis are 
presented in Chapter 5. We also considered that step 4 survivors could give us a 
hint about which host cellular sequences could be affected by vector integration 
and possibly lead mutant generation. At step 4 of mutagenesis assay, cultured 
transduced cells are starved from growth factor and certain selection of gene 
expression related to cell survival is expected. Pooled step 4 survivors were also 
analysed by RNA-Seq in the next chapter. 
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Chapter 5 
 
Identification of host-vector 
fusion mRNAs and assessing 
their relevance for cell survival 
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5.1 Introduction 
 
The purpose of the experiments in this Chapter was firstly to the identify 
host-vector fusion transcripts present in the clone IL-3I. Due to the fact 5’ RACE 
had failed to identify such transcripts, I decided to employ RNA-Seq. In this 
method cDNA is synthesized from mRNA, and because I was looking for 
host-vector fusion transcripts I optimised a primer within the LV sequence for this 
first strand cDNA synthesis. After successful identification of two fusion 
transcripts in the clone IL-3I, I reasoned that I could apply this method to 
examine fusion transcripts in bulk populations of LV transduced Bcl15 cells 
(Fig.5-1). I therefore also analysed host-vector fusion transcripts in an IL-3 
starved population and unstarved control cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5-1 The harvest of transduced bulk populations 
Two bulk populations were harvested at the different steps in the second IM assay for 
Illumina RNA sequencing to compare the expression profile of fusion mRNAs.  
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In order to estimate the possible relevance of the detected transcripts to cell 
survival or proliferation I planned to employ two methods. Firstly, BAF3 cells (the 
parent of Bcl15) have been extensively studied as a model for haematopoietic 
cell survival and growth. I therefore prepared a table of genetic modifications of 
BAF3 cells that have been reported to enhance survival or proliferation (Table 
5-1). Since Collins et al demonstrated that BAF3 cells could be used to express 
heterologous receptors making them responsive to new ligands EGFR and IL2R 
(Collins et al., 1988) (Collins et al., 1990), a large number of groups have used 
these cells for receptor function analysis (Table 5-1, Group 1). Secondly, 
oncogenic proteins identified in human tumours have been shown to render 
BAF3 cells tumourigenic in mice (Table 5-1, Group 2). Thirdly, activated 
signaling molecules (sometimes forms found in human tumours) or inhibitors of 
signaling pathways have been expressed in the cells to examine which 
pathways lead to survival or proliferation (Table 5-1, Group 3). Finally, three 
retroviral or LV mutagenesis screens have been carried out in these cells to 
identify IL-3 independent mutants. The screen by Marvel and colleagues 
identified Bcl-X as a common retroviral insertion site in four cell clones that were 
resistant to multiple apoptotic stimuli (Thomas et al., 1998). The screen by Koh 
and colleagues, using transduction of a cDNA library in a retroviral vector, also 
identified Bcl-X, a number of kinases and two transcription factors (Koh et al., 
2004). The screen of BAF3 and Bcl15 cells from our group by Bokhoven et al 
showed that many LV insertional mutants selected by IL-3 removal had activated 
expression of the growth hormone receptor (ghr) and those selected after 
gammaretroviral mutagenesis had insertion into IL-3 itself and a number of other 
genes (Bokhoven et al., 2009). My assays were performed in Bcl15 cells, 
already expressing a high level of Bcl2, so upregulation of Bcl2 or its homologue 
Bcl-X was unlikely to be detected. However, I decided that one useful analysis of 
any fusion transcripts that I detected would be to see if their cellular partner had 
previously been reported to have an effect on survival or proliferation of BAF3 
cells in the literature summarised in Table 1.  
 
Secondly, Bokhoven et al noted that almost all mutants isolated in their RV or LV 
screens, but not control clones, had at least one insertion into a site identified in 
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the Retrovirus Tagged Cancer Gene Database (RTCGD) (Akagi et al., 2004). 
This database provides a summary of all genes with insertions of retroviruses or 
transposons, where these agents have been used to induce tumours in a variety 
of animal models. I updated the analysis of genes identified in Bokhoven et al, 
then analysed the genes identified in the BAF3 cell screens by Marvel et al and 
Koh et al (Table 5-2) and found that 48 out of 54 independent clones showed 
insertion in (or expression of in case of Koh) genes featured in the RTCGD. Thus, 
genes that render BAF3 cells able to survive or proliferate in the absence of IL-3 
largely overlap with genes that are activated by retroviral or transposon 
integration in animal tumour models. Therefore, I decided that I would also 
examine the cellular partners of fusion transcripts to see if they were 
represented in RTCGD. A combination of these two approaches should indicate 
any candidate fusion transcripts that might be expected to influence cell survival 
or proliferation. 
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Table 5-1 Identified genes related to cell proliferation and survival using BAF3 cells 
 
Group 1 
Gene Gene name Reference 
EGFR Epidermal growth factor receptor  (Collins et al., 1988) 
IL2R Interleukin 2 receptor (Collins et al., 1990) 
GMCSFR 
Granulocyte macrophage 
colony-stimulating factor receptor 
(Park et al., 1986) 
IL5R Interleukin 5 receptor (Sakamaki et al., 1992) 
EPOR Erythropoietin receptor (Frederiks et al., 1978) 
PDGFR Platelet-derived growth factor receptor (Satoh et al., 1993) 
GCSFR 
Granulocyte colony-stimulating factor 
receptor 
(Dong et al., 1993) 
MPL/thrombop
oietin 
Myeloproliferative leukemia virus 
oncogene/thrombopoietin 
(Drachman et al., 1995) 
FGFR Fibroblast growth factor receptor (Wang et al., 1994) 
PRLR Prolactin receptor (O'Neal and Yu-Lee, 1994) 
CNTFR Ciliary neurotrophic factor receptor (Kruttgen et al., 1995) 
IL11R Interleukin-11 receptor  (Nandurkar et al., 1996) 
c-Met Hepatocyte growth factor receptor (Schwall et al., 1996) 
IL7R Interleukin-7 receptor (van der Plas et al., 1996) 
IL12R Interleukin-12 receptor (Zou et al., 1997) 
LEPR Leptin receptor (Ghilardi and Skoda, 1997) 
PAR2 Proteinase-activated receptor 2 (Mirza et al., 1997) 
Flt3 Fms-related tyrosine kinase 3 (Shibayama et al., 1998) 
IL9R Interleukin 9 receptor  (Louahed et al., 1999) 
IL21R Interleukin 21 receptor (Parrish-Novak et al., 2000) 
IL6R Interleukin 6 receptor (Jostock et al., 2001) 
IL22R Interleukin 22 receptor (Rutherford et al., 2001)  
c-Kit Mast/stem cell growth factor receptor Kit (Ueda et al., 2002) 
IL27R Interleukin 27 receptor (Pradhan et al., 2007) 
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GHR 
  
Growth hormone receptor 
(Barclay et al., 2007) 
TFRC Transferrin receptor (Shi et al., 1997) 
 
 
Group 2 
  
 
Group 3 
 
Gene Gene name Reference 
MKK1 MAP kinase kinase 1 (Perkins et al., 1996) 
Akt RAC-alpha serine/threonine-protein kinase (Ahmed et al., 1997) 
Gene Gene name Reference 
BCL-2 Apoptosis regulator Bcl-2 (Collins et al., 1992) 
Bcr/Abl 
Breakpoint cluster region /ABL proto- 
oncogene 1, non-receptor tyrosine 
kinase 
(Bazzoni et al., 1996) 
Tel/PDGF 
ETS variant 6/platelet-derived growth 
factor receptor beta 
(Sjoblom et al., 1999) 
ALK/ATIC 
ALK tyrosine kinase receptor/5- 
Aminoimidazole-4-Carboxamide 
Ribonucleotide Formyltransferase/IMP 
Cyclohydrolase 
(Ma et al., 2000) 
Tel/Syk ETS variant 6/Spleen tyrosine kinase (Kuno et al., 2001) 
E2a/Pbx1 
Transcription factor E2-alpha/Pre-B-cell 
leukemia transcription factor 1 
(Rutherford et al., 2001) 
BCR/FGFR1 
Breakpoint cluster region/Fibroblast 
growth factor receptor 1  
(Demiroglu et al., 2001) 
NPM/ALK 
Nucleophosmin/Anaplastic lymphoma 
kinase 
(Kasprzycka et al., 2006) 
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Ras Related RAS Viral (R-Ras) Oncogene Homolog (Suzuki et al., 1997) 
JNK c-Jun N-terminal kinase (Smith et al., 1997) 
mSos Son of sevenless homolog 1 (Tago et al., 1998) 
Btk Tyrosine-protein kinase BTK (Deng et al., 1998) 
Rac RAC-alpha serine/threonine-protein kinase (Nishida et al., 1999) 
STAT5 Signal transducer and activator of transcription 5A (Zhang et al., 2000b) 
SHP-1 Src homology phosphatase-1 (Paling and Welham, 2002) 
Lyn LYN Proto-Oncogene, Src Family Tyrosine Kinase 
(Lannutti and Drachman, 
2004) 
Pim1 Pim-1 Proto-Oncogene, Serine/Threonine Kinase (Kim et al., 2005) 
ALK Anaplastic Lymphoma Receptor Tyrosine Kinase (Wan et al., 2006) 
Jak2 Janus Kinase 2 (Walz et al., 2006) 
Lck LCK Proto-Oncogene, Src Family Tyrosine Kinase (Shi et al., 2006) 
Daxx Death-Domain Associated Protein (Muromoto et al., 2010) 
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Table 5-2 Genes related to oncogenesis derived from BAF3 IM assays 
 
Referene 
Surviving 
clones 
Gene 
Number of 
RTCGD hits 
Bokhoven 
(Bokhoven et al., 
2009)  
C10 Dusp6 4 
C40 Osbpl3 4 
C57 Sema4b 5 
C96 Zfp36/Plekhg2  9 
G18 Il3 0 
10 LV clones Ghr 6 
HV48 Senp1 2 
HV72 Primpol 0 
Marvel (Marvel et 
al., 1994) 
4 clones Bcl2l1 (Bcl-X) 7 
Koh (Koh et al., 
2004) 
5 clones Fms 6 
4 clones Fes 1 
2 clones Tyk2 0 
2 clones Araf 1 
2 clones Map3k8 16 
2 clones  Map2k3 0 
1 clone Hhex 41 
1 clone  Hlx 0 
1 clone Bcl2l1  7 
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5.2 Aims 
 
1. To identify host-vector fusion transcripts in the clone IL-3I by developing a 
vector-primed RNA-Seq protocol 
2. To use this protocol to identify host-vector fusion transcripts in an 
IL-3-starved population of Bcl15 cells, compared to unstarved controls 
3. To assess the possible relevance of such host-vector fusion transcripts in 
promoting cell survival with reference to the BAF3 cell literature and the 
RTCGD 
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5.3 Results 
 
5.3.1 RNA deep sequencing to analyse the fusion mRNAs in the clone IL-3I 
 
Theoretically, a host-vector fusion transcript can be generated when the model 
vector is integrated downstream of a cellular promoter in the same orientation as 
the host transcription, allowing the Ghr exon 2 SA to be used with the host gene 
SD (Fig.5-2A). To detect host sequences and splicing patterns in fusion 
transcripts, a specific reverse transcription (RT) primer, SA1, was designed to 
anneal 47 nt downstream from the beginning of the Ghr exon 2. This RT primer 
contains a region designed to anneal to the vector (red) and an overhang 
sequence (green) (Fig.5-2B). After single-stranded cDNA is generated, 
double-stranded DNA is synthesised by using a random octamer with a different 
overhang sequence (Fig.5-2C) (M.M 2.6.5). 
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Fig.5-2 The scheme of cDNA preparation for MiSeq RNA sequencing 
(A) Host-virus splice-in fusion mRNAs can be expressed by integration of our model 
vector in the same orientation with host transcriptional direction. In order to detect the 
splice-in chimeric transcripts, a reverse transcription (RT) primer was designed, SA1. A 
red arrow with a green tail in the RT primer indicates a complementary sequence to the 
vector-specific region and an overhang sequence (tag), respectively. (B) The RT primer 
sequence. (C) The second strand of the cDNA is synthesised using a random primer 
(octamer) with overhang sequences (tag). Using the primer pair that anneals to the tag 
sequences at both ends of transcripts, PCR can be performed to enrich target DNA 
fragments. 
 
 
 
 
A 
B 
C 
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5.3.2 Testing the SA1 primer in DNA amplification and RT priming 
Initially, one RT primer candidate (SA1) was tested for the general amplification 
from gDNA extracted from untransduced Bcl15 cells and the IL-3I clone (M.M 
2.6.4). DNA amplification was tested semi-quantitatively on 1:5 dilutions of 
gDNA from a starting amount of 100 ng. This RT primer anneals to Ghr exon 2 
and a forward primer anneals to the introduced Ghr region. Therefore, the 
amplification is detected in both cell populations (Fig.5-3A, the middle part in the 
gel picture). When the SA1 primer was used with the forward primer annealing to 
the vector backbone (upstream of the introduced Ghr), only the IL-3I clone 
amplified (Fig.5-3, the right side of the gel picture). Puro amplification was tested 
as a positive control for the IL-3I clone; amplification was observed in the IL-3I 
clone, not in the Bcl15 as expected. Therefore, SA1 can prime DNA synthesis by 
annealing to the expected site on the vector sequence as shown by amplification 
products of the expected size. 
 
Three different RT primers were then tested by SYBR green qPCR: SA1, SA2 
and IRES, in order to choose an RT primer with optimal amplification (M.M 2.6.4). 
I decided to use a bulk transduced cell population at this point as a test of RT 
priming; this might be more stringent as many transcripts could be present at a 
lower level than those in the IL-3I clone. Therefore, mRNA from Bcl15 and the 
transduced Bcl15 cells with pGhr IRES-Puro cultured in puromycin (Bulk-Puro, 
see Fig.5-1) was reverse transcribed with one of three candidate RT primers and 
qPCR was performed with three primer pairs: Ghr, puromycin (Puro) and mouse 
beta-actin (Fig.5-3B). When the cycle number detected in parental Bcl15 cells 
would be regarded as negative, the lowest cycle number 32.44 with RT primed 
by SA1 and detected by Ghr primers could be a threshold in this reaction. With 
this regard, positive PCR amplification by the Ghr primer (the orange Fw primer 
and a green tag sequence of each RT primer) was only observed with SA1, but 
not with two other RT primers (the upper part of the table in Fig.5-3B). As 
controls, PCR amplification of puromycin and mouse beta-actin was also tested 
in the same qPCR reaction. Since only transduced cells selected by puromycin 
have puroR mRNA expression, Bulk-Puro mRNA had PCR amplification with 
puro primers but Bcl15 cells did not (the middle part of the table in Fig.5-3B). 
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While both Bcl15 cells and Bulk-Puro showed PCR amplification of mouse 
beta-actin. Across three PCR primers amplification was not observed in negative 
control (No RTase-oligodT). PCR amplification with puro primers is similar 
among three candidate RT primers, suggesting the presence of host-vector 
fusion mRNAs. However, the fact that PCR amplification with Ghr primers was 
only detectable with SA1 implies that SA2 and IRES RT primers probably did not 
efficiently prime reverse transcription. Therefore, SA1 was selected as an 
optimal RT primer for mRNA library preparation for RNA sequencing. Ideally this 
experiment should have been duplicated but it was not. 
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qPCR primers RT primers Bcl15 Bulk-Puro 
Ghr oligodT ND ND 
SA1 32.44 21.34 
SA2 ND ND 
IRES 37.14 ND 
No RTase-oligodT ND 38.38 
Puro oligodT ND 19.03 
SA1 ND 19.12 
SA2 ND 19.40 
IRES ND 19.61 
No RTase-oligodT ND 37.73 
A 
B 
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Mbeta-actin oligodT 19.38 17.84 
SA1 19.89 18.86 
SA2 19.29 18.27 
IRES 19.85 19.09 
No RTase-oligodT 33.05 33.93 
 
Fig.5-3 Design of an RT primer 
(A) PCR was performed on gDNA extracted from parental Bcl15 cells and the IL-3I clone 
to test the specific amplification by three different pairs of primers including a RT primer 
(SA1); a pair of puromycin primers (puro, blue arrows), Ghr (orange arrow) and vector 
(purple arrow). The Ghr primer (orange) and the vector primer (purple) were paired with 
primer SA1. gDNA samples were serially diluted (1:5, 5 points) from the starting amount 
of 100 ng. The furthest left lane of three reactions (divided by dashed line) is negative 
control (no gDNA). PCR was performed by GoTaq G2 DNA polymerase (Promega). (B) 
In order to choose an optimal RT primer, target amplification by two other RT primers 
SA2 and IRES were compared with by SA1. The annealing site of each RT primer is 
indicated on the vector provirus schematic by the red arrows with the green tails. cDNA 
was synthesised using mRNA extracted from Bcl15 cells and Bulk-Puro. As a control RT 
primer, oligo dT was tested alongside. qPCR was then performed by QuantiTect SYBR 
green (Qiagen) using three pairs of primers: Puro primers used in (Fig. 5-3A), the green 
tag sequence of each RT primer (indicated with green) with a forward primer of Ghr exon 
2 (an orange arrow in the schematic) and mouse actin primers. Amplification by those 
primer pairs was summarised by a cycle number in the table. Ghr: primer pairs for 
growth hormone receptor; Puro: primer pairs for puromycin resistant gene; mActin: 
primer pairs for mouse beta actin; ND: non-detectable 
 
 
5.3.3 mRNA prepared by direct lysis showed nonspecific amplification of 
DNA in the untransduced negative control  
Initially, mRNA was prepared by direct lysis and then poly(A)-tailed mRNA was 
selected by oligotex beads (Qiagen) (M.M 2.6.2). Then, the mRNA of Bcl15 and 
Bulk-Puro cells was reverse transcribed with SA1 primer at three incubation 
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conditions of 42, 45 and 50 oC. Double-stranded DNA was synthesised from a 
single-stranded cDNA template using a forward primer with a 3’ random octamer. 
Using a pair of primers which anneal to the overhang sequence on the RT and 
random octamer primer, PCR was performed to amplify DNA in the range of 100 
bp to 1 kb. However, a smear of DNA bands was observed in both Bcl15 and 
Bulk-Puro cells. In addition, non-specific bands were also observed in the water 
control prepared for this PCR analysis (Fig. 5-4A). 
 
There are some steps in this pipeline that could be improved. For instance, the 
protocol for second strand DNA synthesis could be modified. As the primer for 
the second strand synthesis is a random octamer that requires low annealing 
temperature (Wong et al., 1996). Therefore, an incubation step at a lower 
temperature was added before the main incubation at 37 oC. However, this did 
not improve the final PCR outcome (Fig.5-4B). Hence, NGS sample preparation 
further upstream in the protocol, the method of mRNA extraction, was changed.  
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Fig.5-4 Non specific amplification by KOD polymerase PCR after second strand 
DNA synthesis was not improved by optimising the incubation temperature of RT, 
double-stranded DNA synthesis and annealing temperature of the KOD 
polymerase-PCR. 
(A) Specific amplification of DNA bands with the range of length from 100 to 1k bp was 
tested by KOD polymerase PCR. Prior to this PCR, mRNA from untransduced Bcl15 
cells and Bulk-Puro was extracted by the direct cell lysis and selection of polyA tailed 
RNAs by oligotex beads (Qiagen) (M.M 2.6.2). 10 ng mRNA was reverse transcribed at 
three different RT temperatures (42, 45 and 50 oC), followed by double-stranded DNA 
synthesis. The double-stranded DNA has a tag sequence at both ends that were 
introduced by the RT primer and the primer to synthesise double-stranded DNA. PCR 
B 
A 
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amplification using tag sequences was performed by KOD polymerase (Novagen) at 
three different annealing temperatures (TA: 55, 60 and 65 oC). As a negative control for 
the PCR, RT control (without RTase) and PCR water control were used. The 
electrophoresed gel (1 %) picture is shown. The lane number in the chart corresponds to 
that indicated in the gel. (B) We assumed that additional incubation steps at the 
synthesis of second strand cDNA could reduce unwanted background amplification. In 
order to increase the binding efficiency of random octamer, a 10-minute incubation at 
three different temperatures (15, 20 and 25 oC) were performed prior to the general 
incubation protocol (37 oC for 60 minutes followed by 75 oC for 20 minutes). KOD PCR 
was then tested at three different annealing temperatures (TA: 55, 60 and 65 oC). The 
electrophoresed gel (1 %) picture is shown. The lane number in the chart corresponds to 
that indicated in the gel. 
 
 
5.3.4 Optimisation of specific RNA amplification 
 
We started from total RNA to extract mRNA by polyA selection (M.M 2.6.2). 
Reverse transcription was then performed, followed by the second strand DNA 
synthesis. In these experiments, I also included a bulk transduced population 
starved of IL-3 (Fig.5-1, Bulk-Survivors) as this might give further host-vector 
fusion transcripts that promote cell survival. The PCR showed a clear difference 
in amplification, showing minimal amplification in untransduced Bcl15 cells but 
smears of DNA bands in the expected size range in the other samples 
(Bulk-Puro, Bulk-Survivors and the IL-3I clone) (Fig. 5-5A). To keep a broad 
variety of DNA species, different low numbers of PCR cycles were tested, and 
22 cycles proved to be adequate (Fig. 5-5B) (M.M 2.6.6). The final PCR samples 
were prepared in triplicate for each sample using 22 cycles, and Fig. 5-5C shows 
an aliquot of each of these final products. The samples were indexed using the 
Nextera XT Index Kit v2 set C (Illlumina) to identify products from each sample 
replicate so that samples could be included in a single sequencing run. The DNA 
fragments were sequenced using the 500-cycle paired-end sequencing kit 
(Illumina). The indexing and MiSeq run were kindly performed by Dr. Edward T. 
Mee (NIBSC) (M.M 2.6.6). 
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Fig.5-5 The amplification by KOD polymerase-PCR 
(A) Four samples were tested: parental Bcl15 cells (Bcl), Bulk-Puro (BP), Bulk-Survivors 
(BS) and the IL-3I clone (6N). mRNA was prepared from total RNA employing poly(A) 
mRNA selection by oligotex (Qiagen). Reverse transcription on 100 ng mRNA of each 
sample was performed at 50 oC, followed by the second strand cDNA synthesis after 
pre-incubation at three different temperatures (15, 20 and 25 oC). KOD polymerase-PCR 
was performed at the annealing temperature of 52 oC with three different cycle numbers 
(25, 30 and 35). The PCR samples were run on a 1 % agarose gel. (B) In order to keep 
diverse species of PCR products, a lower PCR cycle number was tested (22) and 
compared to the amplification pattern with the cycle number 25. (C) The PCR 
amplification was performed at a cycle number 22 before indexing and performing RNA 
 
A 
B 
C 
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sequencing (Dr. Edward T. Mee at NIBSC). Triplicate samples were prepared from each 
cell sample and aliquots of these PCR samples were run on a 1 % agarose gel. 
 
 
5.3.5 Successful MiSeq run showed a small number of reads with vector 
specific sequences   
 
The sequencing run generated a total of 14,867,601 reads passing filter, with 
62.11 % of total bases having a Phred quality score of 30 (Q30) or greater, 
which is the benchmark of sequencing quality. Q30 shows the error rate of 
sequencing of 1 in 1000 chance. This number of reads and high quality showed 
the MiSeq run to have been successful. The raw data of RNA-Seq was obtained 
using the sequencing analysis tool, trimmomatic (http://www. 
usadellab.org/cms/?page=trimmomatic), which was kindly performed by Dr. 
Mark Preston (NIBSC). The average number of three replicates of each sample 
is described (Table 5-3 the left-hand column). The raw sequencing reads were 
filtered by a Phred quality score of 30 to obtain sequencing with a high accuracy 
(Ewing and Green, 1998). The number of raw reads and reads after the Q30 
filtering are summarised as the total number of forward and reverse reads of 
each sample in Table 5.3 the middle column.  
 
To investigate host-vector fusion mRNAs, the forward reads were firstly 
analysed. I chose 47 nt sequence including the additional 27 nt vector-specific 
sequence at 5’ side of SA1. The 47 nt should be present on fusion mRNA 
whether the Ghr exon 2 SA that is immediate upstream of the 47 nt sequence is 
used or not because the sequence was read 3’ downstream of the 47 nt. No 
cryptic splice sites were predicted in the 47 nt when analysed by Netgene2 in the 
Chapter 3. The forward sequence was filtered by the 47 nt sequence, kindly 
performed by Dr. Mark Preston (NIBSC) (Table 5-4 the left-hand column). The 
number of reads passing the filter was unexpectedly small compared to the total 
number of reads (Table 5-3, the left-hand column).  
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Ssample name Reads Total Reads Q30 Read Length (nt) 
IL-3I cone 576218.7 258234.3 176.5 
Bcl15 173222 22289.3 160.3 
Bulk-Puro 493918 221837.3 176.5 
Bulk-Survivors 570168.7 254106.7 174.7 
 
Table 5-3 The summary of RNA-Seq reads 
The sequence read number of four tested samples (the IL-3I clone, Bcl15 cell, Bulk-Puro 
and Bulk-Survivors) are summarised in three categories; total number of reads 
generated by RNA-Seq (reads total, the left-hand column), filtered reads passing Phred 
quality score of 30 (reads Q30, the middle column) and the average read length of 
filtered reads (read length, the right-hand column).	 Each number represents the 
average of three replicates of samples. The analysis of the reads were performed by a 
flexible read trimming tool for Illumina NGS data trimmomatic 
(http://www.usadellab.org/cms/?page=trimmomatic), which was kindly performed by Dr. 
Mark Preston (NIBSC). 
 
Sample name Vector reads 
The IL-3I clone 147.3 
Bcl15 5 
Bulk-puro 60 
Bulk-survors 117 
 
Table 5-4 The number of forward sequence reads with the 47 nt vector sequence 
The forward sequence reads with the 47 nt vector sequence were extracted from total 
forward sequence reads, which was kindly performed by Dr. Mark Preston (NIBSC) 
using trimmomatic (http://www. usadellab.org/cms/?page= trimmomatic) as in the Table 
5-3. The number in this table is the average read number of three replicates of each 
sample. 
 
 
All the filtered reads with the 47 nt were then clustered by Clustal X (Jeanmougin 
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et al., 1998) for fast screen of possible fusion mRNAs (M.M 2.6.6). The two 
typical alignments are shown in Fig.5-6. In the majority represented by Fig.5-6 
(blue), only vector sequences that multiply spliced within the vector were 
detected. In minority sequences represented by Fig.5-6 (orange), the vector 
sequence at the 5’ side joined the 3’ region of sequence that did not align to the 
vector sequence. One representative sequence was then selected in each 
clustered read. The FASTA format of the accumulated representative sequence 
reads was blasted to host mouse genomic sequence (GRCm38.p4) using 
Ensembl (http://www.ensembl.org/ index. html) to see if a mouse sequence is 
present on the reads. In addition, to detect splicing patterns within vectors and 
the boundary between the host and vector sequence, the FASTA sequence was 
blasted to mouse genomic sequence (GRCm38.p4) and pGhr IRES-Puro 
provirus sequence by NCBI nucleotide blast (https://blast.nc 
bi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_
LOC=blasthome). Because the read is paired-end, the corresponding reverse 
reads to the minority sequences that had host sequences on were blasted to 
host mouse genomic sequence (GRCm38.p4) using Ensembl (http://www. 
ensembl.org/ index. html) to see whether the same gene locus appears as in the 
forward reads. Once this process is done, separately, all reverse reads were 
blasted to the mouse genomic sequence (GRCm38.p4) using NCBI nucleotide 
blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE 
=BlastSearch&LINK_LOC=blasthome) to search any new host mouse sequence 
because the reverse reads were primed by a random octamer (Fig.5-2C). 
However, we could obtain more numbers of reverse reads that had the already 
identified host sequences but not find such new gene locus by this approach. 
The details of the identified host sequences and the splicing patterns are 
described in the next section 5.4.7. 
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Fig.5-6 The overview of sequence reads clustered by ClustalX (e.g one of three 
replicates from the IL-3I clone) 
Forward (Fw) sequence reads of the IL-3I clone were clustered using ClustalX with a 
basic default setting (M.M 2.6.6). The majority of sequences with the vector sequence 
(blue) and the minor sequences having host mouse sequences (orange) are clustered 
as shown. The output of Fw sequence reads is reverse reading. The sequence in the 
Ghr exon 2 SA (CT in the sequence) and its position are highlighted by the blue bar. 
 
 
 
  
…gagacCTgcaa… 
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5.3.6 Identity of host sequences in fusion transcripts 
 
A summary of the host mRNAs found in fusion transcripts is presented in Table 
5-5. I separately reported the number of sequences with each host sequence in 
three categories as a result of each blasting step described in 5.3.5. The forward 
sequence was firstly analysed by clustering and blasting, and, the number of 
sequence hits were counted. Then we investigated the reverse reads paired to 
the forward sequence that had host cellular sequence. The number of reverse 
reads that hit the same gene locus were obtained. Separately, by blasting all 
reverse sequences we found more reverse reads with the already identified host 
cellular sequences.  
 
To obtain the known gene functions, the gene ontology data was extracted from 
the UniProt online database (www.uniprot.org/) (Table 5-6). This database 
provides protein sequences and their functional annotations (Consortium, 2010). 
Biological and molecular functions of each gene as extracted are described. I 
also examined whether any of these genes had been reported to serve a 
survival or proliferation function in the BAF3 cells (summarized in Table 5-1) and 
whether any appeared in the RTCGD and CIS. This very limited set of data does 
suggest that the genes detected in the Bulk survivor population either have a 
known role in BAF3 cell survival, like transferrin receptor (Shi et al., 1997), or 
appear in the RTCGD or CIS, whereas those in the control group (Bulk-Puro) do 
not. For the clone IL-3I the detection of an Angpt1 fusion transcript confirms that 
this insertion site detected by LM-PCR (Chapter 4) does give rise to a fusion 
transcript.  
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Table 5-5 The summary of identified genes in fusion transcripts and its analysis of 
sequence reads 
 The number of sequence reads with the listed host cellular sequences was obtained as 
a result of analysis as in Fig.5-6 and blasting (M.M 2.6.6). The first column on the right 
side of “Gene name” shows the number of forward sequence reads. The second one 
shows reverse sequence reads that was identified from the corresponding sequence of 
the forward reads in the first column. The third one is the reverse reads obtained by 
blasting all reverse reads against mouse genomic sequence (GRCm38.p4) by NCBI 
nucleotide blast. The fourth one is the sum of the first and the third columns, which 
presents the total number of sequence reads of each identified host sequence. 
 
 
 
 
 
Sample Genesymbol Gene name
Read
hits Fw
Read
hits Rv
Read
hits Rv
new
Potential
total read
number
Chromosome
number
Activity in
Baf3 assay RTCGD hits CIS hits
-
9
-
21 16 - 2
-
-
-
-
-
-
2 16 + -
Eif4a2 Eukaryotic TranslationInitiation Factor 4A2 0 0 1
3 5 - 9
Tfrc Transferrin Receptor 2 2 0
11 17 - -
Actb Actin, Beta 3 1 0
15 - -
Bulk-Survivors
Hsp90ab1
Heat Shock Protein
90kDa Alpha (Cytosolic),
Class B Member 1
2 1 9
6 - -
Arid2 AT Rich InteractiveDomain 2 1 1 0 1
2 - -
Mtpn Myotrophin 1 0 0 1
15 - -
Nudt5
Nudix (Nucleoside
Diphosphate Linked
Moiety X)-Type Motif 5
1 0 0 1
Pabpc1 Poly(A) Binding Protein,Cytoplasmic 1 4 3 1 5
3 14 7 - 2
-
9 6 - -
Bulk-Puro
Ctsc Cathepsin C 11 2
14 15 - 2
Mtpn Myotrophin 5 1 4
The IL-3I clone
Angpt1 Angiopoietin 1 12 4 2
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Table 5-6 (continued) 
Ref*: reference; 1: (Davis et al., 1996); 2: (Pennica et al., 1995); 3: (McGuire et al., 
1997) ; 4: (Wang et al., 1992); 5: (Yang et al., 2000); 6: (Wilsker et al., 2005); 7: 
(Mazzarella and Green, 1987); 8: (Alonso et al., 1986); 9: (Stearne et al., 1985) ;10: 
(Nielsen and Trachsel, 1988) 
 
 
5.3.7 Use of splice sites in the fusion transcripts.  
 
I examined the use of vector splice sites in the fusion transcripts by aligning the 
sequencing reads with vector and host sequences, these alignments are shown 
in Fig.5-7. 
 
The Angpt1 and Nudt5 loci were found to have a splice-out fusion mRNA. The 
vector insertion at these loci was found in the reverse orientation relative to the 
host gene transcriptional direction. In the reverse sequence of the Ghr intron 1, a 
cryptic splice donor (SD) at 1847 of vector provirus sequence was detected 
which formed a fusion transcript with the splice acceptor (SA) of exon 9 of 
Angpt1 or exon 2 of Nudt5. This cryptic SD at the position of 1847 was not 
predicted by Netgene2 in silico analysis (Chapter 3). Since the reverse 
transcription primer was designed to anneal downstream of the Ghr exon 2, the 
full sequence of these transcripts – including the transcriptional starting site – is 
unknown.  
 
Many of the other loci showed splice-in between a SD in the host gene and 
cryptic SAs within (232) or near the 5’ LTR (294). The Netgene2 analysis in 
Chapter 3, only site 294 appeared as a predicted SD with 0.16 confidence and 
others were even predicted. The 232 and 294 SAs were detected in a genome 
wide screen for LV fusion transcripts previously (Cesana et al., 2012). Following 
this splice-in, in 6 transcripts the HIV major SD generated 2 further introns 
between the SD and the known HIV-derived SA at	 1507 (Chapter 3 and 
(Cesana et al., 2012)), and between the cryptic SD at 1614 (Cesana et al., 2012) 
and the Ghr exon 2 SA. In a further six transcripts, the HIV major SD spliced 
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directly to the Ghr exon 2 SA. A direct splice from a cellular SD to the Ghr exon 2 
SA was only found in three transcripts. In many gene loci, several of the different 
splicing patterns were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5-7 Angpt1 and Mtpn were present in the host-virus fusion mRNAs expressed 
in the IL-3I clone. 
The blast result showed that Angpt1 and Mtpn were present in fusion mRNA expressed 
in the IL-3 clone. The vector provirus integration is shown in the each gene locus. 
Splicing pattern was estimated by obtained sequence. Thick black line shows the region 
presented on the detected fusion mRNA. The cryptic SA 232, or cryptic SD 1847 in the 
vector sequence is indicated. Chromosomal number of each gene locus (Ch) is shown 
next to the gene name.  
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Fig.5-8 Bulk-Survivors expressed fusion mRNA in Hsp90ab1, Actb, Tfrc and 
Eif4a2 locus. 
The vector provirus integration is shown in each gene locus. The splicing pattern was 
estimated by an obtained sequence. The thick black line shows the region presented on 
the detected fusion mRNA. Multiple splicing patterns were observed in the identified 
fusion mRNAs. In addition to the splice acceptor (SA) that is boundary of host-vector 
sequence, other splice sites on vector sequence were also indicated. Chromosomal 
number of each gene locus (Ch) is indicated next to the gene name. 
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Fig.5-9 Bulk-Puro expressed fusion mRNA in Ctst, Pubpc1, Nudt5, Mtpn and Arid2 
locus. 
The vector provirus integration is shown in each gene locus. The splicing pattern was 
estimated by an obtained sequence. The thick black line shows the region presented on 
the detected fusion mRNA. Multiple splicing patterns were observed in the identified 
fusion mRNAs. In addition to the splice acceptor (SA) that is boundary of host-vector 
sequence, other splice sites on vector sequence were also indicated. The chromosomal 
number of each gene locus (Ch) is indicated next to the gene name. 
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5.4 Discussion 
 
The identification of two fusion transcripts in the clone IL-3l brings the total 
number of detected integrants in this clone to 15. Angpt1 was the only gene 
identified by more than one method, in this case LM-PCR for integration site 
(Fig.4-5, Chapter 4) and also vector-primed RNA-Seq (Fig.5-7). It is clearly likely 
that many integration sites may not generate fusion transcripts. Also the 
LM-PCR dataset is incomplete as Mtpn does not appear there. The time limit for 
my PhD meant that I was unable to perform further experiments after the 
RNA-Seq run. So at this point I can only propose candidates that may be 
involved in clone IL-3l survival.  
 
 
5.4.1 Angpt1 can be the potential candidate gene related to IL-3 
independence of the clone IL-3I 
 
Angpt1 is clearly one good candidate for promoting survival or proliferation of the 
clone IL-3l and this gene loci was found by LM-PCR (Fig.4-5B). Firstly, Angpt1 
can act as a survival factor for haematopoietic progenitor cells (Arai et al., 2004). 
Secondly Angpt1 has two insertion sites and its receptors Tie1/Tek have three 
insertion sites in the RTCGD. So while the most reported effect of Angpt1 are on 
vascularisation (reviewed in (Yancopoulos et al., 2000)), an effect on a 
haematopoietic progenitor cell line is not unlikely. It is hard to predict the effect of 
the LV insertion in Angpt1 on the expression of the protein without further 
information. It is possible that the insertion reduces protein expression from this 
allele, however it is also possible that the fusion transcript is more stable and 
increases protein expression. Time limitation prevented me from confirming this 
hypothesis during my PhD, but this work will now be completed in the lab. Key 
experiments will be to examine whether Angpt1 mRNA level differs between 
Bcl15 and the clone IL-3l cells, whether the clone IL-3l produces Angpt1 and 
whether recombinant Angpt1 can promote survival or growth of Bcl15 cells.  
 
It should be noted that the Angpt1 fusion mRNA does not encode puroR 
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therefore this must come from a puroR expressing integration site, likely Mtpn or 
Myh9 in the IL-3I clone. It is also possible that other integration sites in the clone 
IL-3l have fusion transcripts, not detected because the RNA-Seq coverage is 
partial, or that LV insertion in other genes regulates gene expression in the 
absence of fusion transcripts. A future plan would be to screen expression of 
mRNA from each of the 15 integration sites, perhaps starting with those in the 
RTCGD. It is also clearly possible that more than one of these integration sites 
contributes to survival or proliferation of the clone IL-3l. I designed the original 
experiment to transduce Bcl15 cells at high copy number so that a large number 
of integration sites would be generated. The isolation of only one clone in these 
experiments demonstrates that this model LV is not highly mutagenic.  
 
 
5.4.2 Host genes in analysed fusion transcripts by RNA-Seq were related 
to Bcl15 cell survival that was previously reported 
 
The Bulk-Survivors are derived from Bulk-Puro cells which then survived IL-3 
starvation. Again the low number of total sequence reads for fusion mRNA 
analysis will have prevented the full repertoire of host sequences being identified. 
However, as an example of shared host sequences, a Mtpn-vector fusion mRNA 
was detected in the same splice-in form in both the IL-3I clone and Bulk-Puro 
cells. Thus the Mtpn locus may be a ‘hot spot’ for efficient splice-in fusion mRNA 
expression. Intriguingly, the genes identified in Bulk-Survivors had all been 
identified as relevant to Bcl15 cell survival or tagged in the RTCGD, whereas 
those in Bulk-Puro have not. Firstly, Tfrc has been shown to be a potent survival 
factor for BAF3 cells (Shi et al., 1997), so up-regulation of its receptor would 
provide a simple survival enhancement mechanism. Secondly, HSP90 is a 
molecular chaperone that controls the stability and function of a number of 
proteins in various signaling cascades, therefore its upregulation is related to 
cancer growth and survival (Neckers, 2007). Breast cancer is one example. The 
cytoplasmic isoform of HSP90, HSP90AB1, is implicated with poor prognosis in 
different subtypes of breast cancer including the aggressive triple negative 
breast cancer (TNBC) subtype (Cheng et al., 2012). Eif4a2 is overexpressed in 
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some tumour types including gliomas (Oblinger et al., 2016) and lymphomas 
(Gupta et al., 2002). It is a factor required for efficient initiation of protein 
synthesis and Eif4a2 inhibitors have been proposed as anti-cancer agents 
(Raza et al., 2015). Finally, beta actin is a common cytoskeletal component 
playing a key role in cell motility and migration, to my knowledge it is not known 
to be regulated at the transcriptional level in cancer. However it does appear 10 
times as an upregulated gene in the RTCGD, with 7 of these studies involving B 
cell tumours (Suzuki et al., 2002) (Suzuki et al., 2006). To come to any 
conclusion about the relevance of these sites it would be necessary to repeat the 
RNA-Seq experiment to achieve greater numbers of Bulk-Survivor and 
Bulk-Puro sequences so that I could estimate whether there was a significant 
difference between appearance of RTCGD hits in the Bulk-Survivor and 
Bulk-Puro population. I could also overexpress or knock-down expression of 
candidate genes in Bcl15 cells to see if this affected cell survival. 
 
 
5.4.3 Variety of fusion mRNAs in the same gene locus were observed 
 
The majority of fusion mRNAs had splice-in forms using a SA site within or near 
the 5’ LTR in the vector sequence. The use of a different SA within the vector in 
the same gene locus suggests that one gene locus affords variety of alternative 
splicing. It is also possible that the different transcripts come from different cell 
clones that harbor different integration sites. To distinguish between these 
possibilities I would need to perform sensitive PCR, with vector and integration 
site primers to determine whether multiple LV integrations are present in the 
identified gene loci. Although the most forward sequence reads showed 
read-through (Fig.5-6), the isolation of fusion mRNAs spliced between a host SD 
the Ghr exon 2 SA suggests the Ghr exon 2 SA contributes to interacting with a 
host SD as designed. Such fusion transcripts could contribute the increased 
transgene expression of pGhr IRES-Puro compared with pIRES-Puro that was 
reported in Chapter 3 (Fig.3-10D), but another RNA-Seq on the both transduced 
construct could explain this possibility by quantitating such fusion reads. 
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5.4.4 The identification of cryptic splice sites; the antisense integration 
raised the cryptic SD in the introduced intron sequence of the Ghr exon 2  
 
Vector integration direction relative to the host gene seems to affect splicing 
patterns, either splice-in or splice-out. The marker gene expression of our 
promoterless vector is detected when splice-in mRNA generation occurs and the 
transcript is translated from a host promoter. By analysing host-vector fusion 
transcripts in this chapter we found cryptic splice sites within the vector 
sequence in the sense integration to cellular transcript. The cryptic SA within 
(232) 5’ LTR was identified in this study, which was previously found in (Cesana 
et al., 2012). 
 
Interestingly, vector integration in the reverse orientation such as Angpt1 and 
Nudt5 showed a splice-out fusion mRNA using a cryptic SD (1847) on the 
negative strand of the vector sequence. The SD was present within the cloned 
Ghr locus fragment. Therefore it was artificially generated but not predicted by 
NetGene2. The SD would be possibly used in other locus and a completed 
RNA-Seq run could answer this possibility because the identified host genes and 
splicing pattern by RNA-Seq in this study are partial. This observation showed 
that exogenous sequence in a vector can be cryptic splice sites, therefore all 
these elements need to be assessed for genotoxic potential in respect to 
aberrant splicing (Knight et al., 2010) (Knight et al., 2012). In this regard the 
biological assay is more valuable than a computer prediction and should be 
carried out to find any cryptic splice sites. 
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6 General discussions 
 
6.1 Using these results to generate safer LV 
 
My results have identified a number of cryptic splice sites in the LV pGhr 
IRES-Puro, detailed in the results of Chapter 4 and 5. All but one of these was 
detected in the LV inserted in the same orientation as gene transcription, and 
likely gave rise to puromycin resistance. Some of these were previously 
described by Cesana et al (Cesana et al., 2012), but those SDs at 1614 and 
1625 were not previously reported. The two assays differ in that Cesana et al 
analysed fusion transcripts from all integrants, whereas I have analysed those 
that give rise to puromycin expression. All of these, apart from the cryptic SDs, 
are in regions of the LV that are required for vector function, namely the LTR 
(232, 235 and 294), HIV-1 major SD (MSD) (343), and SA within Env (1507). So, 
to produce safer vectors all these cryptic splice sites should be mutated in pGhr 
IRES-Puro. In the study of Cesana et al (Cesana et al., 2012), a mutation in the 
HIV-1 MSD critically reduced background transcripts although virus infectivity 
also declined greatly. This is not surprising as the MSD is known to be critical for 
inhibition of polyadenylation at the 5’ LTR (Furger et al., 2001) and more subtle 
mutations in this site should be tested. Mutations of multiple splice sites, 
including the SA within Env (1507), were also performed but the transcript 
expression affected by that specific SA was not investigated. In our vector case, 
the titre of the novel LV would need to be checked to make sure that the 
combination of mutations did not affect vector function and another splicing 
assay should be performed to check that Ghr exon 2 SA is then used.  
 
I also detected one cryptic SD in the reverse orientation LV insertion into Angpt1 
in the clone IL-3l, reported in Chapter 5, which did not lead to puromycin 
resistance (5.4.4). In this case the SD was in the intron 1 of Ghr that was cloned 
with the exon 2 SA and is not found in other LVs so is not relevant for future 
mutation. However, it would be valuable to perform a similar assay with the 
promoterless puromycin gene inserted into the reverse orientation of a LV, the 
vector pGhr IRES-Puro reverse as described in Chapter 3. This would allow 
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puromycin selection to then identify cryptic SAs in the reverse orientation. It is 
also possible that removal of the Ghr exon 2 SA from the test vectors would 
reveal further cryptic SA sites.  
 
Finally, my results, and those of Cesana et al (Cesana et al., 2012), were 
obtained in different cell lines; in their case a human lymphoblastoid cell line and 
primary haematopoietic cells, in my case a mouse haematopoietic cell line. It is 
still unclear why a particular splice acceptor is chosen in a particular integration 
locus. Also, as many of my fusion transcripts were cloned from a bulk population, 
I don’t know whether a single integration locus may choose more than one SA. 
Therefore, to optimise vector safety a more extensive screen of candidate 
clinical LV should probably be carried out in the relevant gene therapy target cell 
population using extensive RNA-seq analysis. 
 
6.2 Improvement of the mutagenesis assay 
 
I initially hoped to identify a locus where LV insertion led to IL-3 independence 
via a splice-in mechanism. This would have allowed a quantitative assay for 
splice-in mutation to be developed in the same way as our group has used the 
Ghr locus as a quantitative assay for LV splice-out mutation (Bokhoven et al., 
2009) (Knight et al., 2010) (Knight et al., 2012). However, I only isolated one IL-3 
independent clone (IL-3I). In this clone I have identified 13 integrants and two 
species of a fusion transcript, in the Angpt1 and Mtpn loci. The Mtpn-vector 
fusion transcripts result from a splice-in event and are likely to be capable of 
giving rise to puromycin expression. In contrast, the Angpt1-fusion transcripts 
result from a cryptic SD in the reverse orientation, and thus cannot give rise to 
puromycin expression.  
 
My hypothesis at present is that these two fusion transcripts contribute to 
puromycin resistance and IL-3 independence, respectively. The fact that two hits 
are needed for this clone to emerge may explain why I did not isolate a similar 
clone when I repeated the assay at a lower multiplicity of transduction. In any 
case I did not identify a candidate locus that could render cells IL-3 independent 
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by a splice-in mechanism. In future assays, if more IL-3 independent clones 
could be isolated, the mechanism of the IL-3 independence could be compared. 
I consider that the puromycin selection step could be improved for this purpose. 
Throughout our IM assay, 1 µg/ml puromycin was kept in the culture. This 
puromycin concentration indeed selected puroR cells over a certain threshold of 
puromycin expression (Fig.3-10A). This may select puroR cells with strong 
puroR gene expression, but this would not necessarily affect cell transformation. 
The LV integration and perturbation of the neighboring gene related to cell 
survival is more important than transduced cells with strong puromycin 
resistance. In this regard, puromycin drug selection could be omitted. 
 
6.3 The implication of these results for IL-3 signalling 
 
Angpt1 regulation remains a good candidate for rendering Bcl15 cells IL-3 
independent. As explained in Chapter 5, Angpt1 is a growth factor which 
supports survival and proliferation of haematopoietic progenitor cells (Huang et 
al., 2010) (Haemmerle et al., 2014). The IL-3l clone secretes a growth factor, 
making this possible up-regulation the most likely mechanism. However, Angpt1 
also appears in the RTCGD as a down-regulated gene linked to tumorigenesis in 
a mouse model (Haemmerle et al., 2014). Sadly the time of my PhD funding 
expired before I could follow up these ideas. The obvious next step would be to 
determine whether Angpt1 is up-regulated or down-regulated in IL-3l cells 
compared to Bcl15 cells. This would be done by qRT-PCR compared to a 
house-keeping gene. Depending on the result, the next step would be to either 
over-express Angpt1 in Bcl15 cells or inhibit its expression and then examine 
cell survival and proliferation. It is hard to predict which possibility is the most 
likely result of the LV anti-sense insertion in the Angpt1 locus. In either case this 
would be a novel result, bringing an intersection between the angiopoietin 
signalling pathway and the IL-3 signalling pathway. 
 
In our assay we use IL-3 dependence to screen genes related to cell 
proliferation and survival. The identified genes isolated in our IM assays might 
be limited by gene expression in murine pro-B Bcl15 cells. To expand our insight 
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about splice-in IM by LV integrations, we can apply our vector model to other cell 
types. For instance, recently established murine IL-7 dependent cell line 
MOHITO (mouse hematopoietic interleukin-dependent cell line) is a candidate 
because splice-in IM can be investigated in the T-cell context using cytokine 
deprivation (Kleppe et al., 2011). In addition, investigating an effect of vector 
integration in human primary cells, including embryonal and induced pluripotent 
stem cells (ES and iPS cells), will give an insight about vector genotoxicity in the 
closer setting to clinical gene therapy. 
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